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1. Summary 
There is increasing evidence that HIV-1 may interact with components 
associated with the nuclear envelope (NE) during the infection of dividing and 
non-dividing cells. This ensures correct nuclear import and integration, 
suggesting that NE may be of greater importance than is currently appreciated. 
Previous studies have shown that HIV-1 interacts with the nuclear pore 
complex, followed by nuclear import of the pre-integration complex and 
preferential integration into genomic areas that are topologically in close 
proximity to the inner nuclear membrane. To identify host proteins that may 
contribute to these processes, we performed an overexpression screen of 
known membrane-associated NE proteins. Two nuclear membrane associated 
proteins SUN1/UNC84A and SUN2/UNC84B, members of the Linker of 
Nucleoskeleton and Cytoskeleton complex, were shown to efficiently block 
nuclear import of certain HIV-1 laboratory strains (HIV-1NL4.3 and HIV-1IIIB) as 
well as natural strains upon overexpression. The amino-terminal 85-90 amino 
acid residues were identified as being required for the SUN1-mediated block 
and it was further demonstrated that the amino-terminal domains of SUN1 and 
SUN2 interact with HIV-1 in a capsid (CA)-specific way. To test whether 
depletion of endogenous SUN proteins causes differences in HIV-1 infection, 
SUN1-/- and SUN2-/- cells were generated with CRISPR/Cas9 and it was found 
that SUN1 absence did not have any detectable effect on HIV-1 infectivity, 
whereas the loss of SUN2 resulted in a modest suppressive effect in the 
accumulation of viral cDNA in the nucleus. The analysis with HIV-2 and other 
retroviruses suggests that SUN2 gene disruption affects HIV-1 specifically and 
does not involve any unspecific block to nuclear import. This block to infection 
was further analyzed in U87MG CD4 / CXCR4 cells with shRNA-reduced SUN2 
expression. In this case, the reduction of SUN2 levels resulted in a 5-fold 
decrease in HIV-1 infection after 24h, in comparison to control cells while 
infection increased to wild type levels 48h post infection. Overall, the data 
suggest that SUN2 may help promote the early stages of HIV-1 infection, while 
the contribution of SUN1 needs to be further investigated.  
 
The role of the CA protein and its connection to IFN-α-induced suppression was 
also investigated, by analyzing the infectivities of HIV-1 CA mutants N74D, 
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A105T, as well as P90A. Despite their relative resistance to ectopically 
expressed MX2, these CA mutants showed an increased sensitivity to the IFN-
α-induced post entry block, which was not dependent on MX2 antiviral activity. 
The data suggests that CA protein and the capsid core may protect incoming 
HIV-1 nucleic acids not only from being detected by cytoplasmic DNA sensors, 
but also from IFN-α-induced effectors, thereby providing dual protection against 
host defense mechanism. 
2. Zusammenfassung 
Es gibt immer mehr Hinweise darauf, dass das humane Immundefizienzvirus 
Typ 1 (HIV-1) während der Infektion von sich-teilenden, sowie ruhenden Zellen 
mit Komponenten der nuklearen Membran interagiert um den sicheren 
Kernimport, sowie die korrekte Integration seines Genoms zu gewährleisten. 
Frühere Studien zeigten bereits die Interaktion von HIV-1 Proteinen mit 
Proteinen des Kernporenkomplexes, gefolgt vom nuklearen Import, sowie 
Integration in transkriptionell aktiven Genomregionen, welche topologisch in der 
Nähe der Kernmembran lokalisieren. Um Wirtsproteine zu identifizieren, die 
dabei eine Rolle spielen könnten, haben wir einen Überexpressions-Screen von 
Proteinen durchgeführt, welche mit der Kernmembran assoziiert sind. Dabei 
identifizierten wir zwei Proteine der inneren Kernmembran, SUN1/UNC84A, 
sowie SUN2/UNC84B, Komponenten des sogenannten LINC Komplexes, 
welche sehr effizient die Infektion mit HIV-1 Laborstämmen NL4.3 und IIIB, 
sowie einigen natürlich vorkommenden Stämmen nach Überexpression 
blockieren. Die aminoterminalen 85-90 Aminosäuren waren dabei essentiell für 
den Block durch SUN1 und wir zeigen weiterhin, dass diese Domainen von 
SUN1 und SUN2 mit HIV-1 CA interagieren können. Um zu testen ob 
endogenes SUN1 oder SUN2 wichtig sind für die frühen Infektionsschritte von 
HIV-1, generierten wir SUN1-/-, sowie SUN2-/- knock-out Zelllinien durch 
CRISPR/Cas9 Technologie. Das Fehlen von SUN1 hatte keinen detektierbaren 
Effekt auf die ersten Infektionsschritte von HIV-1, wobei das Fehlen von SUN2 
die HIV-1 Infektion und insbesondere die Akkumulation von viraler DNA im 
Nukleus moderat reduzierte. Dieser Effekt konnte in verschiedenen 
Zellmodellen gezeigt werden, z.B. THP-1 und U87MG, über knock-out durch 
CRISPR/Cas9, sowie shRNAs-induzierte Reduktion der Expression. Die 
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Resultate schliessen auf einen Defekt im Kerntransport von HIV-1 wenn SUN2 
abwesend ist, sowie eine dadurch resultierende Reduktion von 
Integrationsereignissen. Zusammenfassend scheint SUN2 die HIV-1 Infektion 
zu fördern, wobei die Rolle von SUN1 im Moment noch unklar ist und weiterer 
Studien bedarf. 
Die Rolle des CA Proteins von HIV-1, sowie eine mögliche Verbindung zur IFN-
alpha induzierten frühen Suppression der HIV-1 Infektion wurde ebenfalls 
untersucht. Dabei wurden verschiedene CA Mutanten (P90A, N74D, sowie 
A105T) analysiert. Erstaunlicherweise, trotz ihrer relative Resistenz gegenüber 
ektopischer Expression des IFN-induzierten Restriktionsfaktors MX2, waren all 
diese CA Mutanten hypersensitiv gegenüber IFN-alpha Behandlung, 
unabhängig von MX2. Die Resultate lassen darauf schliessen, dass CA nicht 
nur, wie bereits vorher beschrieben das virale Genom vor Wirtszellfaktoren 
schützt, welche die virale Nukleinsäure erkennen und eine antivirale Reaktion 
der Zellen hervorrufen, sondern auch beteiligt daran ist, das Virus vor eben 
diesen IFN-induzierten Restriktionsfaktoren zu schützen. Zukünftige Studien 
sollten darauf zielen, diese Wirtsfaktoren zu identifizieren und Strategien zu 
entwickeln, wie diese anti-HIV Faktoren als therapeutisches Mittel genutzt 
werden können.  
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3. Introduction 
3.1. Human immunodeficiency virus (HIV) 
3.1.1. Discovery of HIV as the cause of AIDS 
Human immunodeficiency virus (HIV) is the etiologic agent of acquired 
immunodeficiency syndrome (AIDS), a condition characterized by a progressive 
failure of the immune system that leads to opportunistic infections and even 
cancer. HIV infection occurs by body fluid contact, i.e., blood, semen, vaginal 
fluid, pre-ejaculate and breast milk, where the virus is present as both free virus 
particles and within infected cells. For this reason, the main routes of 
transmission are unsafe sex, contaminated needles, breastfeeding and 
perinatal transmission [1]. AIDS was first clinically recognized in 1981 in the 
USA, when an increasing numbers of young homosexual men died following 
unusual opportunistic infections and rare malignancies [2].  
In 1983, Francoise Barré-Sinoussi, Jean-Claude Chermann and Luc Montagnier 
from the Institute Pasteur in Paris identified and isolated, from the lymph node 
of a patient suffering from persistent generalized lymphadenopathy, a T-
lymphotropic retrovirus [3]. The isolate, named as LAVBRU, replicated very 
poorly in cell culture and was contaminated by a more rapidly and robustly 
replicating second AIDS isolate, named LAVLAI. Without knowing about this 
contamination, Luc Montagnier sent his first isolate LAVBRU to other labs 
including the lab of Robert Gallo at the U.S. National Institute of Health. On May 
4, 1984, Gallo and his collaborators reported the isolation of a T-cell tropic 
retrovirus robustly replicating in cell culture, named human T-cell lymphotropic 
virus type III (HTLV-III), which subsequently was identified to be identical to the 
isolate LAVLAI [4]. Assignment of priority for the discovery of HIV has been 
controversial. Montagnier's group had published their discovery a year and a 
half earlier than Gallo, but they reported that HIV's role in causing AIDS 
"remains to be determined”[5], whereas Gallo's group also demonstrated that 
the virus was the cause of AIDS. Furthermore, Gallo's lab developed the 
techniques for growing T cells and for virus isolation in the lab, used also by 
Montagniers’s lab [6] and that made the discovery possible. Subsequently, the 
chain of events was reconstructed by Simon Wain-Hobson’s lab [7] and in 2008 
Barré-Sinoussi and Montagnier obtained the Nobel Prize for Medicine for their 
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discovery. In 1986, the new virus was called human immunodeficiency virus 
because of its relatedness with a group of known lentiviruses. In 1986, a second 
distantly related human immunodeficiency virus (HIV-2) was isolated from AIDS 
patients in West Africa. HIV-2 displayed the same modes of transmission as HIV-1 
and was also associated with the development of AIDS and similar opportunistic 
infections, however in fewer numbers of infected people compared to HIV-1. 
Since HIV-1 is more virulent and has a higher transmission rate, it is the primary 
agent of AIDS worldwide while HIV-2 is restricted to Western and Central Africa 
[8].  
HIV infection is now at a pandemic scale and a major global public health issue 
(Fig. 1). By the end of 2017, HIV affected approximately 36.9 million people and 
caused more than 35 million deaths worldwide. In the same year, 1.8 million 
new infections were reported and a total of 940000 people died due to HIV-
related causes. Of all the HIV-infected patients, 17 million were on antiretroviral 
treatment [9]. The treatment relies on highly active antiretroviral therapy 
(HAART), which is a cocktail of at least three drugs targeting early stages of 
HIV-1 replication, thereby decreasing the viral load of the patient [10]. Due to its 
impact on human health and society, HIV-1 is the most extensively studied 
lentivirus today but is still only partially understood. 
 
Figure 1. Worldwide Human Immunodeficiency Virus (HIV) prevalence in adults aged 15 to 49, in 2017. 
Figure adapted from [9] 
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3.1.2. Retroviridae family and HIV classification 
HIV is an enveloped retrovirus, belonging to Lentivirus subgroup of the 
Retroviridae family. Viruses from the Retroviridae family display genomes that 
vary in complexity (Table 1). The Alpharetrovirus, Betaretrovirus, 
Epsilonretrovirus and Gammaretrovirus subgroups are characterized by a 
simple genome composed of the three main coding regions: gag (group specific 
antigen), pol (polymerase) and env (envelope), whereas Lentiviruses, 
Spumaviruses and Deltaretrovirus subgroups display more complex genomes 
that additionally code for a series of accessory proteins that are generated by 
multiple splicing [11-13]. Reverse transcription of the viral RNA genome by the 
viral enzyme Reverse Transcriptase (RT) represents the uniting feature of the 
family of Retroviridae [14, 15]. HIV-1 strains are classified in four groups: group 
M (main), group O (outlier), group N (non-M/non O) and group P. HIV-1 group 
M occurs worldwide and responsible for the majority of the global HIV epidemic, 
whereas HIV-1 groups N, O and P are confined to West-Central Africa. 
Similarly, HIV-2 strains are also classified in groups A-H [2], all confined to 
Western and Central Africa [8]. Each group of HIV-1 originated from 
independent transmission events across species from simian immunodeficiency 
virus (SIV) to humans [16]. A recently published study suggests that 
transmission of the HIV-1 group M to humans probably happened in the early 
1900s and the origin of the AIDS pandemic has been traced to the 1920s in the 
city of Kinshasa, Democratic Republic of Congo [17]. This area is known for 
many of the first registered cases of AIDS and for having a large genetic 
diversity in HIV strains, suggesting that SIV was transmitted to humans a 
number of different times [18]. Around 1960s, rapid population growth, rail link 
developments and emigration enabled the virus to spread to different regions. It 
is believed that the HIV-1 epidemic crossed the Atlantic and entered the USA 
around 1970s, via New York City, from a pre-existing Caribbean epidemic [19]. 
Although its relatedness to HIV-1 was only discovered in 1986 [20], one of the 
oldest known lentiviruses is the equine infectious anaemia virus (EIAV), 
discovered in 1904 as a filterable agent causing autoimmune haemolytic 
anaemia in horses [21]. After the discovery of HIV, similar lentiviruses were 
identified in cats and in diverse non-human primates, respectively named feline 
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immunodeficiency virus (FIV) [22] and simian immunodeficiency virus (SIV) [23-
26]. 
 
Table 1. Classification of retroviruses by genera and genome type. Simple genome 
retroviruses have gag, pol and env genes, which encode matrix, capsid, nucleoprotein, integrase, 
protease, reverse transcriptase and Env proteins. Complex genome retroviruses additionally have 
regulatory and accessory genes, which encode proteins that increase their infection and replication 
abilities. Gag expression vectors from bold highlighted viruses have been analyzed in this study 
Genera Species Genome type 
Alpharetrovirus Avian leukosis virus 
Rous sarcoma virus 
Simple 
Betaretrovirus Mouse mammary tumour virus 
Mazon-Pfizer monkey virus 
Simple 
Deltaretrovirus Human T-Lymphotropic virus 
Bovine leukaemia virus 
Complex 
Epsilonretrovirus Wallabee dermal sarcoma virus Simple 
Gammaretrovirus Murine leukaemia virus 
Feline leukaemia virus 
Simple 
Lentivirus Human immunodeficiency virus 1 
Human immunodeficiency virus 2 
Simian immunodeficiency virus 
Equine infectious anemia virus 
Feline immunodeficiency virus 
Complex 
Spumavirus Human foamy virus Complex 
 
3.1.3. Genome organization and structure of HIV-1 
The HIV-1 genome consists of two copies of positive sense unspliced single 
stranded RNA. Like cellular mRNAs, both viral RNA molecules are 5’ capped 
with 7-methylguanosine and possess a 3’ polyA tail. They are around 10kb in 
length and able to dimerize through their dimer initiation sites [27]. The viral 
genomic RNAs are packaged into the nascent HIV-1 particles during replication 
and are the template for reverse transcription in infected cells, generating viral 
DNA that is integrated into the host genome establishing a provirus. They 
contain cis-acting elements like the trans-activating responsive region (TAR), 
the Rev responsive element (RRE), the primer binding site (PBS), packaging 
signal (Ψ), a 3’ and the central polypurine tracts (PPT), that are required for 
different steps during the virus life cycle. The viral genome (Fig. 2) consists of 
three structural genes (gag, pol and env), two regulatory genes (tat, rev) and 
four accessory genes (nef, vif, vpr and vpu). There are two long terminal repeat 
sequences (LTRs) of about 600 nucleotides at the 5' and 3' ends, each 
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composed of three subregions (U3, R, and U5), which have an essential role in 
reverse transcription and integration of the viral genome into host DNA. The 5’ 
LTR also contains promoter elements that drive transcription, while both the 
sequences are characterized by complementary regions at the 5’ and 3’ termini 
that serve as self-priming sequences during the reverse transcription process 
[28]. All the proteins are expressed from different splice forms of a single RNA 
transcript and are important for a natural occurring infection. 
 
                   
Figure 2. Genome organization of HIV-1. Structural genes (gag, pol and env), two regulatory genes 
(tat, rev) and four accessory genes (nef, vif, vpr and vpu). The gag gene comprises MA (p17), CA (p24), 
NC (p7) and p6. The pol gene comprises RT (p66/51), RNAse H (p15) and IN (p31). The env gene 
comprises SU (gp120) and TM (gp41), the two components of viral Env protein. Viral cis acting elements 
include the two long terminal repeats (LTR’s), the trans-activating responsive region (TAR) required for Tat 
binding and transcription activation, the Rev responsive element (RRE) required for Rev binding and 
nuclear export of partially spliced and unspliced RNAs, the primer binding site (PBS), RNA packaging 
signal (Ψ), a 3’ and the central polypurine tracts (PPT). Figures derived from [28] 
The gag gene encodes a 55kDa precursor polyprotein Gag (group-specific 
antigen) that comprises independently folded domains connected by flexible 
linkers: matrix (MA), capsid (CA), nucleocapsid (NC) and p6. Two spacer 
peptides are located between CA and NC (SP1) and between NC and p6 (SP2) 
(Fig 3A) [29]. Every domain of Gag fulfills a variety of functions during the viral 
replication cycle. MA protein (p17) contains a highly basic region (HBR) [30, 31] 
and a co-translationally attached myristoyl residue, both required for membrane 
targeting and binding [32-35]. Furthermore, MA is also responsible for the 
incorporation of the Env glycoprotein spikes into viral particles [36-38]. CA 
protein (p24) drives Gag assembly, builds the viral core in mature particles and 
regulates the import of the viral genome into the nucleus of infected cells [39]. 
The protein is composed of two domains, the amino‐terminal domain (CA-NTD) 
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and the carboxy‐terminal domain (CA-CTD) connected by a flexible hinge 
region. The CA-NTD is formed by six to seven α-helices and a flexible loop 
region involved in binding of cellular host factors, like cyclophilin A (CypA) [40]. 
The CA-CTD is constituted by four α-helices and contains the major homology 
region (MHR), a stretch of approximately 20 well conserved residues that 
represents the second most conserved region of retroviruses after RT [41]. NC 
(p7) is a nucleic acid binding protein composed of a domain containing 
positively charged regions and one or two zinc-finger like motifs required for 
recruiting and binding of viral RNA [42]. It also has a nucleic acid chaperone 
activity [43]. Phosphoprotein p6 is responsible for the recruitment of the ESCRT 
(endosomal complex required for transport) machinery during particle release 
and incorporates Vpr into the virion [44].  
The pol gene encodes enzymes that are necessary for viral replication: 
protease (PR), reverse transcriptase (RT) and integrase (IN). For the 
expression of the pol gene, HIV-1 utilizes a programmed ribosomal 
frameshifting that occurs at the slippery site in the p6 sequence, allowing the 
translation to continue to pol and generate the 160kDa GagPol polyprotein. This 
mechanism permits the virus to translate structural and enzymatic domains in a 
defined proportion required for replication [45]. PR is active as a dimer and 
mediates the proteolytic maturation of newly formed HIV-1 particles by cleaving 
Gag at five and GagPol at nine distinct positions, leading to a complete 
remodelling of the virus architecture [46, 47]. The order of cleavage is 
conserved and starts with processing between SP1 and NC and ends with 
removal of the SP1 peptide from CA [48, 49], which triggers rearrangement of 
an immature lattice into the final mature conical shape (Fig. 3B) [50]. 
Proteolytic processing of viral polyproteins is essential for HIV-1 infectivity [32, 
51, 52]. RT is the enzyme essential for generating viral double-stranded cDNA 
from the single-stranded genomic RNA template, in a process named reverse 
transcription. This enzyme acts as an asymmetric p51/ p66 heterodimer and 
has three activities: RNA-dependent DNA polymerase activity, RNaseH activity 
for RNA digestion and DNA-dependent DNA polymerase activity [53]. IN is the 
enzyme required for the viral genomic cDNA to be integrated into the host cell 
genome, establishing the provirus. The enzyme acts as tetramer and consists of 
an amino-terminal zinc-binding domain that probably supports the 
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multimerisation, a central catalytic domain and a carboxy-terminal DNA binding 
domain that associates non-specifically with DNA [54].  
The env gene encodes the precursor polyprotein gp160, which is synthesised in 
the rough endoplasmic reticulum where it is heavily glycosylated at asparagine 
residues. Gp160 then transits the Golgi apparatus where the mannose 
glycosylation is further refined [55, 56] and is cleaved by cellular protease furin 
into surface glycoprotein (SU or gp120) and transmembrane protein (TM or 
gp41) [57, 58]. Mutations that alter the cleavage of the precursor polyprotein 
gp160 or that alter the association of the gp120 and gp41 subunits render HIV 1 
non infectious [59]. Both proteins remain non-covalently attached and are 
transferred to the plasma membrane where three gp120 and two gp41 
glycoproteins combine in a trimer of heterodimers to form the envelope spike 
(Fig. 3B). Each newly formed virion incorporates between 10 and 100 trimers of 
gp120/gp41, depending on the isolate [60]. Gp120 protein domain is 
responsible for target-cell recognition and viral tropism and was one of the first 
targets of HIV vaccine research, but the conserved regions shielded by variable 
loops and the extensive glycosylation makes the neutralization by antibodies 
extremely difficult [61]. The glycoprotein gp41 anchors Env in the viral 
membrane and promotes fusion of the viral and target cell membranes [62].  
In addition to the structural proteins and viral enzymes, HIV-1 encodes 
accessory proteins Vpu, Vif, Vpr and Nef, which interact with diverse host 
factors at different stages of the viral life cycle (Fig. 9) with the aim to contrast 
their antiviral activity and promote the infection [63]. Furthermore, Tat and Rev 
are encoded which are required for viral transcription and export of mRNA from 
the cellular nucleus, respectively [64]. 
HIV forms spherical particles with a diameter of about 120-140 nm that are 
enveloped by a phospholipid bilayer membrane derived from the host cell 
plasma membrane. Viral particles released from infected cells are in an 
immature and non-infectious state, where together with GagPol forms a curved 
hexameric lattice underneath the viral envelope, in which MA interacts with the 
membrane, CA forms important protein–protein lattice contacts and NC, bound 
to the viral genome, is located toward the center of the particle. The released 
immature Gag shell comprises a large gap that define the shape of a truncated 
spherical structure (Fig. 3B) [65-67]. Proteolytic processing of Gag and Gag-Pol 
   
8 
 
during viral maturation, leads to a rearrangement of the single structural 
proteins where MA remains associated with the viral envelope, whereas NC and 
the vRNA form a condensed ribonucleoprotein complex surrounded by the CA 
cone-shaped core (Fig. 3B) [46, 47]. Only through the maturation process the 
HIV-1 particle acquires infectivity and a new virion is born [32, 51, 52].  
 
 
 
Figure 3. Structure of HIV-1. A) HIV-1 Gag polyprotein domain structure, showing the locations of MA, 
CANTD, CACTD, SP1, NC, SP2, and p6. Arrows indicate the PR cleavage sites and numbers show the 
order of cleavage. B) After budding from the plasma membrane, immature HIV-1 particles contain 
uncleaved Gag and GagPol proteins. The viral RNA dimer is associated with the NC domain of Gag. In 
mature virions, MA remains associated with the viral lipid envelope, NC coats the viral RNA genome, and 
the liberated CA proteins reassemble into the mature conical capsid enclosing viral genomic RNA and 
enzymes. C) Cryo-EM tomograms showing the central slice of an immature and mature HIV-1 particle [47]. 
Gag subunits in illustrations are color-coded according to (A). Figure adapted from [68] 
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3.2. HIV-1 replication 
The life cycle of HIV-1 (Fig. 4) can be divided in an early and a late phase. 
During the early phase, the virus infects and integrates the viral genomic DNA 
into the target cell genome establishing the provirus. In the subsequent late 
phase, the virus employs and manipulates the transcriptional and translational 
machinery of the host cell to produce the progeny virus particles. The typical 
characteristic of lentiviruses is that they cause persistent infections, 
characterized by a latent state between the two life cycle phases during which 
the integrated virus genome is silenced but conserves the potential to 
reactivate, resume replication and produce new infective viral particles.  
     
Figure 4. HIV-1 life cycle. Schematic representation of HIV-1 infection. In the early phase, after fusion 
of the HIV-1 virion via CD4 and CXCR4 or CCR5 co-receptor engagement, the viral core is released into 
the cytoplasm where it initiates its trafficking toward the nucleus, during which the capsid core starts 
disassembling (uncoating) and the RNA genome is reverse transcribed by RT in double stranded DNA. 
Subsequently, the established PIC enters the nucleus through the NPCs and integrates the viral DNA into 
cellular chromatin. In addition, circularised viral DNA (2-LTR circles) is found. Integrated viral DNA can be 
silenced through various epigenetic mechanisms, leading to the creation of silent viral reservoirs (proviral 
latency). Alternatively, in the subsequent late phase, viral transcription is followed by splicing and nuclear 
export of viral mRNAs with the aid of Rev (Rev independent: Tat, Rev, Nef), which are translated into Gag, 
GagPol and Env proteins. Full-length viral genome RNAs are also packaged into new viral particles during 
assembly at the plasma membrane. Budding of new viral particles from the plasma membrane is mediated 
by the host ESCRT-I/II/III and is followed by a maturation process during which the viral particles become 
infectious following the proteolytic cleavage of Gag. Figure modified from [69] 
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The HIV-1 life cycle starts with the interaction of gp120 viral proteins with CD4+ 
receptor of the target cell. Upon binding to one of the two co-receptors, CXCR4 
or CCR5, the fusion of viral and cellular membranes is promoted and is followed 
by the entry of the viral core in the cytoplasm, where the viral RNA genome 
(vRNA) is reverse-transcribed to proviral cDNA by the viral RT. Once 
synthetized, the viral cDNA is transported to the nucleus and is integrated into 
the cellular genome with the help of the viral IN [69]. Integrated viral DNA can 
be silenced through various epigenetic mechanisms, leading to the creation of 
silent viral reservoirs (proviral latency). Alternatively, upon cell activation, 
transcription factors may be recruited to the promotor in the 5’LTR and initiate 
the expression of proviral genes [70]. Early transcription leads to expression of 
Tat and Rev regulatory proteins. Tat is essential for efficient LTR-dependent 
expression of all HIV-1 proteins and the unspliced genomic RNA, whereas Rev 
is required for the nuclear export of both unspliced viral mRNAs encoding Gag 
or Gag-Pol, and singly spliced viral mRNAs encoding the viral Env or the singly 
accessory proteins Vif, Vpr and Vpu [71, 72]. Env is synthesized on ER-
associated ribosomes and is transported to the plasma membrane via the 
secretory pathway [73], while Gag and Gag-Pol are synthesized on free 
ribosomes in the cytoplasm and are targeted to the plasma membrane after 
myristoylation and selective binding of two copies of the single stranded RNA 
genome [74]. HIV-1 assembly occurs predominantly in cholesterol and 
sphingolipid rich lipid rafts [75], where the interaction of highly HBR region of 
Gag with phosphatidylinositol 4,5- bisphosphate (PI(4,5)P2) leads to an 
exposition of the N-terminal myristoyl group that gets anchored in the plasma 
membrane [35]. Extensive multimerization of Gag and GagPol proteins drives 
the formation of a hexameric lattice with small irregular defects that defines the 
shape of the the nascent HIV-1 bud at the cell membrane [67]. Further viral and 
cellular components including the viral Pol and Env proteins as well as the 
accessory proteins Vif, Nef and Vpr are recruited to the assembly sites [47]. The 
release of the the newly assembled HIV-1 particles from the plasma membrane 
is mediated by the cellular ESCRT machinery through a fission process, 
following the direct interaction between the C-terminal p6 domain of HIV-1 Gag 
with the proteins Tsg101 and Alix [76]. Cellular proteins, such as CypA [77] and 
APOBEC3G [78-82] are also packaged into HIV-1 budding virions. Initially, the 
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newly formed particles have a non-infectious immature morphology where Gag 
shell is only 70% complete, forming a truncated sphere (Fig. 3B), presumably 
derived from the ESCRT mediated particle release prior to assembly of the 
complete sphere [65-67]. During or concomitant with viral particle release from 
the infected cell, PR is activated and cleaves Gag as well as Gag- into their 
components (as described in 3.1.3.) leading to the dramatic morphological 
changes required for creation of a mature, infectious virion (Fig. 3B) [46, 47]. 
 
Since the early steps of HIV-1 life cycle represent the major focus of this thesis, 
the following sections give a more detailed introduction. 
3.2.1. Attachment of HIV-1 and cell entry 
HIV-1 infects CD4+ T cells and, to a lesser extent, macrophages using CD4 as 
a receptor [83]. In addition to CD4, the binding to either CCR5 or CXCR-4 as 
co-receptor is required for infection [84, 85]. CD4 is a type I transmembrane 
glycoprotein of 58 kDa member of the immunoglobulin (Ig) superfamily and 
contains four immunoglobulin domains (D1 to D4) that are exposed on the 
extracellular surface of the cell. CD4 acts as a co-receptor that amplifies the 
intracellular signal coming from the T cell receptor (TCR) when it binds to the 
peptide antigen bound to major histocompatibility (MHC) class II molecule on an 
antigen-presenting cell (APC) [86]. The role of CD4 in the life cycle of HIV-1 
was first identified when CD4+ Jurkat T cells developed very large 
multinucleated syncytia in response to HIV-1 glycoproteins [83, 87]. The role of 
HIV-1 co-receptors CXCR-4 and CCR5 was later recognized in 1996 [84, 85]. 
CXCR-4 and CCR5 are integral membrane proteins that belong to the 
chemokine receptor family [88]. Furthermore, the chemokine receptor CCR3 
has also been suggested as co-receptor for HIV-1 [89]. Depending on which co-
receptor is used for the entry, the viruses can be differentiated as CCR5 tropic 
and CXCR-4 tropic or as dual tropic. The importance of the co-receptor for HIV-
1 infection is highlighted by the findings that a homozygous 32 bp deletion in the 
coding region of CCR5 genes leads to a truncated and non-functional receptor, 
which render some people partially resistant to HIV-1 infection [90, 91].  
HIV-1 cell entry involves binding of the trimeric viral envelope glycoprotein 
gp120/gp41 (as described in 3.1.3) to the cellular receptor/co-receptor complex. 
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During the first step gp120 binds to CD4 (Fig. 5A), which causes a 
conformation change in gp120 and exposes a binding V3 loop that attaches to 
the co-receptor (Fig. 5B). Binding to the co-receptor induces a series of 
conformational changes, which lead to the exposure of the gp41 fusion peptide 
and the formation of a gp41 helix bundle intermediate that permits the annealing 
of virus and target cell membranes (Fig. 5C). The gp41 fusion peptide inserts 
into the cell membrane, leading to the fusion of the virus membrane with the 
target cell membrane and formation of a fusion pore [92]. The fusion of viral and 
target cell membranes has been shown to occur in endosomes and not directly 
at the plasma membrane [93]. However, endocytosis does not significantly 
contribute to productive infection in T cells [94].  
              
Figure 5. HIV-1 entry. A) HIV-1 attaches to cell membrane associated CD4 via the gp120 protein.   
B) Attachment brings the virus closer to the cell membrane and induces a conformational change in the 
gp120 protein allowing coreceptor binding, mediated in part by the V3 loop of gp120, and the subsequent 
exposure of the gp41 fusion peptide that inserts into the target cell membrane. C) Formation of a helix 
bundle leads to annealing of virus and cell membranes causing membrane fusion, which may occur after 
endocytosis. Figure modified from [95] 
 
Host factors can also negatively influence HIV-1 entry. Serine incorporator 3 
and 5 (SERINC3/5 ) [96, 97] and interferon-induced transmembrane (IFITM) 
[98-100] proteins are incorporated into budding HIV-1 virions and prevents 
fusion of the viral envelope with the plasma membrane (Fig. 9). SERINC3/5 are 
counteracted by HIV-1 accessory protein Nef [96, 97]. 
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3.2.3. Trafficking toward the nucleus and reverse transcription 
of HIV-1 
The fusion of the viral and cellular membrane leads to the release of the viral 
core into the cytoplasm where reverse transcription occurs. In this process, viral 
RNA genome is transcribed by the viral RT into double-stranded cDNA [14, 15].  
During its trafficking toward the nucleus, the viral core follows a highly ordered 
disassembly process, named uncoating, which is essential for an optimal 
delivery of viral DNA to the nucleus in target cells. This process is characterized 
by an accurate and balanced stability of the viral core, which ensures a 
structural opening for an efficient reverse transcription [101], as well as a proper 
shielding from host factors, such as innate sensor cGAS [102-104] or cytosolic 
exonuclease TREX1 [105], which can detect viral RNA/DNA intermediates and 
induce an antiviral response with production of type I interferons (IFN) [102-
104]. Evidence suggest that the HIV-1 core likely interacts with multiple host cell 
factors capable to benefit the uncoating process and ensure a proper trafficking 
of the viral core to the nucleus. Cyclophilin A (CypA) is a peptidyl-prolyl ci-trans 
isomerase that has been shown to promote HIV-1 replication in some target cell 
types through its direct interaction with CA [77, 106, 107]. CypA binds a 
conserved proline rich NTD loop on HIV-1 CA [40, 108, 109] and catalyzes the 
cis-trans isomerization of the peptide bond between residues G89 and P90 
[110]. The inhibition of CypA binding to CA through treatment of infected cells 
with cyclosporin A (CsA) reduces HIV-1 reverse transcribed DNA levels, 
indicating that CypA may influence uncoating and hence reverse transcription 
[111, 112]. Interestingly, infection by the closely related virus HIV-2 induces 
type 1 IFN production in DCs [103, 113] but the introduction of a HIV-1 CypA-
binding loop in HIV-2 CA suppressed its IFN activation [103]. The cyclophilin-
binding loop CA mutant P90A binds with lower affinity to CypA, and is resistant 
to CypA-mediated isomerization of the G89-P90 peptide bond in CA [114-116]. 
Reverse transcription occurs in a complex of viral and cellular RNA and 
proteins, referred to as the reverse transcription complex (RTC) that is thought 
to arise as a result of the viral core uncoating [117]. During this process an 
aberrant circularised form with a single LTR (1-LTR circle) can form through 
recombination of the LTRs. In addition, cellular DNA repair enzymes of the non-
homologous end-joining pathway can join ends of the linear DNA molecule and 
   
14 
 
generate a second circular form denoted as 2-LTR circles. The formation of 
2-LTR circles is considered a marker for nuclear entry since it involves ligases 
Ku70 and Ku80, which are nuclear enzymes [118].  
The host factor apolipoprotein B mRNA editing enzyme, catalytic polypeptide-
like 3G (APOBEC3G) can prevent production of functional viral proteins by 
inducing G to A hypermutations during reverse transcription process, whereas 
sterile α motif and histidine-aspartate domain-containing protein 1 (SAMHD1) is 
a deoxynucleotide-triphosphohydrolase that inhibits reverse transcription by 
depleting the pool of cellular deoxynucleotide triphosphates (dNTPs). 
APOBEC3G is counteracted by HIV-1 accessory protein Vif [119-121] whereas 
SAMDH1 is counteracted by HIV-2/SIV accessory protein Vpx [122, 123] (Fig. 
9).  
3.2.4. Nuclear import of HIV-1 PICs 
After HIV reverse transcription, an integration-competent nucleoprotein 
complex, named pre-integration complex (PIC), is established. Viral elements 
associated with the PIC, such as MA [124], IN [125, 126] and Vpr [127-129], 
contain nuclear localization signals (NLS) and have been proposed to mediate 
nuclear localization of the HIV-1 complex. 
HIV-1 and other lentiviruses are able to productively infect non-dividing 
cells nearly as well as dividing cells by using active transport [130-135]. On the 
other hand, other retroviruses, such as the murine leukemia virus (MLV), 
require cell division and the nuclear envelope breakdown to reach the target cell 
DNA and finalize the infection. Several data indicate that the main determinants 
for infection of non-dividing cells are mapped in CA [136-138]. Furthermore, it 
has been observed that nuclear PICs were almost always CA-positive in 
monocyte-derived macrophages [139, 140], suggesting that even if disassembly 
of the conical capsid structure takes place before the nuclear import, CA or a 
CA-like structure remains associated with the PIC likely to facilitate downstream 
steps in viral replication. Several host factors interacting with CA have been 
implicated in nuclear translocation of the viral genome. HIV-1 PIC is thought to 
be actively guided to enter the nucleus by passing through nuclear pore 
complex (NPC) [141-144] (Fig. 6, Fig. 7). NPCs are large macromolecular 
channels that span the nuclear envelope (NE) and mediate the bidirectional and 
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selective transport of cargoes between the nucleus and cytoplasm [145, 146]. 
NPC consists of an approximately cylindrical central framework, residing within 
the NE and containing cytoplasmic and nuclear ring moieties, eight cytoplasmic 
filaments and a nuclear basket that is composed of eight filaments that join into 
a distal ring (Fig. 6) [147]. Nucleoporins (Nups) are the molecular building 
blocks of the NPC and comprise ~30 different proteins, a subgroup of which 
contains phenylalanine-glycine (FG) repeats that project from both the 
nucleoplasmic and cytoplasmic regions creating a hydrophobic meshwork that 
functions as a docking platform for receptor-cargo complexes and plays an 
important role in modulating the selectivity and the kinetics of nucleocytoplasmic 
transport [148-150]. 
 
         
Figure 6. Structure of the nuclear pore complex (NPC). The main components of the pore include the 
central framework (yellow), the cytoplasmic ring moiety and attached filaments (blue), the nuclear ring 
moiety and the distal ring of the nuclear basket (orange). Nuclear membranes are depicted in grey. Figure 
derived from [151] 
 
Two components of NPCs, Nup358 and Nup153, were identified by three 
genome wide screens aiming to identify cellular factors required for HIV-1 
infection [152-154]. Nup358 [141-143] is the main cytoplasmically-oriented 
component of the NPC and possesses a CypA-domain that can bind HIV-1 CA 
[141] but is not required IN Nup358 for HIV-1 infection [155]. Knockdown 
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studies have revealed that depletion of Nup358 lead to a 6 to 8-fold reduction of 
HIV-1 infectivity with unaltered reverse transcription and reduced 2-LTR circle 
formation, suggesting that the anti-viral effect is linked to nuclear entry of the 
virus [141, 156, 157]. Interestingly, immunofluorescence analysis based on CA 
staining at 6 hpi showed that depletion of Nup358 leads to a decrease in 
perinuclear CA signal, suggesting that this cytoplasmically-oriented nucleoporin 
may be involved in HIV-1 docking at the nuclear envelope [156]. Nup153 
localizes to the nucleoplasmic side and directly binds CA through its FG repeats 
[144]. In addition, Nup153 shRNA-mediated depletion led to a reduction of HIV-
1 infectivity with reduction of of 2-LTR circles formation and unalterated reverse 
transcription [156, 158, 159], indicating that this nucleoporin also plays a role in 
viral nuclear entry. Thus, it is suggested that both Nup358 and Nup153 play 
distinct roles in HIV-1 nuclear entry. While Nup358 may mediate HIV-1 PIC 
docking at the nuclear pore, Nup153 may play an active role required for HIV-1 
PIC to enter the nucleus and finalize the infection [160]. Other NPC related 
proteins Nup98 and Nup214 have also been proposed to have a role in HIV-1 
infection [156, 158, 161]. Interestingly, the knockdown of Nups 98 and 214 
leads to reduction of HIV-1 infectivity but doesn't affect nuclear entry, as 
assessed by measuring 2-LTR circles in infected cells [156, 158]. However, the 
exact mechanism for nuclear transport of PIC through the NPC remains to be 
investigated. 
The importin-β-like karyopherin TNPO3 and the cleavage and polyadenylation 
specific factor 6 (CPSF6) (Fig. 7, Fig. 8) are other host factors that have been 
shown to be involved in HIV-1 infection and whose viral determinants have 
been mapped to the CA protein [152, 162-166]. TNPO3 is a karyopherin that 
binds arginine/serine-rich splicing factors (SR proteins) promoting their nuclear 
import. Studies have suggested that TNPO3 binds to HIV-1 CA [167, 168] and 
that TNPO3 depletion restricts HIV-1 infection with a decrease of 2-LTR circle 
formation [141, 157, 169], indicating a role of this karyopherin in the nuclear 
translocation of the viral PIC. However, it has been suggested that TNPO3 
might promote HIV-1 nuclear import only indirectly [167, 169]. CPSF6 is a pre-
mRNA splicing factor that shuttles between nucleus and cytoplasm [170] with a 
carboxy-terminal nuclear-targeting arginine/serine-rich (SR) domain [140, 164]. 
CPSF6 was found to be involved in HIV-1 infection through a cDNA expression 
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screen for host restriction factors [163]. The screen identified a carboxy-
terminally truncated CPSF6 lacking the SR domain (CPSF6-358). This protein 
accumulated largely in the cytoplasm and was a strong inhibitor of HIV-1 
infection with reduction of of 2-LTR circles formation, indicating impairment of 
the viral nuclear entry. Additionally, this phenotype was observed also against 
other primate lentiviruses, such as HIV-2 and SIV but not against MLV [163], 
suggesting that CPSF6 plays a role in the ability of primate lentiviruses to infect 
non-dividing cells. Of particular interest, the HIV-1 CA mutation N74D disrupt 
the interaction between CA and CPSF6-358 and the consequent viral restriction 
is abolished [163, 164]. N74D CA mutant infectivity is unaffected by TNPO3 
depletion, Nu358 depletion and Nup153 depletion [163, 167, 168, 171, 172], 
suggesting that this CA mutant may enter the nucleus using another pathway. 
Additionally, A105T CA mutantion has been shown to render HIV-1 resistant to 
inhibition by CPSF6-358 [169]. Intriguingly, CPSF6 depletion had no effect in 
HIV-1 infectivity, suggesting that endogenous CPSF6 is not fully essential for 
HIV infection [163, 173]. 
The roles of TNPO3 and CPSF6 in HIV-1 infection are now considered 
interconnected: CPSF6-mediated import of the PIC to the nucleus requires 
TNPO3, which transports CPSF6 and other SR-family proteins to the nucleus. It 
has been showed that, in TNPO3 depleted cells, endogenous CPSF6 does not 
localize at the nuclear envelope and remains mostly cytoplasmic, such as its 
truncated mutant. However, in this cells HIV-1 infectivity is rescued when 
ectopically-expressed CPSF6 is retargeted to the nuclear envelope, suggesting 
that infectivity decrease in TNPO3-depleted cells may be a consequence of the 
cytoplasmic re-localization of endogenous CPSF6 [169]. CPSF6 is indeed 
capable of inhibiting HIV-1 replication only when it accumulates in the cytosol, 
where it binds to CA via the pocket where N74 and A105 are located [163], thus 
stabilizing the HIV-1 CA core and inducing a delay in uncoating and in nuclear 
import of the PIC. Therefore, it is conceivable that TNPO3 promotes HIV-1 
infectivity indirectly, by shifting the CA-binding protein CPSF6 to the nucleus 
thus preventing its interaction with HIV-CA.  
Since viral nuclear entry is reduced and not entirely suppressed, it is possible 
that other host partners besides Nups, CPSF6 and TNPO3 may be involved 
during this stage. 
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3.2.5. Integration of HIV-1 DNA into the host genome 
For a productive infection the viral double stranded linear DNA molecule has to 
integrate into the host genome establishing a provirus. The HIV-1 PIC does not 
integrate randomly into the host genome but prefers transcriptionally active 
regions [174], in close correspondence with the NPC [175] (Fig. 8). Particularly, 
it has been demonstrated that Nup98, Nup153 [156, 158] and Nup358 [141, 
176] influence HIV-1 integration by favouring the integration in transcriptional 
units and in regions characterized by an open chromatin configuration [141, 
156, 158, 176]. Furthermore, translocated promoter region (TPR) (Fig. 8), a 
protein of the inner basket of the NPC, has been suggested to be involved in 
regulating the expansion of heterochromatic regions in proximity to the NPC 
and depositing open chromatin marks on HIV-1 target genes [177, 178]. 
Therefore, HIV-1 nuclear import pathway seems to be directly linked to 
integration site selection [141]. Additionally, depletion of endogenous CPF6 
resulted in a redistribution of HIV-1 integration sites away from transcriptionally 
active genes, thus providing clear evidence for an important role for 
endogenous CPSF6 (Fig. 7 and Fig. 8) in directing HIV-1 integration into 
actively transcribing genes, despite there were not relevant change in infection 
[179, 180]. 
Another important factor that dictates the target site preferences of HIV 
integration is the host chromatin binding protein lens epithelium-derived growth 
factor p75 (LEDGF/p75) product of the PSIP1 gene (Fig. 7 and Fig. 8), which 
binds lentiviral IN [181, 182] and mediates IN-chromatin binding [183, 184]. 
Studies showed that in the absence of LEDGF/p75, HIV integration in 
transcription units is severely compromised [185-187]. Furthermore, TPR 
stabilizes LEDGF/p75 in the nuclear periphery [177], suggesting that the two 
proteins may work together to direct HIV-1 DNA preferentially into regions of 
open chromatin and transcriptionally active sites in the outer shell of the 
nucleus, in proximity to the NPC 
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Figure 7. HIV-1 nuclear import of pre-integration complex (PIC). The capsid of HIV-1 is an 
important viral factor for both uncoating and nuclear entry of the PIC. Other viral factors like Vpr, MA and 
IN are also involved in entry of PIC into the nucleus. Different cellular factors such as CypA, NUP358 
(RANBP2), NUP153 and CPSF6 play also roles in the nuclear entry of the PIC on the cytosolic side of the 
NPC. TNPO3 is involved in shuttling through the NPC. NUP153 and CPSF6 have a role in target site 
selection, together with LEDGF, which is the most important chromatin-tethering factor involved in HIV-1 
integration. Figure derived from [188] 
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Figure 8. HIV-1 integration at the nuclear periphery. Binding of the chromatin-tethering factor 
LEDGF to HIV-1 IN and binding of CPSF6 to the CA lead to HIV‐1 integration into transcriptionally active 
genes and regions of open chromatin. Furthermore, NUP153, NUP98 and TPR also play an important role 
in HIV-1 integration, which preferentially occurs in the outer shell of the nucleus in proximity to the NPC. 
Intriguingly, TPR is a protein of the inner basket of the NPC that regulates the expansion of 
heterochromatic regions in proximity to the NPC and deposits open chromatin marks on HIV-1 target 
genes. 1 μm beneath the nuclear envelope. LAD, lamin-associated domain. Figures derived from [188] 
 
Viral DNA integration occurs with the activity of the viral enzyme IN (see 
paragraph 3.1.3), which promotes two distinct reactions. First, the enzyme 
removes di- or trinucleotides from double stranded viral DNA ends to expose 3′-
hydroxyls from the conserved CA dinucleotides (3′-processing reaction). 
Second, in a reaction named strand transfer, a phosphodiester bond in the host 
genomic DNA is attacked by the two reactive hydroxyl-groups previously 
created.  Subsequently, IN ligates the viral DNA into the host DNA, generating a 
five base pairs single-stranded DNA segment at each end of the host DNA and 
a two nucleotide 5’ viral DNA flap. After that, the cellular DNA repair machinery 
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fills the gaps and ligates the synthesised DNA into the host genome [189]. In 
addition, tetrameric IN complexes have been shown in vitro to cleave the 
junction sequence between two LTRs leading to the linearization of 2-LTRc 
circles [190].  
 
3.3. HIV-1 and host immunity 
The mammalian immune system comprises an adaptive and an innate 
component and both are essential for efficient protection from infection by 
pathogens, such as viruses or bacteria.The innate immunity is the first line of 
host defense and involves multiple mechanisms and cells (macrophages, DCs 
and natural killer cells (NKs)) that act rapidly to restrict virus replication and to 
provide time for the organism to activate the second arm of defense, the 
adaptive immune system. This operates through selection and expansion of T 
and B cells and the production of specific antibodies directed against the 
invading pathogen. Furthermore, it prepares the host for future challenges by 
generating an immunological memory that enhances the host response to 
subsequent encounter with the same pathogen [191]. Activation of B and T 
lymphocytes relies on antigen-presentation, a process that is taken by 
professional antigen-presenting cells (APCs) such as DCs, macrophages and B 
cells. These cells internalize and process exogenous antigens into peptides and 
display them complexed with MHC class II on the surface, which are recognized 
via TCR expressed by helper CD4+ T cells that have the crucial role of assisting 
other leukocytes, as it is the case of antibody secretion by B cells [192]. 
Whereas all nucleated cell types can present on their surface antigens 
originating inside the cell and complexed with MHC class I, which are then 
recognized by TCR expressed on the surface of CD8+ cytotoxic T lymphocytes 
(CTLs), that induces programmed cell death to the target cells [193]. 
3.3.1. Innate immunity against retroviruses 
The main innate immune response is inflammation, which is initiated by the 
recognition of pathogen-associated molecular patterns (PAMPs), by the pattern 
recognition receptors (PRRs), such as toll-like receptors (TLRs), receptors 
present on macrophages and DCs. This recognition allows cell activation and 
release of inflammatory cytokines, like TNF-α, IL-1 and the production of IFNs, 
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small molecules that are able to induce an antiviral state in the proximity of an 
infection [194].The innate immune system of mammals also comprises a 
diverse group of intracellular factors, named restriction factors, which are able 
to efficiently counteract viral infection in several ways. These factors are 
generally interferon inducible and their expression is upregulated during early 
infection. They often operate in a species-specific way; however, they may also 
block viruses from related species. Since host restriction factors present a major 
hurdle to incoming virions, it is not surprising that virus species have evolved 
measures to counteract host restriction factors. The simultaneous evolution of 
host-encoded restriction factors and the corresponding viral counter measures 
causes host and pathogen to co-evolve and leads to an evolutionary arms race. 
 
Studies on retroviruses have revealed many of the molecular mechanisms that 
underpin our understanding of these viral countermeasures. By understanding 
the antagonistic relationship between restriction factors and their viral 
countermeasures is not just an academic exercise, but has also enabled the 
development of drug targets for diseases like AIDS [195]. Known retroviral 
restriction factors and viral countermeasures to prevent or inhibit these factors 
are depicted in Fig. 9. 
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Figure 9. Host retroviral restriction factors and countermeasures by viral accessory 
proteins. Cellular antiviral factor are highlighted in red, while countermeasures by viral accessory 
proteins are highlighted in blue. Innate DNA sensor (cGas, IFI16) and the cytosolic exonuclease TREX1 
and SLX4 endonuclease complex are also shown. Figure modified from [196] 
3.3.1.1. Type I interferon responses in HIV Infection 
Acute HIV-1 infection starts with a marked decrease of CD4+ T cells and the 
production of considerable quantities of cytokines [197, 198], which contribute 
to initial restriction of viral spread and facilitates the partial recovery of CD4+ T 
cell counts [199]. Type I IFNs, , such as IFN-α and IFN-β, are a group of 
cytokines expressed and secreted by plasmacytoid dendritic cells in response 
to recognition of pathogen-associated molecular patterns (PAMPs) during the 
acute phase of viral infection [200]. Within the first week of HIV infection, 
endogenous type I IFN production stimulates the expression of a large number 
of interferon-stimulated genes (ISGs) that limit viral replication in MDMs and 
CD4+ T cells by operating at multiple stage of the viral replicative cycle, from 
reverse transcription (SAMHD1 and APOBEC3) to nuclear entry (MX2) to 
transcription (Schlafen 11) and budding (tetherin), leading to the establishment 
of generalized antiviral state [201-206]. Therapies combining IFN-α treatment 
has therefore been examined as a treatment strategy for HIV-1 infection and 
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other human pathogens infections, like hepatitis C virus (HCV). Despite a 
considerable reduction in viral load was detected in chronic infection, viral 
rebound over time indicates that HIV-1 may overcome IFNα-induced antiviral 
response [207, 208]. It is therefore important to identify the host cell effectors 
induced by type I IFNs and the viral determinants associated to the overcome 
the IFN-α- induced blocks. Transmitted founder (T/F) viruses, which are the 
selected viral strains that establish de novo infections, replicate more efficiently 
in the presence of type I IFNs than their viral counterparts from chronic infection 
[209, 210], indicating that some HIV-1 strains have evolved to escape type I 
IFNs inhibition, emphasizing IFNs physiological importance during the early 
course of HIV-1 infection [199].  
The GTPase myxovirus resistance 2 (MX2 [also called MXB]) is a recently 
discovered type I IFN-induced factor able to inhibit HIV-1 infection after reverse 
transcription at the level of nuclear entry [204, 205, 211]. Certain T / F viruses 
show some degree of resistance to the antiviral activity of MX2, indicating a 
functional role of MX2 in restricting HIV-1 transmission [212]. Interestingly, MX2 
restriction of HIV-1 seems to be sensitive to changes in the HIV-1 CA protein 
[204, 205, 211, 213]; P90A and N74D CA mutants were less sensitive to 
inhibition by overexpressed MX2 than wild type HIV-1, suggesting that the CypA 
binding [211] as well as CPSF6 binding [204, 205] to the HIV-1 capsid may also 
be involved in the MX2 antiviral mechanism. However some of these CA 
mutants are still strongly inhibited by type I IFNs [214]. Consistent with this, In 
vitro studies suggest direct binding of MX2 to CA [215, 216]. Two different 
human MX proteins have been identified, MX1 and MX2 that are different in 
localization and activity. While it has been shown that MX1 possesses a broad 
antiviral activity towards certain RNA and DNA viruses [217, 218], different 
studies have found MX2 to be restrictive only against few viruses such as 
Vesicular stomatitis virus (VSV), mouse herpes virus type 68 (MHV-68), and 
HIV-1 [206, 219, 220]. MX2 localizes to the cytoplasmic part of NPCs [221, 
222]. Although MX2 antiviral activity is clearly dependent upon Nups, 
knockdown data suggest that nuclear localization is not essential for antiviral 
activity [223, 224]. Contrarily to MX1, the antiviral activity of MX2 against HIV-1 
is independent of its GTPase domain [204, 205] and requires higher order 
structures and oligomerization [225]. Additionally, the determinant for MX2 
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antiviral effect maps to the first 25 amino acids in the amino-terminal region of 
the protein, in which a triple-arginine motif is required for interaction with the CA 
and consequent restriction [223, 226]. 
3.4. Nuclear envelope: structure and function 
NE is the double membrane surrounding the eukaryotic cell nucleus, composed 
of two lipid bilayer membranes: an inner nuclear membrane (INM) and an outer 
nuclear membrane (ONM), a continuum of the endoplasmic reticulum (ER). A 
20–50 nm perinuclear space (PNS) separates the two membranes, which are 
connected to each other at annular junctions that form aqueous channels 
between the nucleoplasm and cytoplasm, and which are occupied by NPCs 
[227]. The INM encloses the nucleoplasm and contains a unique spectrum of 
integral membrane proteins, at least 50–60 of which have been identified [228]. 
Furthermore, INM is covered by the nuclear lamina, a network of intermediate 
filaments important in stabilizing the nuclear membrane and involved in 
chromatin function. The major components of the nuclear lamina are the A- and 
B-type lamins (LMNA/B), a group of type-V intermediate filament proteins [145]. 
The ONM is invariably studded with ribosomes and contains nesprin (Nesp) 
proteins, which connect cytoskeletal filaments to the nucleoskeleton [229], 
contributing to nuclear positioning and to the cell’s mechanosensory function 
[230].  
3.4.1. Nuclear envelope and HIV-1 
HIV and other lentiviruses possess a mechanism to bypass the intact NE to 
ensure correct nuclear import and integration, and accordingly are able to 
productively infect most non-dividing cells nearly as well as dividing cells, while 
Gammaretroviruses such as the MLV and spleen necrosis virus (SNV) require 
mitosis and the NE breaking down for productive infection and are blocked from 
integrating into non-dividing cells [137]. CA has been revealed as the dominant 
determinant of retroviral infectivity in non-dividing cells [136-138] and HIV-1 
PIC is thought to be actively guided to enter the nucleus by passing through 
NPC [141-144] and to integrate in actively transcribed chromatin regions [174], 
in close correspondence with the NPC [175]. Of note, NE-associated proteins 
have been implicated in transcriptional memory processes [231, 232]. Nup98 
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and Nup153 were shown to confer cell identity by interacting with super-
enhancers and modulating cell-specific transcription [233]. It is therefore 
possible that HIV-1 uses a distinct nuclear import pathway that leads to 
integration into chromatin areas that are under control by such transcriptional 
memory processes to better facilitate reactivation from latency. Components of 
the INM, including SUN proteins, LMNs or emerins (EMDs), have functions in 
chromatin organization and decondensation after mitosis [234-241], suggesting 
that dysregulation of these proteins could affect orderly HIV-1 integration or 
gene expression from integrated provirus . Previous studies examined whether 
HIV-1 uses INM components during infection, and indicated that EMD interacts 
with the host protein BAF in the HIV-1 pre-integration complex through its LEM 
domain, promoting HIV-1 infection [242]. Conversely, other studies have shown 
that EMD and lamina-associated polypeptide 2α (LAP2α) are not important for 
HIV-1 infection [243, 244]. However, the molecular details of how HIV-1 targets 
preferred sites for provirus establishment and the consequences of site 
selection for virus replication or latency, as well as the identity and functions of 
other involved host proteins, are mostly unknown. 
Finally, there are also evidences for IFNs modulating the NE composition and 
proteins in the NE. The IFN-inducible protein IFI16 interacts with the NPC 
component TPR [245], possibly affecting its function in nuclear transport. 
Likewise the type I IFN-induced nuclear envelope-associated protein MX2, 
recently identified as an inhibitor of HIV-1 infection, partially co-localizes with 
NPC components, suggesting a possible link with its antiviral function [204, 205, 
211, 213]. Furthermore, expression of some nucleoporins, such as Nup96 and 
Nup98, is modulated directly by IFNs [233] and an involvement of Nup98 in 
HIV-1 nuclear import has been suggested [158, 161]. Furthermore a recent 
screen to identify ISGs affecting HIV-1 infection, showed that overexpression of 
inner nuclear membrane protein SUN2 blocke HIV-1 infection moderately [206], 
to similar level observed for the IFN-induced protein MX2. It is therefore 
possible that the inhibition of HIV-1 infection by type I IFNs involves NE-
associated proteins.  
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4. Objective of the study 
There is an estimated that 36.9 million people worldwide are HIV-positive. Every 
year another 1.8 million new infections occur and close to a million people will 
go on to die from AIDS [9]. This indicates that HIV, more than 30 years after its 
discovery, still impacts a significant health burden on the human population.  
The intial steps of HIV infection, involving numerous interactions between 
incoming virions and host proteins, represent a vulnerable phase that is critical 
for virus spead. This is underlined by the observation that type 1 IFN treatment 
of macrophages and CD4+ T cells, both natural targets for HIV-1, causes a 
potent block at multiple post-entry stages. There is increasing evidence that 
implicates components of the NE as an important interaction partners for HIV-1 
during the early stages of infection. This includes the CA-dependent 
engagement of NPC specific proteins [141-144, 174, 175] in contrast to antiviral 
effects of NE-associated proteins such as MX2 [204, 205, 211] and SUN2 [206]. 
To address the potential role of the NE during the early steps of HIV-1 infection, 
the current thesis investigated several NE-associated proteins. Thus, the 
following objectives were established:  
1. Identification of NE membrane-associated proteins that potentially affect 
HIV infection by performing an overexpression screen. 
2. Determination of the ability of the identified proteins to affect different 
retroviruses as well as different strains of HIV-1. 
3. Determination and characterization of viral determinants by generating 
chimeras between sensitive and insensitive viruses. 
4. Determination and characterization of cellular determinants by 
generating multiple deletion mutants of the identified proteins. 
5. Determination of the physiological relevance of the identified 
endogenous proteins in HIV-1 infection. On this purpose, shRNA-
mediated protein expression reduction and CRISPR/Cas9-mediated 
gene disruption in different cell lines were achieved. 
Besides understanding the NE-HIV interaction, the current thesis also aimed to 
elucidate the role of the CA protein in IFN-α-induced suppression of HIV-1 
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infection. Thus, the sensitivity of HIV-1 CA mutants N74D, A105T, and P90A, to 
IFN-α-induced blocks was analyzed. 
Together the proposed research will likely advance our understanding of the 
early steps of HIV-1 infection. The results may uncover some host cell barrier, 
which could contribute to the low permissivity for HIV-1 infection in certain cell 
types, e.g. CD4+ resting T cells, and may reveal novel targets for therapeutic 
intervention.  
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5. Materials and Methods 
5.1. Materials 
5.1.1. Laboratory equipment  
Name Company 
Analogue tube rollers SRT6 Stuart® Cole-Parmer, Vernon Hills, USA 
Biological Safety Cabinet Class II SterilGARD® III 
Advance°  
The Baker Company, Sanford, USA 
Centrifuge Heraeus™ Megafuge™ 40R  Heraeus, Kleinostheim, Germany 
Centrifuge J2HS with rotor JA-10 
Beckman Coulter, Brea, USA  
CO2 incubator Heracell™ 150i Thermo Fisher Scientific, Waltham, 
USA 
Confocal Laser Scanning Microscope Leica TCS 
SP5 
Leica Microsystems, Wetzlar, Germany 
Confocal Laser Scanning Microscope Leica TCS 
SP8 
Leica Microsystems, Wetzlar, Germany 
ECL ChemoCam Imager INTAS Science Imaging, Göttingen, 
Germany 
Electrophoretic Transfer Cell Mini Trans-Blot®  BioRad, Hercules, USA  
Flow cytometer BD FACSVerse™ Becton Dickinson, Franklin Lakes, USA 
Gel iX Imager (Agarose gel UV-imager)  INTAS Science Imaging, Göttingen, 
Germany 
Horizontal Electrophoresis Unit MIDI Standard Carl Roth, Karlsruhe, Germany 
Incubator Shaker Multitron Pro Infors AG, Basel, Switzerland 
Inverted Laboratory Microscope Leica DM IL LED Leica Microsystems, Wetzlar, Germany 
Magnetic Stirring Hotplate Mr 3001 Heidolph Instruments, Schwabach, 
Germany 
Microcentrifuge Heraeus™ Biofuge Fresco™ Heraeus, Kleinostheim, Germany 
NanoPhotometer P300 Implen, München, Germany 
Power Supply PowerPac™ Basic BioRad, Hercules, USA  
Real Time PCR detector CFX96 Touch™ BioRad, Hercules, USA  
Tetra Vertical Electrophoresis Cell Mini-
PROTEAN® 
BioRad, Hercules, USA  
Thermal Cycler C1000 Touch™ BioRad, Hercules, USA 
Thermoblock Eppendorf ThermoMixer® comfort Eppendorf, Hamburg, Germany 
Ultracentrifuge L8-60M with SW28 rotor Beckman Coulter, Brea, USA 
Vortex Mixer Reax Top Heidolph Instruments, Schwabach, 
Germany 
Water bath Type 1008 GFL mBH, Burgwedel, Germany 
Wide-field fluorescence microscope Zeiss Axiovert 
200M 
Carl Zeiss Imaging Solutions GmbH, 
München, Germany 
Table 2. Equipment used in this work 
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5.1.2. Laboratory materials 
Name Company 
Blotting paper 3MM Chr Whatman, Dassel, Germany 
Cell Culture Flasks (25, 75 and 175 cm2) CELLSTAR® Greiner Bio-One, Kremsmünster, 
Austria 
Cell Culture Multiwell Plates (6, 12, 24, 48 well) 
CELLSTAR® 
Greiner Bio-One, Kremsmünster, 
Austria 
Cell Culture Dishes (100 x 20 mm) CELLSTAR® Greiner Bio-One, Kremsmünster, 
Austria 
Counting Chamber Neubauer-improved Paul Marienfeld GmbH & Co.KG, 
Lauda-Königshofen, Germany 
Cover glasses thickness No. 1 circular Paul Marienfeld GmbH & Co.KG, 
Lauda-Königshofen, Germany 
Disposable Nitrile Gloves TouchNTuff® 92-600 Ansell, Richmond, Australia 
Filtered Tips AvantGuard™ (20 μl) Midwest Scientific, Valley Park, 
USA 
Filtered Tips OneTouch™ (10 μl, 200 μl, 1000 μl) Sorenson BioScience, Salt Lake 
City, USA 
Fluid aspiration system BVC professional VACUUBRAND, Wertheim, 
Germany 
Microscope slides thickness approx. 1 mm Paul Marienfeld GmbH & Co.KG, 
Lauda-Königshofen, Germany 
Multichannel Pipettes 8- and 12-channel (10 μl, 100 μl, 
and 300 μl) Eppendorf® Research® plus  
Eppendorf, Hamburg, Germany 
Nitrocellulose Transfer Membran Rolls Protran® BA85 Whatman, Dassel, Germany 
Plastic paraffin film Parafilm® Bemis Company, Neenah, USA 
PCR Tubes (0,2 mL) Eppendorf tubes® Eppendorf, Hamburg, Germany 
PIPETBOY acu 2 INTEGRA Biosciences AG, Zizers, 
Switzerland 
Pipetting Reservoirs (25 mL) Argos Technologies, Vernon Hills, 
USA 
Polypropylene Tubes (15 ml, 50 ml) CELLSTAR® Greiner Bio-One, Kremsmünster, 
Austria 
Tubes (0,5 ml, 1.5 ml, 2 ml) SafeSeal Sarstedt, Nürnbrecht, Germany 
Serological pipette (5 ml, 10 ml, 25 ml, 50 ml) Sarstedt, Nürnbrecht, Germany 
Single Channel Pipettes (P2μl, P10μl, P20μl, P200μl, 
P1000μl) PIPETMAN Neo® 
Gilson Inc., Middleton, USA 
Surgical Disposable Scalpels B. Braun Melsungen, Melsungen, 
Germany 
Syringes (1ml, 3ml, 5 ml, 10 ml, 60 ml) BD Luer-Lok™ Becton Dickinson, Franklin 
Lakes,USA 
Syringe filters units (0.22 μm, 0.45 μm) Millex® Merck Millipore, Billerica, USA 
Syringe filters units (0.45 μm) Rotilabo® KH55.1 Carl Roth, Karlsruhe, Germany 
Table 3. Materials used in this work 
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5.1.3. Kits 
Name Company 
CD4+ T Cell Enrichment Cocktail 
RosetteSep™ 
Stemcell Technologies, Vancouver, Canada 
CD4+ T Cell Isolation Kit - T cells, human Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Monocyte Isolation Kit II, human Miltenyi Biotec, Bergisch Gladbach, 
Germany 
NucleoBond® Xtra Midi EF Macherey-Nagel, Dueren, Germany 
NucleoSpin® Gel and PCR Clean-up Macherey-Nagel, Dueren, Germany 
QIAamp® DNA Mini Kit Qiagen, Hilden, Germany 
QIAprep® Spin Miniprep Kit Qiagen, Hilden, Germany 
QuikChange Site-Directed Mutagenesis Kit Agilent Technologies, Santa Clara, USA 
Table 4. Kits used in this work 
5.1.4. Chemicals and reagents 
Name Company 
Acrylamide Solutions TGX™ FastCast™ BioRad, Hercules, USA 
Ammonium Persulfate (APS) Sigma-Aldrich, St. Louis, USA 
Ampicillin Carl Roth, Karlsruhe, Germany 
Agarose Janssen-Pharmaceuticalaan, Geel, Belgium 
Aqua ad iniectabilia Braun B. Braun Melsungen, Melsungen, Germany 
β-Mercaptoethanol Sigma-Aldrich, St. Louis, USA 
Biocoll Separating Soultion Biochrom GmbH, Berlin, Germany 
Boric acid (H3BO3) Carl Roth, Karlsruhe, Germany 
Bromophenolblue  Chroma, Furstenfeldbruck, Germany 
BSA 100X New England Biolabs, Ipswich, USA 
Cyclosporine (Sandimmune®) Novartis International AG, Basel, 
Switzerland 
Clarity™ Western ECL substrates BioRad, Hercules, USA 
Dimethyl sulfoxide (DMSO) Merck Millipore, Darmstadt, Germany  
DNA ladder 1kb Plus Thermo Fisher Scientific, Waltham, USA  
dNTP Set 100 mM Solutions Thermo Fisher Scientific, Waltham, USA 
Dulbecco’s Modified Eagle Medium 
(DMEM), High Glucose, GlutaMAX™ 
Supplement 
Gibco, Life Technologies, Carlsbad, USA 
EDTA Carl Roth, Karlsruhe, Germany 
Efavirenz SUSTIVA® 30 mg/ml oral 
solution 
Bristol-Myers Squibb Pharma EEIG, 
Uxbridge, UK 
Ethanol (99 %) (EtOH)  Zentralbereich INF, Heidelberg, Germany  
Fetal Calf Serum (FCS)  Biochrom GmbH, Berlin, Germany  
Gel Loading Dye, Purple (6x) for DNA  New England Biolabs, Ipswich, USA  
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Glycerol Sigma-Aldrich, St. Louis, USA 
Glycine Carl Roth, Karlsruhe, Germany 
Granulocyte-macrophage colony-stimulating 
factor (GM-CSF), human recombinant 
R & D Systems, Minneapolis, USA 
Hoechst 33258  Thermo Fisher Scientific, Waltham, USA  
Interferon α-2a Roferon®-A Roche Holding AG, Basel, Switzerland 
Interleukin-2, human recombinant (rHuIL-2) Biomol, Hamburg, Germany 
Isopropanol (C3H8O) Sigma-Aldrich, St. Louis, USA  
Kanamycin Carl Roth, Karlsruhe, Germany 
LB Broth (Lennox) Sigma-Aldrich, St. Louis, USA 
Methanol (MeOH)  Sigma-Aldrich, St. Louis, USA 
Mowiol 4-88 Sigma-Aldrich, St. Louis, USA 
DNA/RNA stain MIDORIGreen Advance Nippon Genetics Europe GmbH, Dueren, 
Germany 
Opti-MEM™ I Reduced Serum Medium Gibco, Life Technologies, Carlsbad, USA 
Paraformaldehyde (PFA) Merck, Darmstadt, Germany 
PBS Dulbecco Powder Biochrom GmbH, Berlin, Germany 
Penicillin Streptomycine (PenStrep) Biochrom GmbH, Berlin, Germany 
Phytohemagglutinin-M (PHA-M) Sigma-Aldrich, St. Louis, USA 
Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich, St. Louis, USA 
Plasmocin™ - Mycoplasma Elimination 
Reagent 
InvivoGen, San Diego, USA 
Polyethylenimine (PEI) Sigma-Aldrich, St. Louis, USA  
Powdered milk Carl Roth, Karlsruhe, Germany 
Precision Plus Protein™ WesternC™ 
Standards  
BioRad, Hercules, USA 
Protease Inhibitor Cocktail EDTA-free 
cOmplete™ 
Roche Holding AG, Basel, Switzerland 
Puromycin dihydrochloride Santa Cruz Biotechnology, Dallas, USA 
Ribonuclease Inhibitor RiboLock™ Thermo Fisher Scientific, Waltham, USA 
RNA from bacteriophage MS2 Roche Holding AG, Basel, Switzerland 
RPMI 1640 Medium, GlutaMAX™ 
Supplement 
Gibco, Life Technologies, Carlsbad, USA 
Sodium azide (NaN3) Sigma-Aldrich, St. Louis, USA 
Sodium chloride (NaCl) Sigma-Aldrich, St. Louis, USA 
Sodium dodecyl sulfate (SDS) Applichem, Karlsruhe, Germany 
Sodium Hydroxide (NaOH) Sigma-Aldrich, St. Louis, USA 
Sucrose Sigma-Aldrich, St. Louis, USA 
SYBR Green , 10000X concentrate  Thermo Fisher Scientific, Waltham, USA 
Tetramethylethylenediamine (TEMED) Carl Roth, Karlsruhe, Germany 
Trypsin/EDTA solution Biochrom GmbH, Berlin, Germany 
Tris[(1-benzyl-1H-1,2,3-triazol-
4yl)methyl]amine 
Sigma-Aldrich, St. Louis, USA 
Triton X-100 Sigma-Aldrich, St. Louis, USA 
Tween 20 Carl Roth, Karlsruhe, Germany 
Table 5. Chemical and reagents used in this work 
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5.1.5. Buffers and solutions 
Name  Component Concentration 
PBS 10x 
 
ddH2O  
NaCl   
KCl   
Na2HPO4   
KH2PO4 
 
1,4 M  
27 mM  
80 mM 
18 mM 
TBE Electrophoresis Buffer 10x  
 
ddH2O 
Tris base 
Boric acid 
EDTA pH 8 
 
890 mM  
890 mM 
20 mM 
SDS Running Buffer 10x 
 
ddH2O  
Glycine 
Tris base 
SDS 
 
1,92 M 
250 mM 
1% 
SDS Blotting Buffer 10x 
 
ddH2O  
Glycine 
Tris base 
 
1,92 M 
250 mM  
SDS Blotting Buffer 1x 
 
ddH2O  
Glycine 
Tris base 
Methanol 
 
192 mM 
25 mM 
10% (v/v) 
SG-PERT  
dilution buffer 1x, pH 8.0 
ddH2O 
(NH4)2SO4  
KCl  
Tris-HCl  
 
5 mM 
20 mM 
20 mM 
SG-PERT  
lysis buffer 2x, pH 7.4  
ddH2O 
KCl 
Tris-HCl 
Glycerol 
Triton X-100 
 
50 mM 
100 mM 
40 % 
0.25 % 
SG-PERT  
PCR reaction buffer 2x  
SG-PERT dilution buffer 
MgCl2 
BSA 
dNTPs 
Primer RT-Assay-fwd 
Primer RT-Assay-rev 
MS2 RNA 
SYBR Green 
GoTaq Hotstart Polymerase 
 
10 mM 
0.2 mg/ml 
400 μM 
1 pmol 
1 pmol 
8 ng 
1:10000 
0.5 U 
Hypotonic lysis buffer  
Tris-HCl 
KCl 
protease inhibitor 
cocktail 
10 mM 
10 mM 
1x 
CANC binding buffer 
Tris-HCl [pH 8] 
NaCl 
50 mM 
100 mM 
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CANC washing buffer 
Tris-HCl 
NaCl 
KCl 
50 mM 
50 mM 
5 mM 
Laemmli Sample Buffer 2X 
Tris-HCl pH 6.8 
SDS 
Glycerol  
Bromophenol blue  
120 mM 
4% (w/v) 
20% (w/v) 
0.02% (w/v) 
WB Stripping Buffer  
ddH2O 
NaOH 
 
0.5 M 
WB Wash Buffer for membranes 
and Dilution Buffer for antibodies 
PBS 
Tween 20 
 
0.05% (v/v) 
WB Blocking Buffer 
PBS 
Milk powder 
 
5% (w/v) 
Mowiol embedding medium  
PBS 
Mowiol 4-88 
 
8mM 
Table 6. Buffer and solutions used in this work 
5.1.6. Bacterial Strains and bacterial culture media  
For plasmid preparation and amplification, the chemo-competent E. coli strain 
Stbl2 was used. Genotype: F- mcrA Δ(mcrBChsdRMSmrr) recA1 endA1 lon 
gyrA96 thi supE44 relA1 λ- Δ(lac-proAB). They are characterized by high 
transformation efficiencies and low recombination rates. 
 
Bacterial culture media 
Name  Component Concentration 
LB 
ddH2O  
NaCl 
Tryptone   
Yeast extract   
adjust to pH 7.2 and autoclave 
 
5 g/l  
10 g/l 
5 g/l 
LB agar plates 
Agar 
LB 
12.5 g/l 
Table 7. Bacterial culture media used in this work 
For selection, Ampicillin (0.1 mg/ml) or Kanamycin (0.1 mg/ml for liquid culture 
and 0.06 mg/ml for plates) was added to the medium.  
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5.1.7. Cells and cell culture media 
Cell lines 
Name Description References 
HEK-293T 
Human embryonic kidney (HEK) 
stem cell line expressing a large 
Simian Vacuolating Virus 40 TAg 
(SV40 T) antigen on their cell 
surface 
[246-248] 
U87MG-CD4/CXCR4 
Uppsala 87 Malignant Glioma 
(U87MG) CD4/CXCR4 is a 
human glioblastoma-astrocytoma 
cell line expressing HIV-1 
receptors CD4 and CXCR4 
[204, 249-255] 
THP-1 
Tohoku Hospital Pediatrics-1 
(THP-1) is a human acute 
monocytic leukemia cell line 
[204, 256-266] 
Jurkat-TAg 
Human acute lymphoblastic 
leukemia T-cell line expressing a 
large Simian Vacuolating Virus 
40 TAg (SV40 T) antigen on their 
cell surface 
[267-271] 
Table 8. Cells used in this work 
Adherent cell lines were routinely grown in Dulbecco's modified eagle’s medium 
Dulbecco’s Modified Eagle Medium (DMEM), High Glucose GlutaMAX™ 
supplemented with 100 U/ml of penicillin and 100 µg/ml of streptomycin and 
10% fetal calf serum (FCS) previously heat-inactivated (heated to 56°C for 30 
minutes in water-bath). Suspension cell lines were normally grown in RPMI 
1640 Medium GlutaMAX™ supplemented with 100 U/ml of penicillin and 
100 µg/ml of streptomycin and 10 % FCS.  
Adherent cell lines were cryopreserved in liquid nitrogen by using FCS 
containing 10% DMSO as freezing medium, whereas suspension cell lines FCS 
containing 10% glycerol. 
 
Primary cells 
Human primary CD4+ T cells and monocyte-derived macrophages (MDMs) 
were obtained from peripheral blood mononuclear cells (PBMCs) of healthy 
volunteer donors and grown in RPMI 1640 Medium GlutaMAX™ supplemented 
with 100 U/ml of penicillin and 100 µg/ml of streptomycin and 10% heat-
inactivated FCS. 
 
   
36 
 
5.1.8. Enzymes  
Table 9. Enzymes used in this work 
5.1.9. Plasmid 
Plasmid  Notes Reference 
HIV-1 pCMV-ΔR8.91 
NL4.3 gag pol, tat and rev expression plasmid. 
ΔvifΔvprΔvpuΔenvΔnef. 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [141, 272] 
HIV-1 pCMV-
ΔR8.91Ex 
NL4.3 gag pol, tat and rev expression plasmid 
modified. 
ΔvifΔvprΔvpuΔenvΔnef 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [273, 274] 
HIV-1 pCMV-
ΔR8.91Ex-SCA 
NL4.3 gag pol, tat and rev expression plasmid 
encoding SIVMAC CA. 
ΔvifΔvprΔvpuΔenvΔnef 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [274] 
HIV-1 pCMV-ΔR8.91-
N74D 
NL4.3 gag pol, tat and rev expression plasmid 
harboring CA mutation N74D. 
ΔvifΔvprΔvpuΔenvΔnef. 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [141, 163] 
HIV-1 pCMV-ΔR8.91-
P90A 
NL4.3 gag pol, tat and rev expression plasmid 
harboring CA mutation P90A. 
ΔvifΔvprΔvpuΔenvΔnef. 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [114, 141] 
HIV-1 pCMV-ΔR8.91-
A105T 
NL4.3 gag pol, tat and rev expression plasmid 
harboring CA mutation A105T. 
ΔvifΔvprΔvpuΔenvΔnef. 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [169] 
HIVac-1 
NL4-3 gag pol, tat and rev expression plasmid 
encoding GFP in place of nef and harboring 
V86I-IAP91LPA-M96L CA mutations. 
ΔvifΔvprΔvpuΔenvΔnef.  
Nicolas Manel (Institut 
Curie, Paris) [103] 
HIV-1 pCSxW HIV-1 vector 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [275] 
HIV-1 pCSxW-HA HIV-1 vector hemagglutinin (HA)- tagged 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [275] 
HIV-1 pCSGW HIV-1 vector encoding GFP 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [141, 276] 
VSV-G Env pMD.G VSV-G expression plasmid  
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [274, 277] 
Name Company 
GoTaq® Hot Start DNA Polymerase Promega, Madison, USA 
Phusion® High-Fidelity DNA Polymerase New England Biolabs, Ipswich, USA 
PfuTurbo DNA Polymerase Agilent Technologies, Santa Clara, USA 
Restriction Endonucleases (ApaI, BamHI, 
BglII, BsmbI, BssHII, DpnI, EcoRI, MfeI, 
MluI, NotI, PspOMI, XhoI) 
New England Biolabs, Ipswich, USA 
RQ1 RNase-Free DNase Promega, Madison, USA 
TaqMan® Universal PCR Master Mix Applied Biosystems, Foster City, USA 
T4 DNA Ligase New England Biolabs, Ipswich, USA 
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MLV pCNCG MLV vector encoding GFP 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [274, 278] 
MLV-N/B pCIG3 N/B MoMLV gag pol expression plasmid 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [274, 279] 
HIV-2pack HIV-2 gag pol expression plasmid 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [274, 280] 
HIV-2GFP HIV-2 vector encoding GFP 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [274, 280] 
FIV pFP93 FIV gag pol expression plasmid 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [274, 281] 
FIV pGinSin FIV vector encoding GFP 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [274, 281] 
EIAV pONY3.0 EIAV gag pol expression plasmid 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [274, 282] 
EIAV pONY8.7GFP EIAV vector encoding GFP 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [274, 283] 
SIV pSIV3+ SIV gag pol expression plasmid 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [274, 284] 
pSIVRMES4 SIV vector encoding GFP 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [274, 284] 
pNL4.3 Full-length NL4.3 molecular clone 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [204, 285] 
pNL4.3-GFP 
Full-length NL4.3 encoding GFP in place of 
Nef followed by an IRES-Nef cassette 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [141, 286] 
pNL4.3-N74D-GFP 
Full-length NL4.3 encoding GFP in place of 
Nef followed by an IRES-Nef cassette 
harboring CA mutation N74D. 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [141, 163] 
pNL4.3-P90A-GFP 
Full-length NL4.3 encoding GFP in place of 
Nef followed by an IRES-Nef cassette 
harboring CA mutation P90A. 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [114, 141] 
pNL4.3-A105T-GFP 
Full-length NL4.3 encoding GFP in place of 
Nef followed by an IRES-Nef cassette 
harboring CA mutation A105T. 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [169] 
pIIIB Full-length IIIB molecular clone 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [204, 287] 
pRHPA Full-length T/F HIV-1-RHPA molecular clone 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [204, 288] 
pWITO Full-length T/F HIV-1-WITO molecular clone 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [204, 288] 
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pTHRO Full-length T/F HIV-1-THRO molecular clone 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [204, 288] 
pSUMA 
Full-length T/F HIV-1-SUMA molecular 
clone 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [204, 288] 
pZM247 
Full-length T/F HIV-1-ZM247 molecular 
clone 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [204, 288] 
pLVX-Puro-MX2 Lentiviral vector encoding Mx2 wild type 
Mirjam Schilling 
(Universitätsklinikum 
Freiburg) [220] 
pLVX-Puro-
MX2(K131A) 
Lentiviral vector encoding Mx2 mutant 
devoid of GTPase activity 
Mirjam Schilling 
(Universitätsklinikum 
Freiburg) [220] 
pLVX-Puro-
MX2(T151A) 
Lentiviral vector encoding Mx2 mutant 
devoid of GTPase activity 
Mirjam Schilling 
(Universitätsklinikum 
Freiburg) [220] 
pLVX-Puro-
MX2(D297N) 
Lentiviral vector encoding Mx2 mutant 
devoid of GTPase activity 
Mirjam Schilling 
(Universitätsklinikum 
Freiburg) [220] 
pLVX-Puro-
MX2(D300N) 
Lentiviral vector encoding Mx2 mutant 
devoid of GTPase activity 
Mirjam Schilling 
(Universitätsklinikum 
Freiburg) [220] 
pLVX-Puro-
MX2(M574D) 
Lentiviral vector encoding Mx2 mutant that 
prevents oligomerization 
Mirjam Schilling 
(Universitätsklinikum 
Freiburg) [220] 
pLVX-Puro-MX2(-
NLS) 
Lentiviral vector encoding Mx2 mutant 
lacking the first 25 amino-terminus 
aminoacids (NLS) 
Mirjam Schilling 
(Universitätsklinikum 
Freiburg) [220] 
pLVX-Puro-MX1 Lentiviral vector encoding Mx1 wild type 
Mirjam Schilling 
(Universitätsklinikum 
Freiburg) [220] 
pLVX-Puro-
MX1(K83A) 
Lentiviral vector encoding Mx1 mutant 
devoid of GTPase activity 
Mirjam Schilling 
(Universitätsklinikum 
Freiburg) [595] 
TopoTA pCR2.1-LUC 
Cloning vector harboring firefly luciferase 
(LUC) cDNA 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [289] 
TopoTA pCR2.1-SUN1 Cloning vector harboring SUN1 cDNA 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [289] 
TopoTA pCR2.1-SUN2 Cloning vector harboring SUN2 cDNA 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [289] 
TopoTA pCR2.1-
LMNA 
Cloning vector harboring LMNA cDNA 
Torsten Schaller 
(Universitätsklinikum 
Heidelberg) [289] 
TopoTA pCR2.1- EMD Cloning vector harboring EMD cDNA 
Juan Martin-
Serrano (King's 
College London) [289] 
TopoTA pCR2.1- 
EMDΔLEM 
Cloning vector harboring EMDΔLEM cDNA 
Juan Martin-
Serrano (King's 
College London) [289] 
pBudCE4.1-NET26 Cloning vector harboring NET26 cDNA 
Rose Goodchild (KU 
Leuven) [290] 
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pBudCE4.1-NET31 Cloning vector harboring NET31 cDNA 
Rose Goodchild (KU 
Leuven) [290] 
pBudCE4.1-NET39 Cloning vector harboring NET39 cDNA 
Rose Goodchild (KU 
Leuven) [290] 
pBudCE4.1-LUMA Cloning vector harboring LUMA cDNA 
Rose Goodchild (KU 
Leuven) [290] 
pBudCE4.1-LBR Cloning vector harboring LBR cDNA 
Rose Goodchild (KU 
Leuven) [290] 
pBudCE4.1-LULL1 Cloning vector harboring LULL1 cDNA 
Rose Goodchild (KU 
Leuven) [290] 
pBudCE4.1-NET3 Cloning vector harboring NET3 cDNA 
Rose Goodchild (KU 
Leuven) [290] 
pBudCE4.1-TSPAN5 Cloning vector harboring TSPAN5 cDNA 
Rose Goodchild (KU 
Leuven) [290] 
pBudCE4.1-TMEM53 Cloning vector harboring TMEM53 cDNA 
Rose Goodchild (KU 
Leuven) [290] 
pBudCE4.1-LAP2 β Cloning vector harboring LAP2β cDNA 
Rose Goodchild (KU 
Leuven) [290] 
pBudCE4.1-TORSA Cloning vector harboring TORSA cDNA 
Rose Goodchild (KU 
Leuven) [290] 
pBudCE4.1-TORSA-EQ 
Cloning vector harboring g TORSA-EQ 
cDNA 
Rose Goodchild (KU 
Leuven) [290] 
pBudCE4.1-NURIM Cloning vector harboring NURIM cDNA 
Rose Goodchild (KU 
Leuven) [290] 
plentiCRISPRv2 
Retroviral vector with a puromycin resistance 
marker to express guide RNAs (gRNAs) 
constructs for CRISPR-mediated genome 
editing. 
Addgene, Cambridge, 
USA 
pSIREN RetroQ vector 
(pSRQ) 
Retroviral vector with a puromycin resistance 
marker to express short hairpin RNAs 
(ShRNAs) constructs for targeted gene 
silencing. 
Clontech, Mountain 
View, USA 
Table 10. Plasmids used in this work 
5.1.10. Primers 
OTS1 ATCGAATTCATGGATTTTTCTCGGCTTCACATGTAC 
OTS2 ATCAGATCTCACCATGGATTTTTCTCGGCTTCACATGTAC 
OTS3 GATGCGGCCGCTCACTTGACAGGTTCGCCATGAACTCTG 
OTS4 ATGCGAATTCATGTCCCGAAGAAGCCAGCGCCTCACGCGCTAC 
OTS5 ATGCAGATCTATGTCCCGAAGAAGCCAGCGCCTCACGCGCTAC 
OTS6 GCATGCGGCCGCCTAGTGGGCGGGCTCCCCATGCACTCTGAAGC 
OTS7 ATCGAATTCATGGAAGACGCCAAAAACATAAAGAAAG 
OTS8 GATGCGGCCGCTTACACGGCGATCTTTCCGCCCTTC 
OTS9 ATCGAATTCTCAGATGCTCTGGATTTTGAGACGGAGC 
OTS10 ATCGAATTCACAGCATGCACCCTGGGGGATGGTGAGG 
OTS11 ATCGAATTCACAAAACAGCGCAGAAGCACAAACAAATCAG 
OTS12 ATCGAATTCGCTTTTAGTATCAACCACGTGTCAAGGCAGGTC 
OTS13 ATCGAATTCGGGAAGGCAGCCTCTGGAGTGTTCTGGTG 
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OTS14 GATGCGGCCGCTCACAGCTGGAGGTGCTCGACTGTGGGCAGGAG 
OTS15 ATGGTGACGCCAACTGGGGCTACTCGGATGTGGACCAG 
OTS16 TCCACATCCGAGTAGCCCCAGTTGGCGTCACCATGCAG 
OTS17 ATCGAATTCATGGTCTCACGGGCGGGCTCCTTACTCTGGATG 
OTS18 GATGCGGCCGCTCATGTCACTCCAATCACACCTTCTTTCTG 
OTS19 AGCAGCTCTGCCGCCGCGAAGAACCGAGCG 
OTS20 TTCTTCGCGGCGGCAGAGCTGCTGGTGCC 
OTS21 TCCCTGGCGGCCGCAAGCGCCAGAACAACAAAAC 
OTS22 TGTTCTGGCGCTTGCGGCCGCCAGGGAGACAGC 
OTS23 AAGAACGCATCGTCCGCAACAACAAAACAGCG 
OTS24 GTTGTTGCGGACGATGCGTTCTTCAGGGAGAC 
OTS25 CCGAGCGAGCGCAGCAGCAAAACAGCGCAGAAG 
OTS26 CTGTTTTGCTGCTGCGCTCGCTCGGTTCTTCAG 
OTS27 GCCAGAGCAGCAGCAGCGCGCAGAAGCACA  
OTS28 TCTGCGCGCTGCTGCTGCTCTGGCCGCTCG 
OTS29 AGGATGCTGTGACGCGTCGGCCTCCTGTATTG 
OTS30 AGGCCGACGCGTCACAGCATCCTGCAGGCTG 
OTS31 GATACGCGTCGACTCACTGTAGTAGGAGGTGTG 
OTS32 ATCGAATTCATCACGCGTATGAATTTCCCACGTGCGCTTGCTGG 
OTS33 GATGCGGCCGCTCAGAGTTTTGTAGCTGCTGTTGGC 
OTS34 GATGCGGCCGCTCAACGCGTCACAGCATCCTGCAGGCTGAC 
OTS35 ATCCAATTGATGGACAACTACGCAGATCTTTCGGATAC 
OTS36 ATCCAATTGATGGACAGGCGGCGGCTCTCGCCCCCCAGC 
OTS37 GATGCGGCCGCCTAGAAGGGGTTGCCTTCTTCAGCCTGCATG 
OTS38 ATCGAATTCATGGAGACCCCGTCCCAGCGGCGCG 
OTS39 GATGCGGCCGCTTACATGATGCTGCAGTTCTGGGGGCTC 
OTS40 ATCGAATTCATGCAGGACACTGGCTCAGTAGTGCC 
OTS41 GATGCGGCCGCCTAATGGGGTCTGTTGAACATACTAAC 
OTS42 ATCGAATTCATGATGCAGGGGGAGGCACACCCTAGTG 
OTS43 GATGCGGCCGCCTACTCGCCAAAGATCCACAATATATTC 
OTS44 ATCGAATTCATGCCAGCTTCCCAGAGCCGGGCCCG 
OTS45 GATGCGGCCGCTCACCAGGCAGAGATGAGCATCTGGC 
OTS46 ATCGAATTCATGGCCGCGAATTATTCCAGTACCAG 
OTS47 GATGCGGCCGCTCACTCCAACTTTTTGGCTGGCACCCG 
OTS48 ATCGAATTCATGCCAAGTAGGAAATTTGCCGATGGTG 
OTS49 GATGCGGCCGCTTAGTAGATGTATGGAAATATACGGTAGGGC 
OTS50 ATCGGATCCACCATGCCAAGTAGGAAATTTGCCGATGG 
OTS51 TGAGGGCCCCTACGCATAGTCAGGAACATCGTATGGGTAGGCGGCCGCGTAG
ATGTATGGAAATATACGGTAG 
OTS52 ATCGAATTCATGGCCGACAGTGGACTTAGGGAACC 
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OTS53 GATGCGGCCGCTTAGAAAAGGCACCCCTGTTCTTCTATG 
OTS54 ATCAGATCTCACCATGGCCGACAGTGGACTTAGGGAACC  
OTS55 GATGCGGCCGCGAAAAGGCACCCCTGTTCTTCTATGC 
OTS56 ATCGAATTCATGGCCACGGCCGTGAGCCGGCCCTG 
OTS57 GATGCGGCCGCCTATTCTTTGAACTCCAAGAACTGTTG 
OTS58 ATCGGATCCACCATGGCCACGGCCGTGAGCCGGCCCTG 
OTS59 GATGCGGCCGCTTCTTTGAACTCCAAGAACTGTTGAAG 
OTS60 ATCGGATCCACCATGTCCGGGAAGCACTACAAGGGTCCTG 
OTS61 GATGCGGCCGCCCAGCTCGCCCTGACAGCTTCGATATC 
OTS62 ATCGGATCCACCATGGCCTCGGCAGAGCTGGACTACACC 
OTS63 GATGCGGCCGCGCAGCGGACGCAGTTGCGCATGAAG 
OTS64 ATCGGATCCACCATGCCGGAGTTCCTGGAAGACCCCTC 
OTS65 GATGCGGCCGCGTTGGATTTTCTAGGGTCAACATG 
OTS66 ATCGAATTCATGAAGCTGGGCCGGGCCGTGCTGGGCCTG 
OTS67 GATGCGGCCGCTCAATCATCGTAGTAATAATCTAAC 
OTS68 ATCGGATCCACCATGAAGCTGGGCCGGGCCGTGCTGGGCCTG 
OTS69 GATGCGGCCGCATCATCGTAGTAATAATCTAACTTG 
OTS70 ATCGAATTCATGGCCCCTGCACTGCTCCTGATCCCTG 
OTS71 GATGCGGCCGCTCACTCTGCCTCCCCATCCTGGGGCCGAG 
OTS72 ATCAGATCTCACCATGGCCCCTGCACTGCTCCTGATCC 
OTS73 GATGCGGCCGCCTCTGCCTCCCCATCCTGGGGCCG 
OTS74 ATCCAATTGATGTTACCGAGTACTTCAGTGAATTCC 
OTS75 GATGCGGCCGCTTATTTCACTCTGTACTTATAGAAAGAAC 
OTS76 ATCGGATCCACCATGTTACCGAGTACTTCAGTGAATTC 
OTS77 GATGCGGCCGCTTTCACTCTGTACTTATAGAAAGAAC 
OTS78 ACTGGAAGGGCTTTAAGACTCCCAACGAAGAC 
OTS79 TTCGTTGGGAGTCTTAAAGCCCTTCCAGTCCC 
OTS80 ATCCCTCAGACCGAAAAAGTCAGTGTGGAAAATC 
OTS81 TCCACACTGACTTTTTCGGTCTGAGGGATCTCTAG 
OTS82 ATCGCGGCCGCTGGTGAGAGATGGGTGCGAGAGCGTCGGTATTAAGCGGGGG 
OTS83 ACCTGATCATACTGTCTTACTTTGATAAAACC 
OTS84 TTGCATCCAGTGCAAGCAGGGCCTATTGCACC 
OTS85 TGCAATAGGCCCTGCTTGCACTGGATGCAATC 
OTS86 AGGATGGATGACAAATAATCCACCTATCCC 
OTS87 ATAGGTGGATTATTTGTCATCCATCCTATTTG 
OTS88 AGCATTGGGACCAGCAGCGACACTAGAAG 
OTS89 TAGTGTCGCTGCTGGTCCCAATGCTTTTAAAATAG 
OTS90 TGCATCCAGTGCACGCAGGCCCTATTGCAC 
OTS91 TGCAATAGGGCCTGCGTGCACTGGATGCAATC 
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OTS92 GCATTACTCCACGGAGGAGAACAAGAAATGGAACCAGTAGATCCTAGAC 
OTS93 TGGTTCCATTTCTTGTTCTCCTCCGTGGAGTAATGCCTATTCTGCTATG 
OTS94 ATTGGGACCAGGAGCTACACTAGAAGAAATG 
OTS95 AGTGTAGCTCCTGGTCCCAATGCTTTTAAG 
OTS96 ATCGGATCCACCATGTCTAAGGCCCACAAGCCTTGGCCCTAC 
OTS97 GATGCGGCCGCGTGGATCTCTTTGCTGGAGAATTGAC 
OTS98 ATCGGATCCACCATGAATTCCTTCCAGCAACAGCCACCGCC 
OTS99 ATCGAATTCATGGTTGTTTCCGAAGTGGACATCGCAAAAG 
OTS100 GATGCGGCCGCTTAACCGGGGAACTGGGCAAGCCGGCGCCG 
OTS101 ATCGGATCCACCATGGAAGACGCCAAAAACATAAAG 
OTS102 GATGCGGCCGCCACGGCGATCTTTCCGCCCTTCTTG 
OTS103 GATCCGCACAAATTGGACCCTGTATTCAAGAGATACAGGGTCCAATTTGTGCT
TTTTTACGCGTG 
OTS104 AATTCACGCGTAAAAAAGCACAAATTGGACCCTGTATCTCTTGAATACAGGGT
CCAATTTGTGCG 
OTS105 GATCCGAGGGAGACTGACTTTATGTTCAAGAGACATAAAGTCAGTCTCCCTCT
TTTTTACGCGTG 
OTS106 AATTCACGCGTAAAAAAGAGGGAGACTGACTTTATGTCTCTTGAACATAAAGT
CAGTCTCCCTCG 
OTS107 GATCCGGGACAGTTCACGTATGATTTCAAGAGAATCATACGTGAACTGTCCCT
TTTTTACGCGTG 
OTS108 AATTCACGCGTAAAAAAGGGACAGTTCACGTATGATTCTCTTGAAATCATACG
TGAACTGTCCCG 
OTS109 GATCCGTCAGAGCACCCTGTTTAATTCAAGAGATTAAACAGGGTGCTCTGACT
TTTTTACGCGTG 
OTS110 AATTCACGCGTAAAAAAGTCAGAGCACCCTGTTTAATCTCTTGAATTAAACAG
GGTGCTCTGACG 
OTS111 GATCCGACGTATGGTGCTTGGTATTTCAAGAGAATACCAAGCACCATACGTCT
TTTTTACGCGTG 
OTS112 AATTCACGCGTAAAAAAGACGTATGGTGCTTGGTATTCTCTTGAAATACCAAG
CACCATACGTCG 
OTS113 GATCCGCCGTTACCTTAGAGCATGTTTCAAGAGAACATGCTCTAAGGTAACGG
TTTTTTACGCGTG 
OTS114 AATTCACGCGTAAAAAACCGTTACCTTAGAGCATGTTCTCTTGAAACATGCTC
TAAGGTAACGGCG 
OTS115 GATCCGACTCAGAAGACCTCTTCATTCAAGAGATGAAGAGGTCTTCTGAGTCT
TTTTTACGCGTG 
OTS116 AATTCACGCGTAAAAAAGACTCAGAAGACCTCTTCATCTCTTGAATGAAGAGG
TCTTCTGAGTCG 
OTS117 CACCGTACGTGTAGCCCGTGTTCTC 
OTS118 AAACGAGAACACGGGCTACACGTAC 
OTS119 CACCGTCGTGGCCAGGCGCAAACTA 
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OTS120 AAACTAGTTTGCGCCTGGCCACGAC 
OTS121 CACCGGACTCGACGGCCTCCTGTAT 
OTS122 AAACATACAGGAGGCCGTCGAGTCC 
OTS123 CACCGCGCCTCACGCGCTACTCCCA 
OTS124 AAACTGGGAGTAGCGCGTGAGGCGC 
OTS125 CACCGAACTGCATGGTGACGCCAAC 
OTS126 AAACGTTGGCGTCACCATGCAGTTC 
OTS127 CACCGCTCCTCTGAGGACGACTACG 
OTS128 AAACCGTAGTCGTCCTCAGAGGAGC 
OTS129 CACCGACACTCTCTGGAGCGGCGTC 
OTS130 AAACGACGCCGCTCCAGAGAGTGTC 
OTS131 CACCGTATGTCCCGGGTACACTCTC 
OTS132 AAACGAGAGTGTACCCGGGACATAC 
OTS133 CACCGAATTGACTTCTCCTCCGGTA 
OTS134 AAACTACCGGAGGAGAAGTCAATTC 
OTS135 CACCGGGCACTGTGCCGAATGGCGG 
OTS136 AAACCCGCCATTCGGCACAGTGCCC 
OTS137 CACCGACAAGCCTTGGCCCTACCGG 
OTS138 AAACCCGGTAGGGCCAAGGCTTGTC 
OTS139 CACCGTGTGGTGGCACTGTGCCGAA 
OTS140 AAACTTCGGCACAGTGCCACCACAC 
OTS141 ACACTGCTGCTGGCCGTGTTTCCTG 
OTS142 AGTCACCAGGATGAACAGATTCAG 
OTS143 AGTAATAGTTGCTCTTGAAAATCCAC 
OTS144 TCGAGACAGGGTGCGGCTTTACAGAC 
OTS145 ACAGTGCAGGGGTGCTTCACAGATC  
OTS146 TGCTGTGTGCTCATACACATGGAGC 
OTS147 TTGTAAAGTTTGAATGTGGC 
OTS148 AAGTCCTCGGTGGCCTTGCG 
OTS149 TGTTGGCCTTAGGTTGCCATAG 
OTS150 AGCACCCACCATGTGTGAGC 
OTS151 AGCAAAGGAACATTGAGACTCTACTG 
OTS152 TTATTGTGGTGGGCTTACATGACAGC 
Table 11. Oligonucleotide sequences used in this study 
 
   
44 
 
5.1.11. TaqMan qPCR primer/ probes/ standards 
Target Primer 1 
5’-3’ 
Primer 2 
5’-3’ 
Probe 5’-3’ 
(F: FAM, Ta:TAMRA) 
Standard 
 
 
GFP 
 
GT139  
(CAACAGCCACAA
CGTCTATATCAT ) 
 
GT140  
(ATGTTGTGGCGGA
TCTTGAAG) 
 
GFP-P 
(F)-CCGACAAGCAGAA
GAACGGCATCAA-(Ta) 
 
pCNCG 
 
 
2-LTR circles 
 
 
2-LTR Fwd 
(AACTAGAGATCC
CTCAGACCCTTTT) 
 
 
2-LTR Rev 
(CTTGTCTTCGTTGG
GAGTGAATT) 
 
2-LTR P 
(F)-
CTAGAGATTTTCCACA
CTGAC-(Ta) 
 
 
p2LTR  
 
2-LTR 
circles++ 
 
 
2-LTR++ Fwd 
(AACTAGAGATCC
CTCAGACCGAAA
A) 
 
2-LTR++ Rev 
(CTTGTCTTCGTTGG
GAGTCTTAA) 
 
2-LTR P 
(F)-
CTAGAGATTTTCCACA
CTGAC-(Ta) 
 
p2LTR++  
 
 
 
MS2 
genomic 
DNA 
 
 
RT-Assay-fwd 
(TCCTGCTCAACTT
CCTGTCGAG) 
 
RT-Assay-rev 
(CACAGGTCAAACC
TCCTAGGAATG) 
 
 
SYBR Green 
 
HIV-1 RT 
Table 12. TaqMan qPCR primer/ probes/ standards 
5.1.12. Generated plasmids 
Name Template Primers 
(PCR) 
Enzymes Target/ SDM 
pCSxW-HA-SUN1 TopoTA pCR2.1-
SUN1 
OTS1  
OTS3 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW-SUN1 TopoTA pCR2.1-
SUN1 
OTS2  
OTS3 
BglII, 
NotI 
pCSxW 
pCSxW-HA-SUN2 TopoTA pCR2.1-
SUN2 
OTS4  
OTS6 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW-SUN2 TopoTA pCR2.1-
SUN2 
OTS5  
OTS6 
BglII, 
NotI 
pCSxW 
pCSxW-HA-LUC TopoTA pCR2.1-LUC  OTS7 
OTS8 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW-HA-SUN1Δ30 pCSxW-HA-SUN1 OTS9 
OTS3 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW-HA-SUN1Δ60 pCSxW-HA-SUN1 OTS10  
OTS3 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW-HA-SUN1Δ90 pCSxW-HA-SUN1 OTS11  
OTS3 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW-HA-SUN1Δ100 pCSxW-HA-SUN1 OTS12 
OTS3 
EcoRI, 
NotI 
pCSxW-HA 
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pCSxW-HA-SUN1Δ355 pCSxW-HA-SUN1 OTS13 
OTS3 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW-HA-SUN1-1-583 pCSxW-HA-SUN1  OTS1  
OTS14 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW- HA-SUN2ΔLBS pCSxW-HA-SUN2 OTS15 
OTS16 
- SDM (pCSxW-
HA-SUN2) 
pCSxW- HA-SUN2Δ157 pCSxW-HA-SUN2 OTS17 
OTS6 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW-HA-SUN2-1-524 pCSxW-HA-SUN2 OTS4 
OTS18 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW-HA-SUN1-
80SAAA83 
pCSxW-HA-SUN1 OTS19  
OTS20 
- SDM (pCSxW-
HA-SUN1) 
pCSxW-HA-SUN1-
84AAAS87 
pCSxW-HA-SUN1 OTS21  
OTS22 
- SDM (pCSxW-
HA-SUN1) 
pCSxW-HA-SUN1-
86ASSA89 
pCSxW-HA-SUN1 OTS23 
OTS24 
- SDM (pCSxW-
HA-SUN1) 
pCSxW-HA-SUN1-
88SAAA91 
pCSxW-HA-SUN1 OTS25 
OTS26 
- SDM (pCSxW-
HA-SUN1) 
pCSxW-HA-SUN1-
90AAAA93 
pCSxW-HA-SUN1 OTS27  
OTS28 
- SDM (pCSxW-
HA-SUN1) 
pCSxW- HA-SUN1MluI pCSxW-HA-SUN1 OTS29 
OTS30 
- SDM (pCSxW-
HA-SUN1) 
pCSxW-HA-SUN2NTD-
SUN1 
 
pCSxW-HA-SUN2 OTS4 
OTS31 
EcoRI, 
MluI 
pCSxW- HA-
SUN1MluI 
pCSxW HA-Fv1n Fv1n cDNA OTS32  
OTS33 
EcoRI-
MluI,  
NotI 
pCSxW-HA 
pCSxW-HA-SUN1NTD-Fv1n pCSxW-HA-SUN1 OTS1 
OTS34 
EcoRI, 
MluI 
pCSxW HA-
Fv1n 
pCSxW- HA-EMD EMD cDNA OTS35  
OTS37 
MfeI,  
NotI 
pCSxW-HA 
pCSxW- HA-EMDΔLEM EMDΔLEM cDNA OTS36 
OTS37 
MfeI, 
 NotI 
pCSxW-HA 
pCSxW- HA-LMNA LMNA cDNA OTS38 
OTS39 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW- HA-NET26 pBudCE4.1-NET26  OTS40 
OTS41 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW- HA-NET31 pBudCE4.1-NET31  OTS42  
OTS43 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW- HA-NET39 pBudCE4.1-NET39  OTS44  
OTS45 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW- HA-LUMA pBudCE4.1-LUMA OTS46 
OTS47 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW- HA-LBR pBudCE4.1-LBR OTS48 
OTS49 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW- LBR-HA pCSxW- HA-LBR OTS50 
OTS51 
BamHI, 
PspOMI 
pCSxW 
pCSxW- HA-LULL1 pBudCE4.1-LULL1 OTS52 
OTS53 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW- LULL1-HA pBudCE4.1-LULL1 OTS54 
OTS55 
BglII,  
NotI 
pCSxW- LBR-
HA 
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pCSxW- HA-NET3 pBudCE4.1-NET3  OTS56  
OTS57 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW- NET3-HA pBudCE4.1-NET3  OTS58  
OTS59 
BamHI, 
NotI 
pCSxW- LBR-
HA 
pCSxW- TSPAN5-HA pBudCE4.1-TSPAN5  OTS60 
OTS61 
BamHI, 
NotI 
pCSxW- LBR-
HA 
pCSxW- TMEM53-HA pBudCE4.1-TMEM53  OTS62 
OTS63 
BamHI, 
NotI 
pCSxW- LBR-
HA 
pCSxW- LAP2β-HA pBudCE4.1-LAP2β  OTS64 
OTS65 
BamHI, 
NotI 
pCSxW- LBR-
HA 
pCSxW- HA-TORSA pBudCE4.1-TORSA  OTS66 
OTS67 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW- TORSA-HA pBudCE4.1-TORSA  OTS68 
OTS69 
BamHI, 
NotI 
pCSxW- LBR-
HA 
pCSxW- HA-TORSA-EQ pBudCE4.1-TORSA-
EQ  
OTS66  
OTS67 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW- TORSA-EQ-HA pBudCE4.1-TORSA-
EQ  
OTS68  
OTS69 
BamHI, 
NotI 
pCSxW- LBR-
HA 
pCSxW- HA-NURIM pBudCE4.1-NURIM  OTS70 
OTS71 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW- NURIM-HA pBudCE4.1-NURIM OTS72 
OTS73 
BglII,  
NotI 
pCSxW- LBR-
HA 
pCSxW- HA-UNCL pBudCE4.1-UNCL  OTS74  
OTS75 
MfeI,  
NotI 
pCSxW-HA 
pCSxW- UNCL-HA pBudCE4.1-UNCL OTS76 
OTS77 
BamHI, 
NotI 
pCSxW- LBR-
HA 
pCSGW+ pCSGW OTS78 
OTS79 
- SDM (pCSGW) 
pCSGW++ pCSGW+ OTS80 
OTS81 
- SDM 
(pCSGW+) 
p2LTR++ p2LTR 2-LTR Fwd 
2-LTR Rev 
- SDM (p2LTR) 
pCMV-ΔR8.91Ex-NRA pRHPA  OTS82  
OTS83 
NotI,  
ApaI 
pCMV-
ΔR8.91Ex 
pCMV-ΔR8.91Ex-H87Q pCMV-ΔR8.91Ex OTS84  
OTS85 
- SDM (pCMV-
ΔR8.91Ex) 
pCMV-ΔR8.91Ex-H120N pCMV-ΔR8.91Ex OTS86 
OTS87 
- SDM (pCMV-
ΔR8.91Ex) 
pCMV-ΔR8.91Ex-G208A pCMV-ΔR8.91Ex OTS88 
OTS89 
- SDM (pCMV-
ΔR8.91Ex) 
pCMV-ΔR8.91Ex- H87Q- 
H120N 
pCMV-ΔR8.91Ex-
H87Q 
OTS86  
OTS87 
- SDM (pCMV-
ΔR8.91Ex-
H87Q) 
pCMV-ΔR8.91Ex- H87Q- 
H120N- G208A 
pCMV-ΔR8.91Ex- 
H87Q- H120N 
OTS88 
OTS89 
- SDM (pCMV-
ΔR8.91Ex-
H87Q-H120N) 
pCMV-ΔR8.91Ex-NRA-
Q87H 
pCMV-ΔR8.91Ex-
NRA 
OTS90 
OTS91 
- SDM (pCMV-
ΔR8.91Ex-
NRA) 
pCMV-ΔR8.91Ex-NRA-
Q87H-N120H 
pCMV-ΔR8.91Ex-
NRA-Q87H 
OTS92 
OTS93 
- SDM (pCMV-
ΔR8.91Ex-
NRA-Q87H) 
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pCMV-ΔR8.91Ex-NRA-
Q87H-N120H-A208G 
pCMV-ΔR8.91Ex-
NRA-Q87H-N120H 
OTS94 
OTS95 
- SDM (pCMV-
ΔR8.91Ex-
NRA-Q87H-
N120H) 
pNL4.3-BRX pRHPA - BssHII,  
XhoI 
pNL4.3 
pNL4.3-BRE pRHPA - BssHII, 
EcoRI 
pNL4.3 
pNL4.3-ERX pRHPA - EcoRI, 
XhoI 
pNL4.3 
pCSxW- MX2-HA pLVX-Puro-MX2 OTS96 
OTS97 
BamHI, 
NotI 
pCSxW- LBR-
HA 
pCSxW- MX2(K131A)-HA pLVX-Puro-
MX2(K131A) 
OTS96 
OTS97 
BamHI, 
NotI 
pCSxW- LBR-
HA 
pCSxW- MX2(T151A)-HA pLVX-Puro-
MX2(T151A) 
OTS96 
OTS97 
BamHI, 
NotI 
pCSxW- LBR-
HA 
pCSxW- MX2(D297N)-HA pLVX-Puro-
MX2(D297N) 
OTS96 
OTS97 
BamHI, 
NotI 
pCSxW- LBR-
HA 
pCSxW- MX2(D300N)-HA pLVX-Puro-
MX2(D300N) 
OTS96 
OTS97 
BamHI, 
NotI 
pCSxW- LBR-
HA 
pCSxW- MX2(M574D)-HA pLVX-Puro-
MX2(M574D) 
OTS96 
OTS97 
BamHI, 
NotI 
pCSxW- LBR-
HA 
pCSxW- MX2(-NLS)-HA pLVX-Puro-MX2(-
NLS) 
OTS98 
OTS97 
BamHI, 
NotI 
pCSxW- LBR-
HA 
pCSxW- HA-MX1 pLVX-Puro-MX1 OTS99 
OTS100 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW- HA-MX1(K83A) pLVX-Puro-
MX1(K83A) 
OTS99 
OTS100 
EcoRI, 
NotI 
pCSxW-HA 
pCSxW-LUC-HA pCSxW-HA-LUC OTS101 
OTS102 
BamHI, 
NotI 
pCSxW- LBR-
HA 
pSRQ_SUN1_sh1 Primer annealing OTS103 
OTS104 
BamHI, 
EcoRI 
pSRQ 
pSRQ_SUN1_sh2 Primer annealing OTS105 
OTS106 
BamHI, 
EcoRI 
pSRQ 
pSRQ_SUN1_sh3 Primer annealing OTS107 
OTS108 
BamHI, 
EcoRI 
pSRQ 
pSRQ_SUN2_sh1 Primer annealing OTS109 
OTS110 
BamHI, 
EcoRI 
pSRQ 
pSRQ_SUN2_sh2 Primer annealing OTS111 
OTS112 
BamHI, 
EcoRI 
pSRQ 
pSRQ_SUN2_sh3 Primer annealing OTS113 
OTS114 
BamHI, 
EcoRI 
pSRQ 
pSRQ_SUN2_sh4 Primer annealing OTS115 
OTS116 
BamHI, 
EcoRI 
pSRQ 
plentiCRISPRv2_SUN1g1 Primer annealing OTS117 
OTS118 
BsmbI plentiCRISPRv
2 
plentiCRISPRv2_SUN1g2 Primer annealing OTS119 BsmbI plentiCRISPRv
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OTS120 2 
plentiCRISPRv2_SUN1g3 Primer annealing OTS121 
OTS122 
BsmbI plentiCRISPRv
2 
plentiCRISPRv2_SUN2g1 Primer annealing OTS123  
OTS124 
BsmbI plentiCRISPRv
2 
plentiCRISPRv2_SUN2g2 Primer annealing OTS125 
OTS126 
BsmbI plentiCRISPRv
2 
plentiCRISPRv2_SUN2g3 Primer annealing OTS127 
OTS128 
BsmbI plentiCRISPRv
2 
plentiCRISPRv2_SUN2g4 Primer annealing OTS129 
OTS130 
BsmbI plentiCRISPRv
2 
plentiCRISPRv2_SUN2g5 Primer annealing OTS131 
OTS132 
BsmbI plentiCRISPRv
2 
plentiCRISPRv2_MX2g1 Primer annealing OTS133 
OTS134 
BsmbI plentiCRISPRv
2 
plentiCRISPRv2_MX2g2 Primer annealing OTS135 
OTS136 
BsmbI plentiCRISPRv
2 
plentiCRISPRv2_MX2g3 Primer annealing OTS 137 
OTS138 
BsmbI plentiCRISPRv
2 
plentiCRISPRv2_MX2g4 Primer annealing OTS139 
OTS140 
BsmbI plentiCRISPRv
2 
Table 13. Plasmids generated in this work 
5.1.13. Antibodies 
Name Antigen Species Application Company 
3F10 HA 
Rat, monoclonal, 
HRP linked 
1:5000 in WB 
Roche Holding AG, 
Basel, Switzerland 
HA.11 16B12 HA Mouse, monoclonal 1:250 in IF 
Covance, Princeton, 
USA 
EPR6554 SUN1 Rabbit, monoclonal 
1:1000 in WB 
1:250 in IF 
GeneTex, Inc., Irvine, 
USA 
EPR6557 SUN2 Rabbit, monoclonal 
1:1000 in WB 
1:250 in IF 
Abcam plc, Cambridge, 
UK 
13750-1-AP 
 
MX1 Rabbit, polyclonal 1:1000 in WB 
Proteintech Group, Inc. 
Chicago, USA 
NBP1-81018 MX2 Rabbit, polyclonal 1:1000 in WB 
Novus Biological, 
Littleton, USA 
183 
HIV-1 
CA/p24 
Mouse, monoclonal 1:1000 in WB NIH, Bethesda, USA 
137F5 MAPK Rabbit, monoclonal 1:1000 in WB 
Cell Signaling 
Technology, Inc., 
Danvers, USA 
H-114 HSP90α/β Rabbit, polyclonal 1:3000 in WB 
Santa Cruz 
Biotechnology, Inc., 
Dallas, USA 
B-5-1-2 Tubulin Mouse, monoclonal 1:3000 in WB 
Sigma-Aldrich, St. 
Louis, USA 
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 Table 14. Antibodies used in this work 
5.1.14. Software 
Name Source 
CFX Manager BioRad, Hercules, USA 
Fiji Open source [291] 
FlowJo V10 FlowJo LLC, Ashland, USA 
Microsoft Office 2010 Microsoft, Redmond, USA 
Table 15. Software used in this work 
5.2. Molecular biology methods 
5.2.1. Bacteria and DNA preparation 
Chemically competent bacteria were transformed using a heat-shock 
procedure. 80 µl of chemo-competent E. coli Stbl2 bacteria suspension was 
incubated with 1 μg plasmid DNA or 5 μl ligation product for 45 min on ice. Heat 
shock was performed for 90 sec at 42°C followed by incubation on ice for 5 min. 
If plasmid DNA with Ampicillin resistance was used, transformed bacteria were 
directly plated on selective agar plates. In the case of kanamycin resistance, 
transformed cells were mixed with 800 µl of LB-medium and incubated for a 
further 30 min at 37 °C while shaking. After centrifugation for 2 min at 6000 rpm, 
supernatants were removed and cells resuspended in 50 µl of LB medium. After 
plating the cells onto selective agar plates (50 mg/l ampicillin or kanamycin), 
colonies were grown overnight at 37 °C. For the amplification of plasmid DNA, 
single colonies were used to inoculate overnight cultures in LB medium 
(containing 100 mg/l ampicillin or 50 mg/l kanamycin) on a shaker at 37 °C. For 
small and medium scale DNA preparations, 2 and 50 ml overnight bacteria 
ECL Mouse 
IgG 
Mouse 
IgG 
Goat, polyclonal 
HRP linked 
1:10000 in 
WB 
Thermo Fisher 
Scientific, Waltham, 
USA 
ECL Rabbit 
IgG 
Rabbit 
IgG 
Goat, polyclonal 
HRP linked 
1:10000 in 
WB 
Cell Signaling 
Technology, Inc., 
Danvers, USA 
AlexaFluor 
488 
Mouse 
IgG 
Goat, polyclonal 1:2000 in IF 
Thermo Fisher 
Scientific, Waltham, 
USA 
AlexaFluor 
488 
Rabbit 
IgG 
Goat, polyclonal 1:2000 in IF 
Thermo Fisher 
Scientific, Waltham, 
USA 
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culture were utilized, respectively. Purification of DNA from bacterial cultures 
was performed using QIAprep® Spin Miniprep Kit or NucleoBond® Xtra Midi EF 
according to the manufacturer’s instructions.  
DNA concentration and purity were measured using a nanophotometer. 1 μl of 
DNA solution was applied to the cuvette top and concentration was measured 
by optical density at 260 nm against the respective Elution buffer. Purity was 
controlled by verifying that OD260nm/OD280nm ratio was between 1.8 and 2.0. 
DNA solutions were adjusted to 1 μg/μl using the respective Elution buffer. 
5.2.2. Polymerase Chain Reaction (PCR) 
PCR is a method to selectively amplify a defined DNA sequence from a 
complex template DNA. The flanking sequences of the target DNA are used to 
generate a sense and an anti-sense oligonucleotide primer (usually 18-30 bp). 
The primers are used as the starting point by the polymerase for amplification. 
Chain elongation in 5´ to 3´direction is achieved by addition of dNTPs. The 
steps of PCR amplification are as follows I) heat denaturation of the double-
stranded template DNA at 95 °C, II) primer annealing to the complementary 
sequences of the single stranded target (45-60 °C), III) extension by the DNA 
polymerase at 68-72 °C. After primer extension the mixture is heated again to 
separate the strands. Cooling down the mixture allows the primers to hybridize 
with the complementary regions of newly synthesized DNA. Each cycle literally 
doubles the amplicon. The reaction mixture was prepared on ice and the 
following components were mixed in a 0.2 ml PCR tube: 
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PCR was performed using Thermal Cycler C1000 Touch™ with the following 
thermocycling program: 
  
Annealing temperature as well as elongation time were set depending on the 
primer composition and the length of the amplified sequence, respectively. 
Usually 34 cycles were performed.  
Successful DNA amplification was monitored by running 5 μl product on a 1% 
agarose gel. All nucleotide sequences of PCR products were confirmed by 
sequencing (GATC Biotech, Konstanz, Germany). 
5.2.3. PCR-based mutagenesis 
To generate plasmids carrying point mutations, PCR based mutagenesis was 
performed as described above using two primers with opposite orientation 
covering the desired point mutation. The reaction mixture was prepared on ice 
and the following components were mixed in a 0.2 ml PCR tube: 
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PCR was performed using Thermal Cycler C1000 Touch™ with the following 
thermocycling program: 
 
PfuTurbo DNA Polymerase was used according to the manufacturer’s protocol. 
After the amplification, the template plasmid was digested by adding 2 µl of 
DpnI directly to the PCR reaction mix and incubation at 37 °C for 2 h. After 
digestion, 10 µl of the mix were transformed into competent bacteria.  
5.2.4. Separation of DNA by agarose gel electrophoresis 
0.5-1 μg DNA fragments were separated by electrophoresis using 1% agarose 
in 1x TBE buffer gels. GelRed was used to stain DNA (diluted 1:10.000 in the 
gel prior to polymerization). DNA was mixed with DNA loading buffer and 
loaded into the wells. Gels were run at 80 V for 30-45 min and size of DNA 
fragments was compared to a size standard (1 kb DNA ladder). Analytical gels 
were analyzed under UV light at 254 nm, while DNA was excised from 
preparative gels under 360 nm illumination and purified by NucleoSpin® Gel 
and PCR Clean-up kit according to manufacturer's instructions. 
5.2.5. Analysis of DNA with restriction enzymes 
Restriction digests of DNA were performed using 2 μg plasmid DNA, 0.5 μl of 
each restriction enzyme and 2 μl 10x NEB buffer according to the enzyme used. 
The reaction was filled up with water to 20 μl. Enzymes and buffers were used 
as recommended by the manufacturer NEB and reaction conditions were set 
according to their protocols.  
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5.2.6. Ligation  
For ligation reactions, 100 ng of digested and purified vector was mixed with the 
digested and purified insert in a 1:3 or 1:5 ratio. Subsequently, 2 μl of 10x T4 
ligase buffer and 1 μl of T4 DNA ligase was added, reactions were filled up with 
water to 20 μl and incubated over night at 4 °C. 5 μl were used for 
transformation of bacteria (see paragraph 5.2.1.). 
5.2.7. Cloning of shRNAs into retroviral vector pSIREN RetroQ 
Suitable silencing RNA target sequences for SUN1 or SUN2 were identified 
using http://bioinfo.clontech.com/rnaidesigner/sirnaSequenceDesignInit.do. 
Oligonucleotide sequences to generate short hairpin RNAs were designed 
using the website http://bioinfo.clontech.com/rnaidesigner/oligoDesigner.do, and 
ordered from Eurofins Scientific (Brussel, Belgium).  
Overlapping oligonucleotides encoding the shRNA were annealed using the 
following protocol. 10 µg of each oligonucleotide (1 µg/ µl) were mixed with 2.5 
µl of 2 M NaCl solution in a total volume of 50 µl. The mix was boiled for 5 min 
at 98°C in a PCR block and subsequently cooled down at a rate of 0.1 °C per 
second. After annealing 350 µl H2O, 40 µl 3 M NaAc and 1100 µl 100 % ethanol 
were added and the solution was briefly vortexed and then placed at -80 °C and 
incubated overnight. To pellet the annealed oligos the solution was spun at 
14000 rpm in a bench top centrifuge at 4 °C for 20 min. The DNA pellet was air 
dried and resuspended in 50 µl H2O. The annealed oligos with overhanging 
single strand ends were then cloned into the EcoRI and BamHI sites in the 
pSIREN RetroQ vector.  
5.2.8. Cloning of gRNAs into retroviral vector plentiCRISPRv2 
Suitable CRISPR/Cas9 target sequences within SUN1, SUN2 or MX2 DNA 
region were identified using the website http://chopchop.cbu.uib.no/ and 
oligonucleotides encoding guide RNA (gRNA), which contains the ~20-
nucleotide targeting sequence and a Cas9 nuclease-recruiting sequence, were 
designed and ordered from Eurofins Scientific (Brussel, Belgium). 
Guide RNA encoding oligonucleotides were annealed following the same 
protocol of paragraph 5.2.6. and cloned into BsmBI-linearized plentiCRISPRv2 
according to the manufacturer’s guidelines. 
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5.3. Cell biology and virology methods 
5.3.1. Cell culture and freezing/thawing of cell lines 
All cells were incubated at 37°C at 5 % CO2 in 95 % humidity. 
293T and U87MG CD4/CXCR4 cell lines were kept in DMEM High Glucose 
GlutaMAX™, supplemented with 10 % FCS, 100 U/ml penicillin and 100 μg/ml 
streptomycin. 
THP-1 and Jurkat TAg cell lines were kept in RPMI 1640 Medium GlutaMAX™ 
supplemented with 10 % FCS, 100 U/ml penicillin and 100 μg/ml streptomycin. 
THP-1 cells were differentiated with 25 ng/ml phorbol 12-myristate 13-acetate 
(PMA) for 24 h.  
Peripheral blood mononuclear cells (PBMCs) were isolated from 50 ml of whole 
blood or from buffy coats of healthy blood donors. To this end, the buffy coats 
were diluted 1:2 with PBS, prior to loading 35 ml of the diluted buffy coat on a 
15 ml Ficoll cushion. Leukocytes were then isolated by gradient. Cells at the 
interphase of Ficoll and plasma was aspirated and washed twice with PBS. 
CD4+ T-cells were then enriched from PBMCs by magnetic bead negative 
selection using the Human CD4+ T Cell Isolation Kit - T cells according to the 
manufacturer’s protocol (Miltenyi Biotec). Alternatively, CD4+ T-cells were 
directly enriched from buffy coats of healthy blood donors using the Human 
CD4+ T Cell Enrichment Cocktail RosetteSep™ according to the manufacturer's 
protocol (Stemcell Technologies). CD14+ monocytes were directly enriched 
from PMBCs by magnetic bead negative selection using the Monocyte Isolation 
Kit II according to the manufacturer's protocol (Miltenyi Biotec). Primary CD4+ T 
cells or CD14+ monocytes were then kept in RPMI 1640 Medium GlutaMAX™ 
with 10% supplemented with 10 % FCS, 100 U/ml penicillin and 100 μg/ml 
streptomycin. CD4+ T-cells were activated with 100 IU/ml interleukin-2 (IL-2) 
and 2 μg/ml phytohemagglutinin (PHA) for 3 days, whereas MDMs were 
differentiated for 7 days using 100 ng/ml granulocyte-macrophage colony-
stimulating factor (GM-CSF). 
Cells were passaged every 3 days at ~ 90% confluent cells. For that purpose, 
adherent cells were briefly washed with PBS, detached with 0.05 % 
Trypsin/EDTA in PBS for 5 min and reseeded in new medium at a ratio of 1:4. 
Suspension cells were separated and then passaged in the appropriate 
   
55 
 
concentration. Cell line stocks were maintained by cryo-conservation in liquid 
nitrogen. For this purpose, cells were pelleted (1200 rpm, 8 min), resuspended 
in 1 ml freezing medium (FCS supplemented with 10 % DMSO or glycerol) and 
transferred into a cryo-conservation tube. Tubes were slowly cooled to -80°C in 
freezing Styrofoam box and then transferred to liquid nitrogen for long-term 
storage. Cells were thawed rapidly and transferred to 75 cm2 flasks or 10 cm 
dishes containing 20 ml pre-warmed fresh medium. The medium was changed 
after 24 hrs and cells were split at 90 % confluency. 
5.3.2. Virus and vector preparation  
Infections and fluorescence activated cell sorting (FACS) were performed as 
described in earlier studies [185, 293, 480, 481]. Viruses and lentivectors (LVs) 
were produced by transient transfection of 293T cells [467] with three plasmids 
using Polyethylenimine (PEI), an organic polymeric polycation that 
spontaneously forms complexes by binding to the DNA phosphate backbone. 
These complexes are taken up into the cell, leading to transfection. 
For lentiviral vector (LV) production, 4.5 μg of HIV-1 viral plasmid (pCSxW 
vector, plentiCRISPRv2 or RetroQ vectors encoding respectively the protein, 
the gRNA or the shRNA of interest; see paragraph 5.1.9.) 3 μg of pCMVΔR8.91 
GagPol encoding plasmid and 3 μg of VSV-G Env expression plasmid pMD.G 
(see paragraph 5.1.9.) were mixed into a separate reaction tube in which 1 ml 
OptiMem was pre mixed with 42 μl of PEI (stock 1mg/ml in H2O). Next, the 
mixture is homogenised by vortexing for short time, incubated for at least 15 
min at room temperature and added drop-wise onto a ~75 % confluent 10 cm 
dish of 293Ts replaced with new fresh 8 ml media. For VSV-G-pseudotyped full-
length HIV-1 production, 8 μg HIV-1 GFP reporter viral plasmid pNLENG-IRES-
Nef (see paragraph 5.1.9.) and 2 μg pMD.G were transfected per plate. To 
generate full-length laboratory strains HIV-1NL4.3, HIV-1IIIB, or HIV-1 
transmitted/founder RHPA, SUMA, WITO, THRO or ZM247 with a copackaged 
GFP lentivirus (LV) minigenome, 4.5 μg pCSGW was cotransfected with 3 μg 
full-length viral plasmid (pNL4.3, pIIIB, pRHPA, pWITO, pTHRO, pSUMA, 
pZM247; see paragraph 5.1.9) and 3 μg pMD.G. For all viral production, 
medium was replaced 24 h post transfection, the viral supernatant was 
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harvested at 48 h and 72 h post transfection, and collections were pooled and 
passed through a 0.45 μm cellulose filters to remove cell debris.  
To determine infectious titres, 105 cells were plated in 6-well plates and infected 
the next day with 1 ml of viral supernatant diluted usually in a three-fold serial 
dilution series to obtain six different concentrations. Infected cells were 
enumerated 48 h post infection by measuring the GFP expression using FACS. 
Subsequently, the cleared supernatant was aliquoted and stored at -80 °C or 
particles were collected by centrifugation through a 20 % (w/v in PBS) sucrose 
cushion (30 ml supernatant on a 7 ml sucrose cushion) in a SW-28 rotor at 
28,000 rpm, at 4°C for 2 h. Pellets were resuspended in 200 μl RPMI and 
stored at -80°C.  
5.3.3. Transduction of cells with VSV-G-pseudotyped HIV-1 LV 
5.3.3.1. Generation of stable cell lines ectopically expressing 
proteins  
Cell lines ectopically expressing proteins of interest were generated by 
transduction of 105 cells in 6-well plates with 1 ml VSV-G-pseudotyped HIV-1 LV 
encoding the individual protein and generated as described in paragraph 5.3.1. 
48 h post-infection, the newly produced cell lines were usually expanded to 10 
cm plates before analysis. 
5.3.3.2. Generation of CRISPR/Cas9 knockout stable cell lines 
THP-1 and Jurkat Tag CRISPR/Cas9 SUN1, SUN2 or MX2 knockout cells 
clones were generated by transduction with VSV-G-pseudotyped HIV-1 LV 
produced using pCMV-ΔR8.91, pMD.G, and plentiCRISPRv2 (see paragraph 
5.1.9.). Transduced cell populations were selected with 2 μg/ml puromycin for 2 
weeks. Single-cell clones were generated by limiting dilution in 96-well plates 
and grown for at least 2 weeks in the absence of puromycin. Subsequently, they 
were usually expanded first to 24-well plates, then to 6-well plates and lastly to 
10 cm plates before analysis. Cell clones without protein expression were 
determined by immunoblotting using specific antibodies. Gene disruption was 
validated by PCR amplification and sequencing of the targeted genomic region 
from isolated total genomic DNA of selected clones. On this purpose, the 
following primer pairs (forward/reverse) were used: OTS141/OTS142 for 
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SUN1g1, OTS143/OTS144 for SUN1g2, OTS145/OTS146 for SUN2g1, 
OTS147/OTS148 for SUN2g2, OTS149/OTS150 for SUN2g3, OTS151/OTS152 
for MX2g2 (see paragraph 5.1.10.). As negative controls, we used either a 
single-cell clone still expressing the protein of interest or parental cells. 
5.3.3.3. Generation of ShRNA-mediated knockdowns cells 
SUN1, SUN2 ShRNA-mediated knockdowns U87MG CD4/CXCR4 and THP-1 
cells were generated by transduction of 105 cells in 6-well plates with VSV-G-
pseudotyped HIV-1 LV produced using pCMV-ΔR8.91, pMD.G and pSIREN 
RetroQ vectors (see paragraph 5.1.9.) expressing individual specific short 
hairpin RNAs to silence proteins gene expression via RNA interference (RNAi). 
Transduced cell populations were selected with 2 μg/ml puromycin for 3 days 
and were usually expanded to 10 cm plates before analysis. Cells without 
protein expression were determined by immunoblotting using specific 
antibodies. 
5.3.4. Infectivity assays  
For infectivity assays, a total of 8 x 104 U87MG CD4/CXCR4, 1 x 105 THP-1 or 
Jurkat TAg cells were plated in 100 μl of medium per well in 96-well plates. In 
the case of IFN-α titration experiments, a total of 5 x 105 THP-1 or CD4+ T cells 
were plated and treated for 24 h with IFN-α. Next, cells were infected with 100 
μl of supernatant containing VSV-G-pseudotyped GFP-reporter lentiviral vectors 
or full-length GFP-reporter virus for 24 to 72 h and virus titrations were usually 
performed with 3-fold serial dilutions of the viral supernatant. Cells were fixed in 
4% paraformaldehyde (PFA), the infectivities were determined from the 
percentage of GFP+ cells by flow cytometry using a FACSVerse system (BD 
Biosciences), and the infectious titers were determined on at least three 
different virus doses. The average infectious titers were calculated using Excel 
with standard deviations depicted as error bars. To compare different CA 
mutants with wild-type GFP reporter vector/virus, viral input was normalized by 
293T infectious titers or by units of reverse transcriptase in the supernatant, as 
determined by SG-PERT assay previously described. 
Experiments with MDMs were performed with 48-well plates, seeding 5 x 105 
monocytes per well prior to differentiation. For analysis by flow cytometry, 
MDMs were trypsinized for at least 30 min, resuspended and fixed in 4% PFA. 
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Virus titrations were usually performed by 3-fold serial dilutions of the viral 
supernatant.  
For experiments using Ciclosporin A (CsA), drug was used at 5 μM in DMSO 
and added at the time of infection with the reporter virus. DMSO was used as 
the vehicle control at the same concentration. 
In the case of IFN-α titration experiments, a single dose of supernatant 
containing reporter virus was used, aiming for a MOI of ≤1. 
5.3.5. Measurement of RT activity: SG-PERT  
Analysis of RT activity in supernatants, as a measure of virus release, was 
performed by SG-PERT (SYBR Green based Product Enhanced Reverse 
Transcriptase) assay [292].  
On this purpose, 5 μl of the virus containing supernatants obtained from virus 
producing cells (see paragraph 5.3.1.) were lysed by incubation with 5 μl 2x SG-
PERT lysis buffer (50 mM KCl, 100 mM Tris-HCl, 40 % Glycerol, 0.25 % Triton 
X-100, pH 7.4), containing 2 U Ribolock RNAse inhibitor. Subsequently, 90 μl 
SG-PERT PCR buffer (5 mM (NH4)2SO4, 20 mM KCl, 20 mM Tris-HCl, pH 8.0) 
was added. From this mixture, 10 μl were added to 10 μl SG-PERT PCR-
reaction mix (PCR buffer containing 10 mM MgCl2, 0.2 mg / ml BSA, 400 μM 
dNTPs, 1 pmol primer RT-Assay-fwd, 1 pmol RT-Assay-rev, 8 ng MS2 RNA, 
and 1:10000 SYBR Green), containing 0.5 U GoTaq Hotstart Polymerase.  
RT-PCR was performed using Real Time PCR detector CFX96 Touch™ 
(BioRad) with the following thermocycling program: 42 ºC for 20 minutes, 95 ºC 
for 2 minutes, 40 cycles of 95 ºC for 5 seconds, 60 ºC for 5 seconds, 72 ºC for 
15 seconds and 80 ºC for 7 seconds. A final melting curve step was included. 
Results were analyzed with the CFX Manager software (BioRad). 
5.3.6. TaqMan qPCR 
Quantitative TaqMan PCR (qPCR) was performed to determine the copy 
numbers of GFP or 2-LTR DNA circles, surrogates for early RT products and 
nuclear import, respectively. Specific primer/probe sets were used (see 
paragraph 5.1.11.). 2 x 105 cells per well (U87MG CD4/CXCR4) or 6 x 105 cells 
per well (THP-1) were seeded in 6-well plates and infected the next day in 
triplicate for 6 h (GFP) or 24 h (2-LTR DNA circles) with equal doses of DNase 
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treated virus (RQ1 RNase-Free DNase; final concentration 70 U/ml for 1h). 
After the incubation time, total DNA was isolated using the QIAamp® DNA Mini 
Kit. To enumerate infected cells, the third sample was subjected to FACS 
analysis 48 h after infection. As a negative control for plasmid contamination 
cells were incubated with the non-nucleoside reverse transcriptase inhibitor 
efavirenz (5 μM final concentration). Extracted total DNA (100-500 ng) was 
subjected to Taqman qPCR and the reaction mixture was prepared on ice. For 
each reaction, the following components were mixed in a 0.2 ml PCR tube: 
Name Component 
ddH2O 5 μl 
TaqMan® Universal PCR Master Mix 12,5 μl 
Forward primer (7,5 μM) 1 μl 
Reverse primer (7,5 μM) 1 μl 
Probe (7,5 μM) 0,5 μl 
Diluted plasmid standard/Total DNA sample 5 μl 
In every experiment, a standard curve of the respective amplicon was 
measured in duplicate ranging from 101 to 105 copies in addition to a no-
template control. To measure GFP the plasmid CNCG served as standard, 
whereas for 2-LTR circles the plasmid 2-LTR was used (see paragraph 5.1.11.), 
and all dilutions were performed in an equal amount of salmon sperm carrier 
DNA in water (100 μg/ ml). The PCR cycling program for the GFP and the LRT-
P amplicon consisted of initial incubations at 50 °C for 2 min and 95 °C for 10 
min, after which 40 cycles of amplification were carried out at 15 s at 95 °C 
followed by 1 min at 60 °C. For 2-LTR circles usually 50 cycles were performed 
with 15 s at 95 °C followed by 90 s at 60 °C. For detection the Real Time PCR 
detector CFX96 Touch™ system (BioRad) was used. 
Since LV-mediated transduction was used to express HALUC, HASUN1 or 
HASUN2 in U87MG CD4/CXCR4 cells, a reporter vector where the 5’- and 3’-
LTRs had been engineered was used (referred to as HIV-1 LV++; see 
paragraph 5.1.12.), such that only the 2-LTR circles produced by the reporter 
virus could be detected by using specific primer (2-LTR++ fwd/rev) and 
standard sets (pLTR++) (see paragraph 5.1.11.). Results were analyzed with 
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the CFX Manager software and usually the number of copies of amplicon per 
100 ng total DNA was calculated and plotted. 
5.4. Biochemistry methods 
5.4.1. SDS-polyacrylamide-gel electrophoresis (SDS-PAGE) 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a 
very common method for separating proteins by their molecular weight under 
denaturing conditions. Cell samples for SDS-PAGE were usually lysed by 
boiling in protein sample buffer at 95 °C for 5 min. After equilibrating to RT, 
aliquots of cell lysates were loaded on a 10 % polyacrylamide gel and 
electrophoresis was performed at 130 V for 90 min in SDS PAGE running buffer 
using the Tetra Vertical Electrophoresis Cell Mini-PROTEAN® system (Biorad). 
Precision Plus Protein™ WesternC™ Standards (Biorad) was used as a protein 
size reference. 
Laemmli gels were generated using Acrylamide Solutions TGX™ FastCast™ 
according to the manufacturer's protocol (Biorad) and an acrylamide 
concentration of normally 10 % for the separating gel and 6 % for the stacking 
gel were utilized. Briefly, for each separating gel 3 ml Resolver A, 3 ml of 
Resolver B, 3 μl of TEMED were mixed in a 50 ml Falcon Tube before starting 
gel polymerisation by adding 30 μl of 20 % ammonium-persulfate (APS). The 
separating gel was quickly poured between two glass plates of the Bio-Rad 
PAGE Gel casting system. To avoid formation of air bubbles, 1 ml of 
isopropanol was carefully pipetted on top of the separating gel. After 
polymerisation the isopropanol was washed away with water and the excess 
water was removed by using Whatman paper strips. To prepare the stacking 
gel, 1 ml of Stacker A, 1 ml of Stacker B and 2 μl TEMED were mixed in a 50 ml 
Falcon tube before starting gel polymerisation by adding 10 μl APS. The 
solution was mixed and carefully added on top of the separating gel avoiding 
formation of air bubbles. The comb was inserted and the gels were left for 15 
min at room temperature for gel polymerisation. The gels were wrapped in wet 
tissues and could be kept at 4°C for up to 1 week.  
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5.4.2. Western Blot 
After separating by SDS-PAGE, the proteins were blotted onto methanol 
activated polyvinylidene difluoride (PVDF) membranes using the Electrophoretic 
Transfer Cell Mini Trans-Blot® system (Biorad) at 100 V for 60 min. Membranes 
were incubated for 1h in PBS containing 0.05 % Tween 20 (PBS-Tween 20) 
and 5 % (w/v) non-fat milk powder to saturate non-specific binding sites. The 
membrane was briefly washed in PBS-Tween 20. The primary antibody was 
diluted in PBS-Tween 20 and the membrane was incubated shaking for 1 h at 
room temperature or overnight at 4 C°. After being washed three times with 
PBS-Tween 20, the membrane was incubated with secondary antibody 
conjugated with peroxidase in TBS-Tween 20 for 1 h shaking at room 
temperature and subsequently washed three times as described above. 
Membrane- bound secondary antibody was detected by chemiluminescence 
using the reagent Clarity™ Western ECL substrates (Biorad). 
Chemiluminescence was measured by the ECL ChemoCam Imager system 
(INTAS Science Imaging). 
 
5.4.3. CANC pulldown  
 
Figure 10. CANC pulldown method data from Malim Lab (KCL, London). Cell lysates from 
293T cells transfected with HALUC, HACPSF6, HASUN1, or HASUN2 were incubated with in vitro-
synthesized CANC nanotubes before centrifugation through a sucrose cushion and analysis of 
supernatants and pellets by immunoblotting using HA- and CA-specific antibodies. I, input; S, supernatant; 
P, pellet 
 
To address the question if SUN proteins may interact with the HIV-1 capsid, the 
Malim lab in London (King’s College London) investigated the binding of the 
different SUN1 or SUN2 mutants to in vitro synthesized HIV-1 CANC complexes 
(capsid-nucleocapsid complexes). 293T cells transfected with pCSxW 
expressing HA-tagged firefly luciferase, CPSF6, or wild-type SUN1 or SUN2 
proteins were lysed with hypotonic lysis buffer using a Dounce homogenizer. 
Lysates were cleared by centrifugation at 20,000 x g for 15 min. For pulldown 
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experiments, 200 µl of cell lysate was mixed with either 40 µl of 40 μM 
assembled CANC (an input sample was taken from this mix) or 40 μl of CANC 
binding buffer containing 5 μM TG50 and incubated at room temperature for 1 
h. The mixture was then overlaid onto a 250 µl 70% sucrose cushion and 
centrifuged at 15,000 x g for 10 min. A sample of the supernatant was 
withdrawn for further analysis, and the pellet was washed with 500 μl of wash 
buffer and centrifuged again at 10,000 x g for 5 min. Finally, the pellet was 
resuspended in 50 µl of 1x SDS-PAGE loading buffer. Input, supernatant, and 
pellet fractions were analyzed by immunoblotting using appropriate antibodies. 
 
5.5. Imaging methods 
5.5.1. Immunofluorescence and confocal microscopy 
Cells lines were seeded on glass cover slips in 24-well cell culture plates at a 
concentration of 2.5 × 104 cells per well. The cells were washed three times with 
warm 1 × PBS and fixed with 500 µl of a 4 % paraformaldehyde (w/v) solution 
for 10 min at room temperature. Subsequently, the cells were washed again 
three times with 1 × PBS and were then either directly used for further 
preparation or stored for up to 3 days at 4 °C. For permeabilization the cells 
were incubated for 5 min with 500 µl of a 0.2 % triton-x-100/ PBS (v/v) solution 
and washed 3 times with warm 1 × PBS prior to incubation with the primary 
antibody. The primary antibody was diluted to the desired concentration in a 1 × 
PBS buffer containing 5 % horse serum (v/v). After 45 min incubation at room 
temperature the cells were washed 3 times with 1 × PBS for 10 min and 
incubated with the secondary antibody conjugated with fluorescent dye Alexa 
488, diluted 1:2000 in a 1 × PBS buffer containing 5 % horse serum (v/v). After 
60 min incubation at room temperature in the dark, the cells were washed three 
times with 1 × PBS. Counterstaining of nuclei was performed using 1:500 
Hoechst 33258 in the secondary antibody solution. Subsequently, cells were 
washed again 3 times with 1 × PBS, rinsed with H2O and mounted on glass 
slides using Mowiol embedding medium (8 mM Mowiol 4-88 in PBS). 
Immunofluorescence pictures were obtained using a Leica confocal microscope 
following protocols provided by the manufacturer. In general, pictures were 
obtained using the 63 × oil immersion objective. 
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6. Results 
6.1. The role of inner nuclear membrane proteins SUN1 and 
SUN2 in early HIV-1 infection steps 
6.1.1. An overexpression screen of NE-associated proteins 
identifies SUN1 and SUN2 as HIV-1 interactors 
SUN2 has recently been described to impact the early stages of HIV-1 infection 
[173, 206, 293, 294], and to address the question whether other membrane 
associated NE proteins would exert similar activity, an overexpression screen 
with a number of HA-tagged human NE-associated proteins (Table 16) was 
carried out by stably transducing U87MG CD4/CXCR4 cells with lentiviral 
vectors encoding the individual NE proteins (see paragraphs 5.1.12. and 
5.3.3.1. in Materials and Methods). The cells were then infected with a VSV-G 
pseudotyped GFP-encoding HIV-1 LV vector for two days, and measured its 
infection rate as the percentage of GFP-positive cells. Whereas most of the NE 
proteins had minimal or null effect, SUN2 overexpression inhibited by 5-fold the 
HIV-1 LV infection, while SUN1 resulted in a 20-fold decrease of the infection 
(Fig. 11A). The protein expression level of HASUN1 and HASUN2 was 
validated by immunoblotting using an HA-specific antibody (Fig. 11B). 
Particularly, using specific antibodies for SUN1 or SUN2, it was confirmed the 
ectopically expressed proteins were considerably more abundant than 
endogenous SUN1/SUN2 (Fig. 12A). Furthermore, subcellular localization of 
endogenous SUN1 and SUN2 was examined in comparison tothe 
overexpressed and HA-tagged SUN1 and SUN2 in U87MG CD4/CXCR4 cells. 
While HA-tagged protein expressions maintained the predominantly perinuclear 
staining pattern, their expressions were also localized in cytosol unlike 
endogenous proteins (Fig. 12B). 
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Table 16. Membrane-associated NE proteins analyzed in the overexpression screen.  
 
 
a N-term HA, N-terminal HA; C-term HA, C-terminal HA. 
b WB assay, Western blotting assay to detect protein expression with indicated antibody. 
c Cell viability was visually judged by the appearance of cytopathic effect and cell death in culture, in comparison to 
parental U87MG CD4/CXCR4 cells (response set as 100%). ++, 90 to 100% relative to response in parental cells; +, 
50% to 89%; -, 0 to 49%. Proteins for which no expression signal was observed or which showed a strong cytopathic 
effect were not investigated further. 
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Figure 11. Overexpression of SUN1 or SUN2 inhibits HIV-1 infection. A) Non-transduced 
U87MG CD4/CXCR4 cells (n.t.) or cells expressing the indicated HA-tagged membrane-associated NE 
proteins or luciferase (LUC; negative control) were infected with VSV-G-pseudotyped HIV-1 GFP LV for 
48h before harvest, fixed in 4% paraformaldehyde (PFA) and analyzed by flow cytometry. Virus titrations 
were usually performed by threefold serial dilutions of the viral supernatant. Infectious titers (in infectious 
units [i.u.] per milliliter) were calculated from at least three virus doses and mean titers are shown. Error 
bars are standard deviations. Representative results from three independent experiments are shown. B) 
Corresponding WB for A). Same numbers of cells were lysed in the same volume of Laemmli buffer and 
subjected to immunoblotting analysis with antibodies targeting HA. MAPK served as a loading control. 
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Figure 12. SUN1 and SUN2 expression in U87MG CD4/CXCR4 cells. A) U87MG CD4/CXCR4 
cells expressing HALUC, HASUN1 or HASUN2 were probed with antibodies targeting SUN1 or SUN2. 
HSP90 served as a loading control. B) U87MG CD4/CXCR4 cells expressing HALUC, HASUN or 
HASUN2 were subjected to immunofluorescence microscopy using SUN1 or SUN2-specific antibodies. 
Nuclei were visualized using Hoechst stain. Scale bar =10 µm 
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6.1.2. Overexpression of SUN1 or SUN2 block full-length HIV-1 
NL4.3GFP 
In order to analyze whether the route of viral entry affects the magnitude of 
SUN1-mediated suppression, U87MG CD4/CXCR4 cells overexpressing 
HALUC (negative control), HASUN1 or HASUN2 were infected for two days 
with a full-length non-pseudotyped CXCR4-tropic HIV-1 GFP reporter virus 
(NL4.3-GFP: see paragraph 5.1.9. in Materials and Methods) [141, 286]. A 
strong suppression of HIV-1 infection by SUN1 was also observed (Fig. 13A), 
suggesting that SUN1 has an inhibitory effect in downstream of membrane 
fusion and independent of viral entry into the cell. 
 
                    
 
Figure 13. Overexpression of SUN1 or SUN2 inhibits HIV-1 infection. A) U87MG CD4/CXCR4 
cells overexpressing HALUC (negative control), HASUN1 or HASUN2 were infected with full-length non-
pseudotyped CXCR4-tropic NL4.3GFP for 48h before harvest, fixed in 4% paraformaldehyde (PFA) and 
analyzed by flow cytometry. Virus titrations were usually performed by threefold serial dilutions of the viral 
supernatant. Infectious titers (in infectious units [i.u.] per milliliter) were calculated from at least three virus 
doses and mean titers are shown. Error bars are standard deviations. Representative results from three 
independent experiments are shown. B) Corresponding WB for A). Same numbers of cells were lysed in 
the same volume of Laemmli buffer and subjected to immunoblotting analysis with antibodies targeting HA. 
Tubulin served as a loading control. 
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6.1.3. Overexpression of SUN1 and SUN2 reduces HIV-1 2-LTR 
circle accumulation 
To determine the stage of the infection block, U87MG CD4/CXCR4 cells 
expressing HALUC, HASUN1 or HASUN2 were infected with DNase-treated 
VSV-G-pseudotyped HIV-1 GFP LV++ (see paragraphs 5.1.12. and 5.3.6. in 
Materials and Methods) and total DNA was isolated at various time points of 
post-infection. Quantitative Taqman PCR was then performed to determine the 
copy numbers of GFP or 2-LTR circles as surrogates for early reverse 
transcription products and nuclear import, respectively. To control for plasmid 
contamination deriving from vector production, analogous samples treated with 
the allosteric reverse transcriptase inhibitor Efavirenz (+RTinh) were included in 
the assay. In parallel, infectivities were determined by flow cytometry 48h after 
infection. Although cells overexpressing HASUN1 or HASUN2 showed 
considerably reduced susceptibility to HIV-1 LV++ infection (Fig. 14A), similar 
levels of GFP reverse transcription products were detected in control, HASUN1 
or HASUN2-expressing cells (Fig. 14B). In contrast, the amount of HIV-1 2LTR 
circles was reduced in SUN1 or SUN2 overexpressing cell lines by 10-fold, (Fig. 
14C) suggesting that inhibitory effect by over expression of these proteins 
occurs at the stage of viral nuclear import. 
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Figure 14. Overexpression of SUN1 and SUN2 inhibits HIV-1 2-LTR circle formation. 
U87MG CD4/CXCR4 cells overexpressing HALUC (negative control), HASUN1 or HASUN2 were infected 
in the presence or absence of 5μM efavirenz (+RTinh) with VSV-G-pseudotyped HIV-1 GFP LV++. A) 
Percentages of infected cells (%GFP+ cells) were determined by flow cytometry 48h post infection. Mean 
infectivities for three samples and standard deviations are shown. Representative results from three 
independent experiments are shown. B-C) Total DNA was extracted at the indicated time points, and early 
reverse transcription products for GFP (B) or 2-LTR circles (C) were measured by qPCR and normalized to 
total DNA input. Representative results from three independent experiments are shown. 
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6.1.4. Overexpression of SUN1 and SUN2 inhibits HIV-1 and 
HIV-2 infection but not other lentiviruses 
In order to investigate the selectivity of the SUN protein-induced inhibitory effect 
for different retroviruses, U87MG CD4/CXCR4 cells expressing HASUN1, 
HASUN2, or HALUC as negative control were infected with a diverse set of 
VSV-G-pseudotyped GFP-encoding retroviral vectors derived from HIV-2ROD, 
SIVMAC, FIV, EIAV, or Moloney murine leukemia virus (MoMLV) (see paragraph 
5.1.9. in Materials and Methods). Only HIV-1 and HIV-2ROD were sensitive to the 
overexpression of SUN proteins compared to the all other retroviral vectors (Fig. 
15), suggesting that the inhibitory effect is specific for that 2 retroviruses in 
terms of nuclear import. Although HASUN1 overexpression inhibited HIV-1 
infection by ~20-fold, HIV-2ROD was suppressed by ~5-fold (Fig. 15A), indicating 
the specificity of virus substrate. A similar profile was observed in cells 
overexpressing HASUN2 (Fig. 15B). 
         
Figure 15. Overexpression of SUN1 and SUN2 inhibits HIV-1 and HIV-2ROD but not SIVMAC, 
FIV, EIAV, or MoMLV infection. U87MG CD4/CXCR4 cells overexpressing HALUC (negative control), 
HASUN1 or HASUN2 were infected with the indicated VSV-G-pseudotyped GFP retroviral vector, for 48h 
before harvest, fixed in 4% paraformaldehyde (PFA) and analyzed by flow cytometry. Virus titrations were 
usually performed by threefold serial dilutions of the viral supernatant. Infectious titers (in infectious units 
[i.u.] per milliliter) were calculated from at least three virus doses and mean titers are shown. Error bars are 
standard deviations. Representative results from three independent experiments are shown.  
   
71 
 
6.1.5. Differential susceptibility of HIV-1 strains to SUN1 and 
SUN2 mediated inhibition 
To understand whether the sensitivity of SUN1- and SUN2-induced inihibitory 
effect varies among different HIV-1 strains, infection by lab strains virus NL4.3 
and IIIB as well as T/F viruses, RHPA, SUMA, WITO, THRO, and ZM247 was 
tested. To measure infectivity a trans-packaging approach was used, whereby 
the individual viruses were produced in the presence of a GFP-encoding vector 
(pCSGW: see paragraph 5.1.9. in Materials and Methods) that was 
transpackaged resulting in GFP expression in infected target cells. The virus 
preparation obtained through this trans-packaging strategy was compared with 
the one using a typical GFP reporter virus, and both generated similar infectious 
titers in 293T cells. Furthermore, the SUN1-mediated inhibitory effect led to a 
~20-fold decrease of the infection for both viruses in U87MG CD4/CXCR4 cells 
(Fig. 16).  
   
Figure 16. HIV-1 sensitivities to the SUN1-induced block. U87MG CD4/CXCR4 cells 
overexpressing HALUC (negative control) or HASUN1 were infected with VSV-G-pseudotyped NL4.3GFP 
reporter virus or virus derived by co-transfecting NL4.3 with the GFP LV pCSGW for 24h before harvest, 
fixed in 4% paraformaldehyde (PFA) and analyzed by flow cytometry. Virus titrations were usually 
performed by threefold serial dilutions of the viral supernatant. Percentages of infected cells (%GFP+ cells) 
were determined from at least four virus doses. Representative results from three independent 
experiments are shown. 
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NL4.3 and IIIB infectivities were suppressed ~20-fold by SUN1 overexpression, 
SUMA, WITO, and THRO were all reduced by 6- to 10-fold, whereas RHPA and 
ZM247 were only mildly affected (Fig. 17A) (hence RHPA served as a good 
control for adverse overexpression effects). Similar reductions in sensitivities of 
these T/F viruses to SUN2-mediated inhibition (Fig. 17B) suggested a common 
mechanism. 
These data show that SUN1 and SUN2 efficiently block nuclear import of 
certain HIV-1 lab strains (NL4.3 and IIIB) as well as natural strains upon 
overexpression, whereas some naturally occurring HIV-1 strains, in particular 
T/F viruses RHPA and ZM247 are resistant to that block in a CA-dependent 
way. 
            
 
Figure 17. HIV-1 strains have differential sensitivities to the SUN1- and SUN2-induced 
block. U87MG CD4/CXCR4 cells overexpressing HALUC (negative control), HASUN1 or HASUN2 were 
infected with the indicated VSV-G-pseudotyped virus produced by co-transfection with the HIV-1 GFP LV 
pCSGW, for 24h before harvest, fixed in 4% paraformaldehyde (PFA) and analyzed by flow cytometry. 
Virus titrations were usually performed by threefold serial dilutions of the viral supernatant. Infectious titers 
(in infectious units [i.u.] per milliliter) were calculated from at least three virus doses and mean titers are 
shown. Error bars are standard deviations. Representative results from three independent experiments are 
shown 
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6.1.6. HIV-1 capsid protein determines sensitivity to SUN1-
mediated inhibition 
Previous works showed that T/F HIV-1 strains were relatively insensitive to MX2 
restriction and the viral determinants were mapped to CA [204, 205, 211, 213]. 
To identify the viral determinants dictating sensitivity to SUN1 mediated 
restriction, GFP-reporter chimeric viruses between the SUN1-sensitive NL4.3 
and the insensitive T/F RHPA were generated by using specific restriction sites 
present in both the viral genomes; BssHII (5=-LTR), EcoRI (Vpr), and XhoI (Nef) 
(Fig. 18).  
                  
Figure 18. Schematic of the generation of chimeric viruses between T/F virus RHPA and NL4.3. 
 
GFP-reporter viruses were therefore produced by co-transfecting pCSGW, and 
infectivity was tested in U87MG-CD/CXCR4 cells expressing HALUC or 
HASUN1. The chimeric virus constituted by the replacement of the region 
between EcoRI and XhoI sites (encoding part of Vpr, Vpu, Env, Nef, Tat, and 
Rev) was still sensitive to SUN1-mediated inhibition (ERX) (Fig. 19). In contrast, 
the chimeric virus BRE, generated by the replacement of the NL4.3 region 
between BssHII and EcoRI sites (encoding Gag, Pol, Vif, and part of Vpr) with 
that of RHPA, was mainly resistant to SUN1-induced suppression (Fig. 19), 
suggesting that the relative insensitivity of T/F HIV-1 to SUN1 or SUN2 may be 
dictated by Gag-Pol.  
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Figure 19. Identification of the HIV-1 determinant for the sensitivity to SUN1-induced 
inhibition. VSV-G-pseudotyped GFP reporter viruses were produced by cotransfection with the pCSGW 
vector, and U87MG CD4/CXCR4 cells overexpressing HALUC (negative control) or HASUN1 were 
infected for 24h before harvest, fixed in 4% paraformaldehyde (PFA) and analyzed by flow cytometry. 
Virus titrations were usually performed by threefold serial dilutions of the viral supernatant. Infectious titers 
(in infectious units [i.u.] per milliliter) were calculated from at least three virus doses and mean titers are 
shown. Error bars are standard deviations. Representative results from three independent experiments are 
shown.  
 
HIV-1 incorporating the CA-p2 of the insensitive SIVMAC (HIV-1 (SCA) chimera) 
(pCMV-ΔR8.91Ex-SCA: see paragraph 5.1.9. in Materials and Methods) [274, 
295] was also largely insensitive to SUN1 or SUN2 (Fig. 20), further indicating 
the CA role in determining sensitivity to SUN-mediated inhibition. 
 
            
Figure 20. HIV-1 incorporating the CA-p2 of the insensitive SIVMAC (HIV-1 (SCA) chimera) 
is largely insensitive to SUN1- or SUN2-induced inhibition. U87MG CD4/CXCR4 cells 
expressing HALUC (negative control), HASUN1 or SUN2 were infected with VSV-G-pseudotyped HIV-1 
SCA GFP LV for 48h before harvest, fixed in 4% paraformaldehyde (PFA) and analyzed by flow cytometry. 
Virus titrations were usually performed by threefold serial dilutions of the viral supernatant. Infectious titers 
(in infectious units [i.u.] per milliliter) were calculated from at least three virus doses and mean titers are 
shown. Error bars are standard deviations. Representative results from three independent experiments are 
shown. 
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CA sequences from sensitive NL4.3 and resistant RHPA show amino acid 
differences at nine positions, some of which are located in proximity, or inside of 
the Cyp-binding loop in CA (Fig. 21).  
 
                       
Figure 21. CA amino acid differences between sensitive HIV-1NL4.3 and resistant HIV-1RHPA. 
Figure adapted from [296] 
 
To further define the specific sequence determinant dictating sensitivity to SUN1 
inhibition, Gag-Pol–encoding vector pCMV-ΔR8.91ExNRA was generated (HIV-
1 NRA LV; see paragraph 4.1.12. in Materials and Methods) by replacing the 
NL4.3 Gag sequence up to the ApaI site in pCMV-ΔR8.91Ex with that of RHPA 
(Fig. 22).  
 
 
Figure 22. HIV-1 LV and HIV-1NRA LV: replacement of the sequence of the SUN1-sensitive HIV-1 
variant NL4.3 up to the ApaI site with that of RHPA. 
 
Wild type HIV-1 LV (NL4.3-based) was inhibited >10-fold by SUN1, whereas 
HIV-1 NRA LV was also largely insensitive (Fig. 23). Subsequently, to further 
define the specific sequence determinant, single or multiple amino acid CA 
substitutions were introduced into the NL4.3 CA region and new compound 
mutants were created, among which the triple mutant H87Q+H120N+G208A 
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that rendered HIV-1 largely resistant to SUN1-mediated inhibition, 
phenocopying HIV-1NRA LV (Fig. 23). To address whether the reciprocal was 
competent, the reverse amino acid substitutions (Q87H+N120N+A208G) were 
introduced into HIV-1NRA and the infectivity compared to HIV-1NRA in HALUC 
or HASUN1 overexpressing U87MG-CD4/CXCR4 cells. Indeed, these three 
changes were sufficient to render HIV-1NRA sensitive to SUN1-induced 
suppression (Fig. 23). 
 
 
 
 
Figure 23. The determinant for the sensitivity to SUN1-induced inhibition maps to CA. 
U87MG CD4/CXCR4 cells overexpressing HALUC (negative control) or HASUN1 were infected with VSV-
G-pseudotyped HIV-1 GFP LV and with VSV-G-pseudotyped chimeric HIV-1 GFP LV (NL4.3H87Q, 
NL4.3H120N, NL4.3G208A, NL4.3H87Q+H120N+G208A, NRA, NRAQ87H+N120N+A208G) for 48h 
before harvest, fixed in 4% paraformaldehyde (PFA) and analyzed by flow cytometry. Virus titrations were 
usually performed by threefold serial dilutions of the viral supernatant. Infectious titres were calculated 
from at least three virus doses and mean titres are shown. Error bars are standard deviations. 
Representative results from three independent experiments are shown. 
 
These results suggest that specific residues in HIV-1 CA are likely the viral 
determinant defining the sensitivity to SUN1 or SUN2-mediated restriction after 
overexpression. 
6.1.7. In vitro-assembled HIV-1 CANC complexes interact with 
SUN1 and SUN2 
Since HIV-1 sensitivity to SUN1 or SUN2-mediated suppression is determined 
by specific amino acid residues in CA, the binding of of SUN proteins to in vitro 
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synthesized HIV-1 CANC complexes (capsid-nucleocapsid complexes) was 
investigated with the Malim lab in London (King’s College London). 
Synthetic CANC nanotubes derived from SUN1- and SUN2-sensitive HIV-1 
strain IIIB or T/F virus RHPA were used to analyze if HASUN1 or HASUN2 
could be co-precipitated from 293T cell lysates. Since it was able to interact 
efficiently with IIIB and RHPA CANC nanotubes, HACPSF6 was used as 
positive control to compare with the negative control, HALUC. Parallel samples 
without adding CANCs were also used as control for unspecific precipitation of 
proteins (Fig. 10). Both HASUN1 and HASUN2 were able to interact with IIIB 
CANC complexes in cell lysates (Fig. 24A). However, they also interacted with 
RHPA CANC complexes, despite they couldn't block RHPA infection (Fig. 24B). 
Therefore, though SUN1 or SUN2 seem to interact with CANCs in vitro, a direct 
correlation between such interactions and the suppression of virus infection in 
cultured cells was not identified. It is possible that RHPA and other SUN1- and 
SUN2-insensitive viruses overcome SUN1 or SUN2-induced restriction in cells 
because physical interaction is absent due to choice of a different trafficking 
pathway towards the nucleus. Likewise, it is possible that interaction is 
necessary but not sufficient for mediating a block to infection.  
   
 
Figure 24. In vitro-synthesized HIV-1 CANC nanotubes capture SUN1 and SUN2 from cell 
lysates. Cell lysates from 293T cells transfected with HALUC, HACPSF6, HASUN1, or HASUN2 were 
incubated with in vitro-synthesized CANC nanotubes before centrifugation through a sucrose cushion and 
analysis of supernatants and pellets by immunoblotting using HA- and CA-specific antibodies. I, input; S, 
supernatant; P, pellet. A) In vitro-synthesized CANC complexes from IIIB were mixed with cell lysates and 
analyzed as described in panel A. B) In vitro-synthesized CANC complexes from RHPA were mixed with 
cell lysates and analyzed as described in panel A. Data from Malim Lab (KCL, London) 
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6.1.8. The amino-terminal domain of SUN1 mediates HIV-1 
inhibition 
To identify which regions of SUN1 are involved in HIV-1 infection suppression, 
amino-terminal and carboxy-terminal deletion mutants (Fig. 25) were generated.  
                  
 
Figure 25. Schematic of the analyzed SUN1 deletion mutants.   
 
Among the amino-terminal SUN1 deletions, removing the first 30 (HASUN1Δ30) 
or 60 (HASUN1Δ60) amino acids had no or minor effects on the SUN1 capacity 
to block HIV-1 infection (Fig. 26A). In contrast, removing the first 90 
(HASUN1Δ90), 100 (HASUN1Δ100) or 355 (HASUN1Δ355) amino acids was 
abrogating the suppression of HIV-1 infection (Fig. 26A). The expression levels 
of the amino-terminal SUN1 deletion mutants were generally higher than the 
wild type protein (Fig. 26B). Deletion of the carboxy-terminal SUN domain 
(HASUN1-1-583) did not interfere with the inhibition of HIV-1 (Fig. 26B), 
suggesting that interaction with nesprin proteins in the perinuclear space and 
LINC complex formation may not be required for the antiviral activity. 
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Figure 26. The amino-terminal domain of SUN1 is required for the block to HIV-1.  
A) U87MG CD4/CXCR4 overexpressing HALUC (negative control), HASUN1, HASUN1Δ30, HASUN1Δ60, 
HASUN1Δ90, HASUN1Δ100, HASUN1Δ355, HASUN1-1-583 were infected with full length VSV-G HIV-1 
GFP reporter virus (NL4.3GFP VSV-G) for 48h before harvest, fixed in 4% paraformaldehyde (PFA) and 
analyzed by flow cytometry. Virus titrations were usually performed by threefold serial dilutions of the viral 
supernatant. Infectious titres were calculated from at least three virus doses and mean titres are shown. 
Error bars are standard deviations. Representative results from three independent experiments are shown. 
B) Corresponding WB for A). Same numbers of cells were lysed in the same volume of Laemmli buffer and 
subjected to immunoblotting analysis. Total protein was determined by UV-activating the gel and served as 
loading control. 
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Furthermore, by indirect immunofluorescence microscopy, it was shown that the 
restriction of wild type HASUN1, HASUN1Δ30 or HASUN1Δ60 did not show 
apparent differences in subcellular localization as compared to the inactive 
HASUN1Δ90 or HASUN1Δ100, particularly all showed cytoplasmic as well as 
perinuclear staining (Fig. 27). In contrast, HASUN1Δ355 mutant mainly 
localizes in a perinuclear cytoplasmic compartment, suggesting that the 
different localization may contribute to the inactivity of this mutant (Fig. 27). 
 
 
 
Figure 27. IF of U87MG CD4/CXCR4 cells expressing HASUN1 wild type or HASUN1 
amino-terminal and carboxy-terminal deletion mutants. U87MG CD4/CXCR4 overexpressing 
HALUC, HASUN1wt, HASUN1Δ30, HASUN1Δ60, HASUN1Δ90, HASUN1Δ100, HASUN1Δ355, HASUN1-
1-583 were stained by immunofluorescence for HA, using Alexa Fluor 488 conjugated secondary antibody. 
Hoechst staining was used to label double stranded DNA and thus visualize nuclei. 
 
Subsequently, to further define the specific antiviral determinants, different 
quadruple alanine mutants of SUN1 were created, each one with different four 
single alanine mutations in the region between 75 to 95 (Fig. 28).  
 
 
Figure 28. Schematic of analyzed SUN1 alanin mutants. 
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Each mutant was overexpressed in U87MG CD4 / CXCR4 cells and infected 
with full-length non-pseudotyped NL4.3GFP for 48h. The SUN1 mutants 
84AAAS87 and 86ASSA89 lost the capacity to block the HIV-1 infection, 
suggesting that the amino acids 85-90 are those relevant in SUN1 antiviral 
activity (Fig. 29A). 
 
     
 
Figure 29. The amino-terminal amino acids 85-90 relevant in SUN1 blocking infection 
capacity. A) U87MG CD4/CXCR4 cells overexpressing HALUC (negative control), HASUN1 or the 
indicated SUN1 alanin mutants were infected with VSV-G-pseudotyped NL4.3GFP for 24h before harvest, 
fixed in 4% paraformaldehyde (PFA) and analyzed by flow cytometry. Virus titrations were usually 
performed by threefold serial dilutions of the viral supernatant. Infectious titers (in infectious units [i.u.] per 
milliliter) were calculated from at least three virus doses and mean titers are shown. Error bars are 
standard deviations. Representative results from three independent experiments are shown. B) 
Corresponding WB for A). Same numbers of cells were lysed in the same volume of Laemmli buffer and 
subjected to immunoblotting analysis with antibodies targeting HA. HSP90 served as a loading control.  
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In order to determine whether SUN1 amino-terminal region would still have the 
capacity to suppress HIV-1 infection when appended to an entirely unrelated 
protein, the fusion protein composed of the first 130 amino-terminal SUN1 
amino acids fused with the entire Fv1N protein was created (HASUN1NTD-Fv1N; 
see paragraph 5.1.12. in Materials and Methods) (Fig. 30).  
     
 
Figure 30. Schematic of analyzed chimeric protein composed of the amino-terminal 130 amino acids of 
SUN1 fused to the restriction factor MLV Fv1N (HASUN1NTD-Fv1N).  
 
Fv1N was chosen as the substrate since this protein is an inhibitor of retrovirus 
infection (MLV B-tropic but not HIV-1) [297] and it is naturally oligomeric [298]. 
Furthermore, this strategy has already been used in previous studies to analyze 
CA binding and antiviral activity of certain protein domains in the context of a 
heterologous fusion partner by Fv1-Cyp [299, 300], or MX2NTD-Fv1 [226]. As 
expected, the expression of the control protein HAFv1N in U87MG CD4/CXCR4 
did not suppress HIV-1 infection. In contrast, the fusion protein HASUN1NTD-
Fv1N was able to reduce the HIV-1 infection (Fig. 31A), without reaching the 
same levels of wild type HASUN1, maybe due to reduced expression level (Fig. 
31B).  
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Figure 31. Fusion of the amino-terminal SUN1 domain to Fv1 generates a potent HIV-1-
inhibiting factor. A) U87MG CD4/CXCR4 cells expressing HALUC (negative control), HASUN1 
(positive control),HAFv1N, or HASUN1NTD-Fv1N were infected with full-length non-pseudotyped CXCR4-
tropic NL4.3GFP for 48h before harvest, fixed in 4% paraformaldehyde (PFA) and analyzed by flow 
cytometry. Virus titrations were usually performed by threefold serial dilutions of the viral supernatant. 
Percentages of infected cells (%GFP+ cells) were determined from at least four virus doses. 
Representative results from three independent experiments are shown. B) Corresponding WB for A). 
Same numbers of cells were lysed in the same volume of Laemmli buffer and subjected to immunoblotting 
analysis with antibodies targeting HA. MAPK served as a loading control.  
 
In addition, it was confirmed that HASUN1NTD-Fv1N mainly shows a strong 
perinuclear cytoplasmatic localization, suggesting that incoming HIV-1 CA could 
interact with the SUN1 amino-terminal domain in the cytoplasm (Fig. 32). 
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Figure 32. IF U87MG CD4/CXCR4 cells expressing HASUN1 wild type HASUN1NTD-Fv1N. 
U87MG CD4/CXCR4 overexpressing HASUN1wt or HASUN1NTD-Fv1N were stained by 
immunofluorescence for HA, using Alexa Fluor 488 conjugated secondary antibody. Hoechst staining was 
used to label double stranded DNA and thus visualize nuclei. 
 
In conclusion, the data confirm that the amino-terminal region of SUN1 is 
necessary and sufficient for the HIV-1 infection suppression. 
6.1.9. The amino-terminal domain of SUN2 mediates HIV-1 
inhibition 
In order to understand which regions of SUN2 are involved in HIV-1 and HIV-2 
infection suppression, amino-terminal and carboxy-terminal deletion mutants 
were also generated (Fig. 33). 
 
        
 
Figure 33. Schematic of the analyzed SUN2 deletion mutants.   
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The results showed that removing the carboxy-terminal SUN domain (HASUN2-
1-524) had no effect on the viral infections (Fig. 34A), suggesting that 
interaction with the nesprin proteins in the perinuclear space may not be 
required for the antiviral activity. Analysis of the amino-terminal SUN2 deletions 
indicated that the elimination of the lamin-binding site (LBS) had minor effects 
on the SUN2 capacity to suppress the viral infections (Fig. 34A), suggesting that 
interaction of SUN2 with lamins in the nucleus is not important for the antiviral 
activity. In contrast, the deletion of the first 157 amino acids (HASUN2Δ157) 
was abrogating the suppression of HIV-1 and HIV-2 infection (Fig. 34A).  
         
 
Figure 34. The amino-terminal domain of SUN2 is required for the block to HIV-1. A) MDMs 
from three independent donors overexpressing HALUC (negative control), HASUN2, HASUN2ΔLBS, 
HASUN2Δ157, HASUN1-1-524 were infected with VSV-G-pseudotyped HIV-1 GFP LV or VSV-G-
pseudotyped HIV-2ROD GFP LV in presence of Vpx for 48h before harvest, fixed in 4% paraformaldehyde 
(PFA) and analyzed by flow cytometry. Virus titrations were usually performed by threefold serial dilutions 
of the viral supernatant. Infectious titres were calculated from at least three virus doses and mean titres 
are shown. Error bars are standard deviations. Representative results from three independent experiments 
are shown. B) Corresponding WB for A). Same numbers of cells were lysed in the same volume of 
Laemmli buffer and subjected to immunoblotting analysis. HSP90 served as a loading control. 
Subcellular localization between the restricting wild type HASUN2, 
HASUN2ΔLBS or HASUN2 1-524 and the inactive HASUN1Δ157 displayed all 
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the variants in cytoplasmic as well as perinuclear staining (Fig. 35), as already 
seen with SUN1 (Fig. 27).  
 
 
Figure 35. IF of U87MG CD4/CXCR4 cells expressing HASUN1 wild type or HASUN1 
amino-terminal and carboxy-terminal deletion mutants. MDMs from three independent donors 
overexpressing HALUC (negative control), HASUN2, HASUN2ΔLBS, HASUN2Δ157, HASUN1-1-524 were 
stained by immunofluorescence for HA, using Alexa Fluor 488 conjugated secondary antibody.  
 
In order to verify if SUN2 amino-terminal can replace the antiviral activity of 
SUN1 amino-terminal, a fusion protein of SUN1 and SUN2 was generated in 
which the first 130 amino-terminal amino acids of SUN1 are replaced with the 
first 90 amino-terminal amino acids of SUN2 (HASUN2NTD-SUN1; see 
paragraph 5.1.12. in Materials and Methods) (Fig. 36). 
 
 
Figure 36. Schematic of analyzed chimeric protein composed of the SUN2 amino-terminal fused to SUN1 
(SUN2NTD-SUN1).  
 
 
 
 
The chimeric protein, HASUN2NTD-SUN1 was able to reduce the HIV-1 infection 
when overexpressed in U87MG CD4/CXCR4 cells (Fig. 37A), without reaching 
to the same levels of wild type HASUN1, maybe due to reduced expression 
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level (Fig. 37B). Thus, it is confirmed that the amino-terminal region of SUN2 is 
necessary and sufficient for the HIV-1 infection suppression, as observed in 
SUN1.  
 
         
 
Figure 37. Fusion of the amino-terminal SUN2 domain to SUN1 generates a potent HIV-1-
inhibiting factor. A) U87MG CD4/CXCR4 cells expressing HALUC (negative control), HASUN1 
(positive control),HASUN2NTD-SUN1 were infected with full-length non-pseudotyped CXCR4-tropic 
NL4.3GFP for 48h before harvest, fixed in 4% paraformaldehyde (PFA) and analyzed by flow cytometry. 
Virus titrations were usually performed by threefold serial dilutions of the viral supernatant. Percentages of 
infected cells (%GFP+ cells) were determined from at least four virus doses. Representative results from 
three independent experiments are shown. B) Corresponding WB for A). Same numbers of cells were 
lysed in the same volume of Laemmli buffer and subjected to immunoblotting analysis with antibodies 
targeting HA. MAPK served as a loading control.  
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6.1.10. CRISPR/Cas9-mediated SUN2 but not SUN1 gene 
disruption decreases HIV-1 infectivity in THP-1 cells 
To verify whether depletion of endogenous SUN proteins have an effect in HIV-
1 infection, THP-1 cells were transduced with CRISPR/Cas9 LVs expressing 
individual specific guide RNAs (gRNA) against SUN1 or SUN2 (see paragraphs 
5.1.12. and 5.3.3.2. in Materials and Methods). Two independent THP-1 single-
cell knockout clones for each gene with complete loss of SUN1 or SUN2 
expression (SUN1g2c5, SUN1g2c7, SUN2g2c1, and SUN2g3c4) were 
generated, as well as various clones with intact SUN1 or SUN2 expression (Fig. 
38A). The knockout was verified by immunoblotting (Fig. 38B) as well as by 
sequencing over the gRNA target site in the cell genome. 
 
 
 
Figure 38. THP-1 single-cell knockout clones for SUN1 or SUN2 genes. A) THP-1 
CRISPR/Cas9 single-cell cloning followed by PCR-based sequencing across the guide RNA target sites 
identified two clones for each gene in which the open reading frame was disrupted. B) The SUN1 or SUN2 
abrogated expression in the individual single-cell clones was verified by immunoblotting using SUN1- or 
SUN2-specific antibodies. Tubulin served as the loading control. 
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All the clones were tested for their sensitivity to VSV-G pseudotyped NL4.3GFP 
or chimeric BREGFP reporter virus’s infection. BRE chimeric virus (Fig. 18) was 
used because it was insensitive to SUN1/2 overexpression (Fig. 19), and thus 
expected to serve as a negative control. The SUN1 gene disruption did not 
show any detectable effect on infection by either virus, while the depletion of 
SUN2 reduced HIV-1 infection by 2 to 3-fold in comparison to a CRISPR/Cas9 
control cell clone (Fig. 39). 
 
 
Figure 39. HIV-1 infection is impaired in CRISPR/Cas9 SUN2-depleted THP-1 cells. A) The 
SUN1 or SUN2 abrogated expression in the individual single-cell clones was verified by immunoblotting 
using SUN1- or SUN2-specific antibodies. Tubulin served as the loading control. B) THP-1 CRISPR/Cas9 
control, SUN1- or SUN2-depleted cells were infected with VSV-G-pseudotyped NL4.3GFP or BREGFP 
reporter viruses for 24h before harvest, fixed in 4% paraformaldehyde (PFA) and analyzed by flow 
cytometry. Virus titrations were usually performed by threefold serial dilutions of the viral supernatant. 
Infectious titers (in infectious units [i.u.] per milliliter) were calculated from at least three virus doses and 
mean titers are shown. Error bars are standard deviations. Representative results from three independent 
experiments are shown. 
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Proliferation assay confirmed that the reduction of infectivity in SUN2 knockout 
clones is independent of cell number (Fig. 40A).  The susceptivity of infection by 
MoMLV-derived-LV and VSV-G-pseudotyped GFP-encoding retroviral vectors 
derived from HIV-2ROD, SIVMAC, FIV, EIAV was also determined (Fig. 40B, 40C). 
It was found that only HIV-1 was sensitive to the SUN2 gene depletion.  
 
 
 
Figure 40. Gene disruption of SUN2 inhibits HIV-1 but not HIV-2ROD, FIV, SIVMAC, EIAV or 
MoMLV infection. A) Growth kinetics of CRISPR/Cas9 SUN2-depleted THP-1 cells in comparison to 
CRISPR/Cas9 control or THP-1 parental cells. At each time point, THP-1 parental, CRISPR/Cas9 control, 
SUN1- or SUN2-depleted cells were harvested and counted. Viable cells are represented. B) THP-1 
control, SUN2-depleted cells were infected with VSV-G-pseudotyped MoMLV GFP LV for 48h before 
harvest, fixed in 4% paraformaldehyde (PFA) and analyzed by flow cytometry. Virus titrations were usually 
performed by threefold serial dilutions of the viral supernatant. Infectious titers (in infectious units [i.u.] per 
milliliter) were calculated from at least three virus doses and mean titers are shown. Error bars are 
standard deviations. Representative results from three independent experiments are shown. C) THP-1 
control, SUN2-depleted cells were infected with the indicated VSV-G-pseudotyped GFP retroviral vector, 
for 48h before harvest, fixed in 4% paraformaldehyde (PFA) and analyzed by flow cytometry. Virus 
titrations were usually performed by threefold serial dilutions of the viral supernatant. Infectious titers (in 
infectious units [i.u.] per milliliter) were calculated from at least three virus doses and mean titers are 
shown. Error bars are standard deviations. Representative results from three independent experiments are 
shown. 
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6.1.11. Nuclear import is impaired in SUN2 CRISPR/Cas9 THP-1 
cells 
To determine which stage of HIV-1 infection is affected by the absence of 
SUN2, THP-1 control cells and SUN2 knockout cells were infected with DNase-
treated VSV-G-pseudotyped NL4.3GFP and the production of GFP reverse 
transcription products or 2-LTR circles was measured by real time PCR as 
described in paragraph 6.1.3. Although SUN2 knockout cells showed reduced 
susceptibility to HIV-1 infection, similar levels of GFP reverse transcription 
products were detected in control and SUN2 knockout cells (Fig.41A). In 
contrast, the amount of 2-LTR circles was reduced by ~3-fold, which correlated 
with the reduction in infectivity (Fig.41A), suggesting that HIV-1 nuclear import 
is impaired in in THP-1 lacking SUN2. Similar infection phenotypes were 
obtained in THP-1 cells previously differentiated by use of phorbol 12-myristate 
13-acetate (PMA) (Fig. 41B). 
 
 
Figure 41. HIV-1 nuclear import is impaired in CRISPR/Cas9 SUN2-depleted cells. A) THP-1 
CRISPR/Cas9 control as well as SUN2-depleted cells (SUN2g3c4) were infected with DNase-treated VSV-
G-pseudotyped NL4.3GFP in the presence or absence of efavirenz (RTinh), and total DNA was isolated 
for TaqMan qPCR 6 h (GFP) or 24 h (2-LTR circles) postinfection (p.i.). Parallel samples were used to 
determine percentages of infected cells (% GFP+) by flow cytometry 48h post infection. Fold changes to 
control cells in the absence of RTinh were calculated. Representative results from three independent 
experiments are shown. B) Same as for panel A, but with PMA treated (24h) THP-1 control cells or 
SUN2g3c4 knockout cells. 
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6.1.12. SUN2 shRNA-mediated knockdown in CRISPR/Cas9 
SUN1-depleted THP-1 cells decreases HIV-1 infectivity 
To examine a possible cooperation of SUN1 and SUN2 in the context of HIV-1 
post-entry steps, double-knockout was employed at first using CRISPR/Cas9-
mediated depletion. However, the depletion of both genes interrupted in cell 
survival for sufficient measurement, as reported in previous study [234]. Thus, 
CRISPR/Cas9 SUN1-depleted THP-1 cells were transduced with pSIREN 
RetroQ vectors expressing individual specific short hairpin RNAs (see 
paragraphs 5.1.12. and 5.3.3.3. in Materials and Methods) to silence SUN2 
expression via RNA interference (RNAi). SUN2 knockdown was verified by 
immunoblotting (Fig. 42B) and resulted in 3 different cell bulks with 3 different 
shRNAs in which SUN2 protein levels were strongly reduced (Fig. 42B). SUN1-
depleted THP-1 cells resulted in a 2- to 3-fold decrease in HIV-1 infection by 
knockdown of SUN2 (Fig. 42A), similar to the results of SUN2-depleted THP-1 
cells. These findings suggest that SUN2 may work independently from SUN1. 
    
 
Figure 42. SUN2 shRNA-mediated knockdown decrases HIV-1 infection in CRISPR/Cas9 
SUN1-depleted THP-1 cells. A) shRNA-reduced SUN2 CRISPR/Cas9 SUN1-depleted THP-1 cells 
were infected with VSV-G-pseudotyped NL4.3GFP or BREGFP reporter viruses for 24h before harvest, 
fixed in 4% paraformaldehyde (PFA) and analyzed by flow cytometry. Virus titrations were usually 
performed by threefold serial dilutions of the viral supernatant. Infectious titers (in infectious units [i.u.] per 
milliliter) were calculated from at least three virus doses and mean titers are shown. Error bars are 
standard deviations. Representative results from three independent experiments are shown. B) 
Corresponding WB for A). Same numbers of cells were lysed in the same volume of Laemmli buffer and 
subjected to immunoblotting analysis. HSP90 served as a loading control. 
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6.1.13. SUN2 shRNA-mediated knockdown in U87MG 
CD4/CXCR4 cells decreases HIV-1 infectivity after 24h 
To clarify the role of endogenous SUN1 and SUN2 proteins in other cell lines, 
SUN1 or SUN2 shRNA-mediated knockdown in U87MG CD4/CXCR4 cells was 
investigated. While SUN1 knockdown was too toxic for the U87MG 
CD4/CXCR4 cells to grow, SUN2 protein levels were efficiently reduced by two 
different shRNAs (Fig. 43B). These cell populations were infected with VSV-G-
pseudotyped NL4.3GFP and resulted in a 5-fold decrease in HIV-1 infection 
after 24h, while it was recovered after 48h (Fig. 43A). Thus, it is suggested a 
delay in nuclear early infection steps, possibly leading to reduced integration 
events. 
 
Figure 43. HIV-1 infection is impaired in shRNA-reduced SUN2 U87MG CD4/CXCR4 cells. 
A) shRNA-reduced SUN2 U87MG CD4/CXCR4 cells were infected with VSV-G-pseudotyped HIV-1 GFP 
LV, in the presence or absence of efavirenz (RTinh). Percentages of infected cells (% GFP+) were 
determined by flow cytometry 24h and 48h post infection. Fold changes to control cells in the absence of 
RTinh were calculated. Representative results from three independent experiments are shown.  
B) Corresponding WB for A). Same numbers of cells were lysed in the same volume of Laemmli buffer and 
subjected to immunoblotting analysis. HSP90 served as a loading control. 
 
6.1.14. CRISPR/Cas9-mediated SUN1 or SUN2 gene disruption 
does not decreases HIV-1 infectivity in Jurkat TAg cells 
Jurkats TAg cells were transduced with CRISPR/Cas9 LVs expressing 
individual specific gRNA against SUN1 or SUN2. Independent Jurkats TAg cells 
single-cell knockout clones for each gene were generated, with complete loss of 
SUN1 or SUN2 expression (SUN1g2c15, SUN1g2c16, SUN2g1c5, and 
SUN2g1c15) as well as various clones with intact SUN1 or SUN2 expression 
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(Fig. 44A). Knockout was verified by immunoblotting (Fig. 44B) as well as by 
sequencing over the gRNA target site in the cell genome. 
     
 
 
 
Figure 44. Jurkat Tag single-cell knockout clones for SUN1 or SUN2 genes. A) Jurkat TAg 
CRISPR/Cas9 single-cell cloning followed by PCR-based sequencing across the guide RNA target sites 
identified two clones for each gene in which the open reading frame was disrupted. B) The SUN1 or SUN2 
abrogated expression in the individual single-cell clones was verified by immunoblotting using SUN1- or 
SUN2-specific antibodies. Tubulin served as the loading control. 
 
All the clones were tested for their sensitivity to VSV-G pseudotyped NL4.3GFP 
or full-length non-pseudotyped CXCR4-tropic NL4.3GFP. SUN1 and SUN2 
gene knockout did not have any effect on infection by either virus (Fig. 45), in 
comparison to a CRISPR/Cas9 control cell clone. 
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Figure 45. HIV-1 infection is not impaired in CRISPR/Cas9 SUN1- or SUN2-depleted Jurkat 
TAg cells. Jurkat TAg Parental, CRISPR/Cas9 control, SUN1- or SUN2-depleted cells were infected with 
VSV-G-pseudotyped NL4.3GFP or full-length non-pseudotyped CXCR4-tropic NL4.3GFP for 24h before 
harvest, fixed in 4% paraformaldehyde (PFA) and analyzed by flow cytometry. Virus titrations were usually 
performed by threefold serial dilutions of the viral supernatant. Infectious titers (in infectious units [i.u.] per 
milliliter) were calculated from at least three virus doses and mean titers are shown. Error bars are 
standard deviations. Representative results from three independent experiments are shown. 
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6.1.15. SUN1 and SUN2 are not required for the CypA 
Restriction in THP-1 cells and Jurkat TAg cells 
Lahaye et al introduced HIVac-1 as a HIV-1 CA mutant restricted by CypA 
[173]. It was reported that SUN2 knockdown rescued HIVac-1 from CypA-
restiction in bone-marrow derived dendritic cells from mice. Thus, HIVac-1 
infectivity was analyzed to compare with HIV-1 wild type in THP-1 cells 
overexpressing CypA and lacking SUN1 or SUN2 expression. The infectious 
titer of HIVac-1 was reduced by 10-fold in comparison to HIV-1 wild type in all 
tested cell lines independently of SUN protein expression (Fig. 46A). HIV-1 wild 
type was blocked by CypA overexpression and no major differences were 
detected between control cells and SUN2 knockout cells. In contrast, HIVac-1 
was not affected by CypA overexpression, possibly because endogenous CypA 
levels already substantially reduced the infectious titre. However, addition of 
cyclosporine A (CsA) increased both HIV-1 and HIVac-1 infectious titres up to 
wild type levels, independently of SUN protein expressions (Fig. 46A). Similary, 
SUN1 or SUN2 gene knockout in Jurkat TAg cell lines resulted in no changes 
for wild-type HIV-1 GFP LV, in the presence or absence of CsA (Fig. 47). The 
infectivity of HIVac-1 GFP LV was significantly reduced in Jurkat TAg control 
cells as well as in Jurkat TAg SUN1 or SUN2 knockout cell clones, and CsA 
treatment rescued infectivity in all cases to the level of wild-type LV (Fig. 47). 
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Figure 46. THP-1 CRISPR/Cas9 SUN1- or SUN2-depleted cells and the CypA restriction of 
HIVac capsids. A) THP-1 CRISPR/Cas9 control as well as SUN1- or SUN2-depleted cells (SUN1g1c5, 
SUN2g2c1) overexpressing CypA were infected with VSV-G GFP-reporter wild type HIV-1 LV or with VSV-
G pseudotyped GFP-reporter chimearic HIVac-1 LV for 48h before harvest, fixed in 4% paraformaldehyde 
(PFA) and analyzed by flow cytometry. Virus titrations were usually performed by threefold serial dilutions 
of the viral supernatant and titres were calculated from at least three virus doses. Mean titres are shown 
and error bars are standard deviations. Cyclosporine (Cs) was used at 5 µM and added at the time of 
infection. DMSO was used as vehicle control at the same concentration. Representative results from three 
independent experiments are shown. B) Corresponding WB for A). Same numbers of cells were lysed in 
the same volume of Laemmli buffer and subjected to immunoblotting analysis with antibodies targeting HA. 
Hsp90 served as the loading control. 
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Figure 47. Jurkat TAg CRISPR/Cas9 SUN1- or SUN2-depleted cells and the CypA 
restriction of HIVac capsids. Jurkat TAg CRISPR/Cas9 control as well as SUN1- or SUN2-depleted 
cells were infected with VSV-G GFP-reporter wild type HIV-1 LV or with VSV-G pseudotyped GFP-reporter 
chimearic HIVac-1 LV for 48h before harvest, fixed in 4% paraformaldehyde (PFA) and analyzed by flow 
cytometry. Virus titrations were usually performed by threefold serial dilutions of the viral supernatant and 
titres were calculated from at least three virus doses. Mean titres are shown and error bars are standard 
deviations. Cyclosporine (Cs) was used at 5 µM and added at the time of infection. DMSO was used as 
vehicle control at the same concentration. Representative results from three independent experiments are 
shown. 
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6.2. The role of CA protein during IFN-α-induced 
suppression of HIV-1 infection 
6.2.1. Determinants of the MX2 antiviral activity and the role of 
GTPase domain 
To test the role of the G domain in anti-HIV-1 activity of MX2, mutations at key 
positions in the G domain located in the amino-terminal domain of MX2 were 
generated based on sequence homologies to MX1 by a collaborator, Mirjam 
Schilling (University of Freiburg) (see paragraph 5.1.12. in Materials and 
Methods). There are six MX2 mutants generated as following: K131A, inhibiting 
GTP binding; T151A, inhibiting GTP hydrolysis; D297A inhibiting GTP binding, 
D300, binding but not hydrolyzing GTP; M574D, a known mutant that prevents 
MX2 from oligomerization [220]. The MX2 mutants, along with MX2 wild type 
and MX2 lacking first 25 amino acids of the amino-terminal region 
(MX2(ΔNLS)), were then overexpressed in U87MG CD4/CXCR4 cells and 
infected for 48h with a VSV-G pseudotyped GFP-encoding HIV-1 lentiviral 
vectors harboring the NL4.3 CA (pCMV-ΔR8.91Ex) or the RHPA CA (pCMV-
ΔR8.91ExNRA) (see paragraph 5.1.10 and 5.1.12 in Materials and Methods). 
U87MG CD4/CXCR4 cells expressing wildtype MX1 or GTPase defective 
MX1(K83A) were used as controls. As expected, none of the mutations reduced 
the capacity of MX2 wild type to restrict HIV-1 (Fig. 48A) except for MX2(ΔNLS) 
and the monomeric MX2(M574D), confirming that the amino-terminal 25 amino 
acids of MX2 are essential for the antiviral activity [226] as well as 
oligomerization [225], whereas both GTP binding and hydrolysis are not 
important for the anti-HIV-1 activity [204, 205]. Intriguingly, MX2 containing the 
T151A mutation, which render the protein deficient in GTP hydrolysis but not 
GTP binding, was anti-virally active against RHPA derived lentiviral vector (Fig. 
48B), suggesting that it may assume an antiviral conformation capable to 
recognize RHPA and block the viral target. 
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Figure 48. GTP binding and hydrolysis are not important for anti-HIV-1 activity of MX2.  
A) U87MG CD4/CXCR4 cells expressing LUC-HA, HAMX1 wt, HAMX1-K83A (negative controls), MX2-HA 
or different MX2 amino-terminal mutants were challenged with a VSV-G-pseudotyped HIV-1 GFP LV. At 
48h post infection, the cells were harvest, fixed in 4% paraformaldehyde (PFA) and analyzed by flow 
cytometry. Virus titrations were usually performed by threefold serial dilutions of the viral supernatant. 
Infectious titres were calculated from at least three virus doses and mean titres are shown. Error bars are 
standard deviations. Representative results from three independent experiments are shown. B) Same as 
for panel A but with VSV-G-pseudotyped chimeric HIV-1-NRA GFP LV C) Corresponding WB for A) and 
B). Same numbers of cells were lysed in the same volume of Laemmli buffer and subjected to 
immunoblotting analysis. Loading was controlled by measuring total protein by UV activation of the gel. 
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6.2.2. HIV-1 CA mutants N74D or P90A display enhanced 
sensitivity to IFN-α-induced blocks 
Previous studies showed that the CA amino acids substitutions N74D and P90 
reduced the sensitivity of HIV-1 to repression by ectopically expressed MX2 
[204, 205, 211, 213]. Hence, it was speculated that these substitutions in the 
HIV-1 CA could reduce the sensitivity of these viruses to the type I IFN-induced 
post-entry-blockage. THP-1 cells were infected after treating with increasing 
doses of type I IFN (subtype IFN-α2A) with HIV-1 wild type or CA mutants N74D 
or P90A. Surprigingly, infectivities of the CA mutants in THP-1, MDMs and 
CD4+ cells were strongly reduced following IFN-α treatment, compared to the 
wild type virus, (Fig. 49A, B, C, D), suggesting an increased sensitivity to the 
IFN-α-induced post entry blockage. 
 
 
Figure 49. HIV-1 CA mutants N74D and P90A have increased sensitivity to IFN-α-induced 
suppression in diverse cell types. A) THP-1 cells were pretreated with increasing doses of IFN-α 
and infected 24 h later with an equal amount of VSV-G-pseudotyped wild-type HIV-1 GFP lentiviral vector 
ΔR8.91 or CA mutant N74D or P90A. At 48h post infection, the cells were harvest, fixed in 4% 
paraformaldehyde (PFA) and percentage of GFP-positive cells (%GFP+ cells) was determined. Error bars 
indicate the standard deviations. Representative results from three independent experiments are shown. 
B) Same as for panel A but with NL4.3GFP-IRES-NEF (NL4.3GFP) viruses. C) Same as for panel A, but 
with MDMs from three independent donors. D) Same as for panel A, but with CD4+ T cells from three 
independent donors.  
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6.2.3. The increased sensitivity of HIV-1 CA mutants to IFN-α 
induced blocks is independent of MX2 
Subsequently, CRISPR/Cas9 MX2 THP-1 knockout cell lines were generated 
using two independent guide RNAs to examine the possible link with MX2 
(MX2g1 and MX2g2; see paragraph 5.1.12. and 5.3.3.2. in Materials and 
Methods). The THP-1 bulk populations expressing either of the two guide RNAs 
showed a ~5 to 8-fold reduced inhibition to HIV-1 NL4.3GFP VSV-G infection 
after IFN-α treatment (Fig. 50A).  On the other hand, THP-1 parental cells and 
control cells with minor susceptibility to HIV-1 infection resulted in similar 
expression levels of MX1 and MX2 upon IFN-α treatment (Fig. 50B). Of note, a 
MoMLV-derived-LV, which is unaffected by ectopic MX2 overexpression [142], 
was significantly inhibited by IFN-α in control cells and MX2 CRISPR/Cas9 cells 
(Fig. 50A). No detectable differences in the absence of IFN-α treatment were 
found, when comparing the infectivity of the HIV-1 NL4.3GFP VSV-G wild type 
with that of the CA mutants N74D, P90A, A105T in single cell clones in which 
MX2 expression was either ablated (MX2g2c4) or reduced (MX2g1c1) (Fig. 
50B). The IFN-α signalling pathway remained intact in those clones, as 
measured by MX1 induction through immunoblot analyzes (Fig. 50B). As 
expected, the infectivity of wild-type virus in parental THP-1 cells decreased by 
10-fold after IFN-α treatment, but only 3- to 5-fold in MX2g1c1 and MX2g2c4 
cells (Fig. 50C). In contrast, the infectivity of the N74D mutant decreased by 43-
fold in parental THP-1 cells and 20-fold in MX2g1c1 and MX2g2c4 cells (Fig. 
50C). SImilary, HIV-1 P90A and A105T showed stronger inhibition by IFN-α 
treatment in parental THP-1, as well as MX2 CRISPR/Cas9 cells, compared to 
the wild type virus (Fig. 50C). These data demonstrate that the increased 
sensitivity of the HIV-1 CA mutants to IFN-α induced blockage was likely to be 
independent of IFN-induced MX2. 
 
   
103 
 
Figure 50. HIV-1 CA mutants are sensitized to MX2-independent IFN-α-induced blocks in 
THP-1 cells. A) THP-1 cells were transduced with HIV-1 LVs encoding a control gRNA (Cntrl) or two 
independent gRNAs against MX2 (g1 and g2) and then puromycin selected for 2 weeks. Parental THP-1 
cells or transduced CRISPR/Cas9 cell bulk populations were treated with 500 U/ml IFN-α and infected 24h 
later with a serial dilution of NL4.3GFP VSV-G reporter virus or Moloney murine leukemia virus GFP VSV-
G vector. At 48h post infection, the cells were harvest, fixed in 4% paraformaldehyde (PFA) and 
percentage of GFP-positive cells (%GFP+ cells) was determined by flow cytometry. The relative 
infectivities were determined. Bars indicate the average infectious titers determined from at least three 
independent viral doses normalized to untreated THP-1 cells, and error bars indicate the standard 
deviations. Representative results from three independent experiments are shown. B) Wild-type THP-1 
cells, a CRISPR/Cas9 control, and two independent MX2 knockout THP-1 single cell clones (g1c1 and 
g2c4) were treated with 500 U/ml IFN-α2 for 24 h. Immunoblots of untreated or IFN-α-treated cells using 
antibodies specific for MX1 and MX2 are shown. Loading was controlled by measuring total protein by UV 
activation of the gel. C) Wild-type THP-1 and the MX2 knockout cell clones (g1c1 and g2c4) were treated 
for 24 h with 500 U/ml IFN-α and then infected with a serial dilution of VSV-G-pseudotyped NL4.3GFP 
wild-type, CA N74D or CA P90A or CA A105T mutant viruses. The figure shows infection measured at 48 
h as in panel A. 
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6.2.4. IFN-α induces an enhanced block to reverse transcription 
and nuclear import of HIV-1 CA N74D 
Parental THP-1 or MX2g2c4 cells were infected with VSV-G-pseudotyped 
NL4.3GFP wild type or N74D CA mutant to examine the stage of infection 
blockage in MX2-depleted cells. Total DNA was isolated at 4h and 24h post 
infection, and Quantitative Taqman PCR was performed to determine the copy 
numbers of GFP or 2-LTR circles as surrogates for early reverse transcription 
products and nuclear import, respectively. In parallel, the infectivities by flow 
cytometry were determined 24h after infection (Fig. 51A). In the IFN-α treated 
cells, 4h post infection the GFP reverse transcription products from HIV-1 wild-
type virus decreased by 4-fold compared to untreated cells with no substantially 
difference between MX2g2c4 cells and parental THP-1 (Fig. 51B). In 
comparison, the levels of GFP reverse transcription products in HIV-1 CA N74D 
infection were reduced by 8-fold and no significant difference was shown 
between MX2g2c4 cells and parental THP-1 (Fig. 51B). In addition, there was a 
strong reduction in copy numbers of GFP reverse transcription products for both 
the wild type and the N74D mutant in IFN-treated cells upon 24h infection (Fig. 
51C). After IFN-α pre-treatment and wild-type HIV-1 infection, 2-LTR circles at 
24h post infection were reduced by 30-fold in parental THP-1 cells and only 
~10-fold in MX2g2c4 cells, associated with MX2 role in blocking nuclear import. 
In HIV-1 CA N74D, the production of 2-LTR circles was blocked by 2-fold in 
parental and MX2g2c4 cells (Fig. 51D). Therefore, the increased sensitivity of 
the HIV-1 CA N74D mutant to IFN-α induced blockage (Fig. 51A) is likely to be 
explained by a stronger reduction in reverse transcription products as compared 
to wild type virus (Fig. 51B and C) and consequent reduced accumulation of 2-
LTR circles, reflecting the suppression of nuclear import (Fig. 51D). 
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Figure 51. Hypersensitivity of the HIV-1 CA mutant N74D to IFN-α occurs at the stages of 
reverse transcription and nuclear import. Parental THP-1 or MX2g2-4 CRISPR/Cas9 cells were 
treated with 500 U/ml IFN-α and infected 24h later with VSV-G-pseudotyped NL4.3GFP wild-type or N74D 
CA mutant virus. A) At 24 h post infection, the cells were harvest, fixed in 4% paraformaldehyde (PFA) and 
percentage of GFP-positive cells was determined by flow cytometry. B-D) Total DNA was extracted at the 
indicated time points. Early reverse transcription products for GFP or 2-LTR circles were measured by 
qPCR and normalized to total DNA input.  
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7. Discussion and perspectives 
7.1. The role of inner nuclear membrane proteins SUN1 and 
SUN2 in early HIV-1 infection steps 
The role of different NE proteins during the early stage of HIV-1 infection was 
analyzed through the development of an overexpression screen with different 
human NE membrane-associated proteins (Fig. 11). This revealed that most of 
the NE proteins had minimal or no effect on HIV-1 infection, while both SUN1 
and SUN2 were identified as having a significant impact on HIV-1 infection. 
Specifically, SUN2 overexpression decreased HIV-1 LV infection by 5-fold, 
while SUN1 resulted in a 20-fold decrease in infection (Fig. 11). The 
overexpression of both SUN1 and SUN2 were shown to reduce HIV-1 2-LTR 
circle formation (Fig. 14), a surrogate for nuclear import. However, the 
ectopically expressed SUN proteins maintained a predominantly perinuclear 
staining pattern, with a further cytosolic localization not present in the case of 
the endogenous proteins (Fig. 12) and did not induce alterations in nucleus 
morphology as previously noted by Donahue et. al.[293]. SUN1 and SUN2 are 
integral type II transmembrane proteins that are widely expressed and 
predominantly localised to the INM, where the nucleoplasmic amino-terminal 
domain interacts with proteins in the nuclear lamina, such as LMNA [301, 302] 
and EMD [303], whereas the PNS carboxy-terminal SUN domain interacts with 
the Klarsicht-ANC1-Syne-homology (KASH) domain of Nesp proteins [301, 302, 
304-309]. Together with Nesp proteins, SUN proteins represent the core 
elements of linker of nucleoskeleton and cytoskeleton (LINC) complexes, which 
span both nuclear membranes and physically connect proteins constituting the 
cytoskeleton (e.g., actin, microtubules, and intermediate filaments) with proteins 
of the nuclear skeleton (e.g., nuclear lamins) (Fig. 52). SUN proteins function as 
transluminal tethers for Nesp proteins in the ONM and seem to have an 
important role in maintaining the regular space between INM and ONM [229]. 
SUN1 and SUN2 are also important for various cellular processes, including 
telomere attachment to the NE during meiosis and for postmitotic cells [310-
314], DNA damage response (DDR), removal of membranes from chromatin 
during mitosis [234], positioning of the nucleus, cell migration and polarization 
[304, 315-319]. SUN1 and SUN2 gene dysfunction has been connected with 
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cardiomyopathies and skeletal myopathies [303, 320] and has been detected in 
certain cancer tissues, suggesting possible tumor suppressor activity [321, 322]. 
SUN1 and SUN2 proteins may also have individual roles, in addition to the 
many redundant cellular functions: for example, SUN2 has been described as a 
protein involved in the trafficking of endosomes by its binding to Rab5 [323], 
while for SUN1 no such role has been described so far.  
 
 
Figure 52. The LINC complex connects nuclear structures to the cytoskeleton. INM SUN-
domain proteins can assemble homodimers or heterodimers and function as transluminal tethers for ONM 
KASH-domain proteins. The nucleoplasmic domain of SUN proteins binds to lamins and/or other nuclear 
components. Cytoplasmic KASH domains of nesprins interact with cytoskeletal elements, including actin, 
plectin, and kinesin. Figure adapted from [229] 
 
Previous studies reported that both SUN1 and SUN2 interact also with the INM 
protein Emerin [302], which has been suggested as a cofactor for HIV 
integration [242]. However, later studies did not validate this and the incapacity 
of a LEM domain-deleted EMD to affect HIV-1 infection (Fig. 11) can be 
considered coherent with the latest reports [243, 244]. SUN2 was proposed to 
be a type I interferon (IFN)-induced gene able to weakly inhibit HIV-1 infection 
[206]. Other recent studies have also reported a possible role of SUN2 in early 
infection steps [173, 293, 294], however they did not confirm changes in SUN2 
protein levels in type I IFN-treated cells [173, 293]. Here it was shown that 
overexpression of SUN1 or SUN2 reduces HIV-1NL4.3 as well as HIV-2ROD 
infection but not the other retroviruses that were tested (Fig. 15), suggesting 
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that the block exerted by the ectopically expressed SUN1 and SUN2 is specific 
for these two laboratory-adapted lentiviruses and does not involve any 
unspecific block to nuclear import. Is still unknown why SIVMAC and the other 
non-primate retroviruses are insensitive to the overexpressed SUN1 and SUN2 
human proteins, but one hypothesis might be that these viruses are only able to 
interact specifically with the SUN proteins of their natural hosts. It has been 
shown that the amino-terminal of SUN1 might have undergone positive 
selection processes during evolution, which could refer to historical occurrences 
of specific species [289]. The establishment of virus infection in a naïve host 
most often results from the transmission and subsequent propagation of a 
single virus strain, termed a transmitted/founder (T/F) virus. The extremely 
diverse HIV‐1 population in the blood of infected donors, suggests that during 
HIV transmission there are one or more strong obstacles that reduce viral 
infectivity, resulting in the transmission of a single T/F virus. Exploring viral 
phenotypes that associate with transmission and determinate whether these 
obstacles are stochastic and restrict all viruses or whether there are selective 
pressures favouring certain phenotypes in the T/F virus, may therefore clarify 
the biology of HIV‐1 transmission and tell novel prevention approaches. SUN 
proteins might have exerterted a strong inhibitory pressure on HIV-1 infection in 
vivo, leading to the occurace of SUN-resistant HIV-1 strains. To address this 
question, the infection by T/F viruses RHPA, SUMA, WITO, THRO, and ZM247 
along with that of lab strain viruses IIIB and NL4.3 was tested in this stydy. 
RHPA, SUMA, THRO and WITO were identified in subjects with early/acute 
subtype B HIV-1 infection, whereas ZM247 in subjects with early/acute subtype 
C HIV-1 infection [288, 324]. In the case of SUN1 many T/F viruses were found 
to be sensitive to some degree except for strains RHPA and ZM247 (Fig. 17A), 
suggesting that only certain HIV-1 strains (and possibly HIV-2 strains) appear to 
be sensitive to SUN1 or SUN2 overexpression. A similar antiviral profile was 
observed for SUN2, despite it being more widely distributed (Fig. 17B). Previous 
works have shown that some of these T/F viruses, including RHPA and ZM247, 
are also hyposensitive to overexpressed MX2 [212], suggesting that these 
viruses may be able to bypass several factors associated with the NE. Infection 
data obtained with GFP-reporter chimeric viruses between the SUN1-sensitive 
NL4.3 and the insensitive T/F RHPA (Fig. 19A, Fig. 19B), suggest that HIV-1 
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CA is likely the viral determinant that is defining the sensitivity to SUN1 or 
SUN2-mediated restriction after overexpression. Furthermore, the HIV-1 
containing the CA from SIVMAC was largely insensitive to SUN1 (Fig. 20) further 
indicating the CA role in determining sensitivity to SUN-mediated inhibition. 
Donahue et al. [293] showed that the HIV-1 CA mutant (P207S) was able to 
overcome the block induced by SUN2 overexpression, but this residue is 
conserved between NL4.3 and RHPA and for this reason it cannot explain the 
insensitivity of RHPA in the data presented here. Therefore, to further 
investigate the insensitivity of RHPA, differences between the insensitive RHPA 
and sensitive NL4.3 CA sequences were analyzed by using HIV-1 chimeric 
viruses between NL4.3 and RHPA and it was found that specific residues in 
HIV-1 CA are likely the viral determinants defining the sensitivity to SUN1 or 
SUN2-mediated restriction after overexpression, since a combination of the 
amino acid substitutions H87R,H120N, G208A in NL4.3 made the virus largely 
insensitive to SUN1 (Fig. 23). 
In addition, HIV-2ROD was also sensitive to both SUN1- and SUN2-induced 
inhibition of infection (Fig. 15) and its amino acid sequences shares only 69% 
identity with that of NL4.3 or IIIB. The H87, N120 and G208 amino acid residues 
in HIV-1 capsid, correspond to P86, R118 and N207 in HIV-2ROD capsid. 
However, these residues are also conserved in SIVMAC, which is insensitive to 
the SUN1- or SUN2-mediated block (Fig. 15); therefore, further analysis is 
needed to determine whether these residues are critical for the sensitivity of 
HIV-2 to SUN1- or SUN2-induced inhibition. The RHPA Q87 amino acid residue 
is located in the CypA binding loop of the CA [108] and it has been shown that 
the NL4-3 H87Q CA mutant was refractory to MX2 inhibition [325], suggesting a 
function of CypA in MX2 antiviral response and that some HIV-1 strains have 
evolved to escape MX2 inhibition at the expense of losing viral capsid binding to 
CypA. Therefore, CypA may play similar role also in SUN1- or SUN2-mediated 
restricon of HIV-1 infection, whereas HIV-2 does not require host CypA for 
efficient replication in human cells [109, 112, 326] and particularly HIV-2 CA 
binds CypA with a much lower affinity than HIV-1 CA [141, 327], suggesting that 
this connection needs to be investigated in further studies. 
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Since HIV-1 sensitivity to SUN1 or SUN2-mediated suppression is determined 
by amino acid residues in CA, the ability of SUN proteins to physically interact 
with the HIV-1 capsid was tested in collaboration with Malim lab (King’s College 
London). Specifically, the binding of different SUN1 or SUN2 mutants to in vitro 
synthesized HIV-1 CANC complexes (capsid- nucleocapsid complexes) was 
investigated. SUN1 as well as SUN2 were able to interact with CANC 
complexes derived from the susceptible virus strain IIIB (Fig. 24A). However, 
they also interacted with RHPA CANC complexes (Fig. 24B), suggesting that 
the insensitivity of RHPA to SUN1 or SUN2 may not be caused by a defect in 
binding. RHPA and other insensitive viruses may overcome SUN1 or SUN2-
induced restriction because the physical interaction is absent due to choice of a 
different trafficking pathway towards the nucleus. Likewise, it is possible that the 
interaction is necessary but not sufficient for mediating a block to infection. 
Comparably, the insensitivity of certain capsid mutants to MX2 restriction could 
also not be correlated to defects in MX2 binding in vitro [215]. SUN1 or SUN2 
induced restriction resembled characteristics, reminiscent of the restriction 
induced by the type I IFN-induced restriction factor MX2, i.e. inhibition of 2LTR 
circle formation and negative antiviral effect against T/F such as RHPA [204, 
205, 212]. Additionally, SUN1 and SUN2 largely localized to the nuclear 
envelope, like MX2 [328]. For this reason, this connection is attractive and 
needs to be investigated in further studies by functional assays of MX2 
restriction in SUN1 or SUN2 depleted cells as well as testing SUN1 or SUN2-
mediated block in MX2 knockout cells. Similar approaches for known or newly 
identified SUN1 and SUN2 interactors needs to be the subject of further studies. 
The domains of SUN1 and SUN2 that are involved in HIV-1 infection 
suppression were analyzed and it was verified that the removal of the carboxy-
terminal region of the proteins had no impact on the block (Fig. 26, Fig. 34), 
suggesting that SUN interaction with nesprin proteins in the perinuclear space 
and LINC complex formation may not be required for the antiviral activity [301]. 
In contrast, by deleting 90 amino acids from the SUN1 amino-terminal and 157 
amino acids from SUN2 amino-terminal it completely abrogated the suppression 
of HIV-1 infection (Fig. 26, Fig. 34). Particularly, amino acids residues 85-90 
were shown to be relevant in the SUN1-mediated blocking on infection (Fig. 29). 
In addition, the SUN1 amino-terminal also showed a potent antiviral activity 
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when artificially fused to Fv1N (Fig. 31) and the SUN2 amino-terminal could 
replace the antiviral activity of the SUN1 amino-terminal (Fig. 37). The chimeric 
HASUN1NTD-Fv1N showed a strong cytoplasmic localization (Fig. 32), 
suggesting that the interaction of the SUN1 amino-terminal domain with 
incoming HIV-1 CA can occur in the cytoplasm. Previous studies suggested that 
SUN1 interacts with NPC [329] through Nup153 [330], which has shown to be 
important for the nuclear import of HIV-1 and HIV-2 [144, 163]. Nup153 
depletion leads to changes in the localization of SUN1 [331] and POM121 [332], 
a protein associated with Nup153 and important for its stability. According to 
these data, overexpression of SUN1 and its subsequent cytoplasmic 
accumulation may inhibit HIV-1 infection by perturbing the required interaction 
between incoming HIV-1 capsids and NPC. However, it is unlikely that SUN1 
overexpression affects Nup153 activity, since SIVmac is insensitive to SUN1 or 
SUN2-induced restriction (Fig. 15) but is similarly sensitive to RNA interference-
mediated Nup153 depletion as are HIV-2 and HIV-1 [144]. Further analysis is 
necessary to gain more insights into possible effects of Nup153 and POM121 in 
SUN1 overexpression, possibly by RNA interference-mediated depletion of 
these proteins in SUN overexpressing cells. 
The role of the endogenous proteins SUN1 and SUN2 in HIV infection in the 
myeloid cell line THP-1 and in the T cell line Jurkat TAg was analyzed, and 
single-cell clones with SUN1 and SUN2 knocked out were generated from both 
the cell lines. In THP-1 cells, SUN2 depletion resulted in a moderate but 
reproducible reduction in HIV-1 infection (Fig. 39), and is in agreement with 
published data in which SUN2 levels were reduced by shRNA [173], while 
SUN1 absence did not show any detectable effect on infection by GFP-reporter 
viruses or GFP-encoding lentiviral vectors (Fig. 39). Furthermore, the lack of 
SUN2 reduced the amount of 2-LTR circles (Fig. 41), suggesting a defect in 
virus nuclear import, and did not affect MoMLV (Fig. 40B) and other retroviral 
strains (Fig. 40C), indicating that the absence of SUN2 does not involve any 
unspecific block to nuclear import and may affect specifically HIV-1 infection. In 
Jurkat TAg cells, SUN1 or SUN2 absence did not have any detectable 
repercussions on infection (Fig. 45), suggesting possible differences in SUN 
expression levels between the cell types tested. The same infection pattern was 
observed with the chimeric virus BRE, which incorporates the T/F RHPA capsid 
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and shows a reduced sensitivity to overexpressed SUN1 and SUN2. However, 
since interactions between RHPA CANC complexes and SUN2 were detected in 
vitro, it indicates that the RHPA capsid may still be able to interact with SUN2, 
regardless of its lack of sensitivity to ectopically expressed SUN2. 
Lahaye et al introduced HIVac-1 as a HIV-1 CA mutant restricted by CypA and 
reported that SUN2 knockdown rescued HIVac-1 from CypA-restiction in bone-
marrow derived dendritic cells from mice. Furthermore, they showed that 
combination of SUN2 depletion with CypA inhibition did not lead to a further 
decrease of HIV-1 infectivity in primary CD4+ T cells, suggesting that SUN2 
SUN2 promotes the positive effects of CypA on HIV-1 replication in CD4+ T 
cells [173]. These results were here challenged and HIVac-1 infectivity was 
analyzed to compare with HIV-1 wild type in THP-1 cells lacking SUN1 or SUN2 
expression and in the presence or absence of CsA. The infectious titer of 
HIVac-1 was reduced by 10-fold in comparison to HIV-1 wild type in all tested 
cell lines independently of SUN protein expression (Fig. 46A). Furthermore, 
addition of cyclosporine A (CsA) increased HIVac-1 infectious titres up to wild 
type levels, independently of SUN protein expressions (Fig. 46, Fig. 47). A 
recent study confirmed these results even in primary CD4+ T cells, in which the 
researchers did not find any connection between SUN2 and CypA [294]. 
Despite the possible differences between mice and human cells or the different 
cell types tested, SUN1 or SUN2 gene disruption in the studied cell lines seems 
to have no impact on the CypA-mediated events during early HIV-1 post-entry 
steps.  
These data support the idea that SUN2 may help promote the early stages of 
HIV-1 infection, but that the contributions of SUN1 are less clear. ShRNA-
mediated SUN2 reduction in SUN1 CRISPR/Cas9 showed a reduction in HIV-1 
infectivity comparable to that seen in THP-1 SUN2 knockout cells (Fig. 42), 
further indicating an independent role for SUN2 in promoting the early stages of 
HIV-1 infection. However, the CRISPR/Cas9-mediated depletion of both genes 
interrupted in cell survival for sufficient measurement, as reported in previous 
study [234]. Thus, further analysis needs to be performed to investigate the 
possible functional redundancy between SUN1 and SUN2, possibly by applying 
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a different CRISPR/Cas9 strategy, i.e. by creating SUN2 knockout cell clones in 
which the SUN1 amino-terminal is also deleted. 
This work therefore adressed the question why NL4.3 infection is reduced by 
either SUN2 overexpression or endogenous gene knockout. This apparent 
contradiction could be accounted for when one compares the distribution of 
overexpressed SUN proteins to that of endogenous SUN proteins. 
Overexpressed SUN proteins are found in the NE and the cytosol, while 
endogenous SUN proteins are absent from the cytosol. Similar observations 
have previously been seen for CPSF6, where the mislocalized truncated protein 
was a strong inhibitor of HIV-1 infection when overexpressed, even while 
knockdown of the endogenous protein had no effect in most cell types and 
despite its well-documented role in promoting nuclear entry and integration into 
actively transcribing genes [163, 164, 169, 173, 179, 180]. Similarly, 
overexpressed SUN proteins may mislocalize to the cytosol where they interact 
with incoming HIV-1 (CA-containing) replication complexes and obscure 
important binding sites for other factors required for HIV infection. This would 
indicate that endogenous SUN may be relevant, as suggested by the effect of 
the SUN2 knockout in THP-1 cells, but potentially not by the mechanisms seen 
upon overexpression. This may also describe the discrepancy that the BRE 
virus is resistant to overexpression, but still affected by SUN2 knockout. 
Mapping of the CA-SUN interface would be a consistent aspect to follow. 
Previous studies showed that NUP98 and NUP153 depletion reduces HIV-1 
integration preferences and that the depletion of endogenous expression of 
another CA binder like CPF6, using CRISPR/Cas technology, changed the 
integration profile of HIV-1 despite there were not relevant change in infection 
[180, 185, 186, 243]. In collaboration with the Debyser lab (KU Leuven, 
Belgium), the integration site selection for HIV-1 in THP-1 cell lines with 
knocked-out SUN1 or SUN2 is currently being investigated. This will hopefully 
identify a possible role of the SUN proteins in dictating HIV-1 integration site 
selection.  
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7.2. The role of CA protein during IFN-α-induced 
suppression of HIV-1 infection 
Whether the susceptibility of the viral determinants targeted by IFN-α-induced 
blocks could be sensitive to changes in the HIV-1 CA protein was also 
investigated in the present study. By analysing the infectivities of previously 
described HIV-1 CA mutants (N74D, A105T, as well as P90A) that are able to 
escape the inhibition of ectopically expressed IFN-α-induced MX2 [204, 205, 
211]. This analysis suggested that the CypA binding to the HIV-1 capsid [211] 
as well as CPSF6 binding [204, 205], are also involved in the MX2 antiviral 
mechanism. Despite their relative resistance to ectopically expressed MX2, the 
infectivities of HIV-1 CA mutants N74D, A105T, as well as P90A were more 
reduced after IFN-α treatment of THP-1 cells, MDMs, or CD4+ T-cells as 
compared to wild type virus (Fig. 49), indicating an increased sensitivity to the 
IFN-α-induced post entry block. This suggests that the HIV capsid may not 
solely protect viral nucleic acids from being detected by cytoplasmic DNA 
sensors such as cGAS [102], but also that the defect of these CA mutants to 
replicate in MDMs can at least in part be explained by an increased sensitivity 
to type I IFN-induced effectors.  
Furthermore, the knockout data indicate that the HIV-1 CA mutants increased 
sensitivity does not depend on MX2 (Fig. 50) and takes place during reverse 
transcription (Fig. 51), suggesting that the interactions between IFN-α-induced 
antiviral effectors and CA are enhanced by that alterations in CA, possibly as a 
consequence of slower capsid uncoating [333], leading to disadvantageous 
exposition of reverse transcription complexes to such effectors. These results 
confirm that IFN-α induces at least two blocks: the first one, sensitive to 
changes in CA, at the level of reverse transcription and the second one at the 
level of nuclear import and involving MX2 [204, 205, 211]. The determinant for 
MX2 antiviral effect maps to the first 25 amino acids in the amino-terminal 
region of MX2, in which a triple-arginine motif is required for interaction with the 
HIV-1 CA and consequent restriction [223] [226].  
MX2 is expressed in two isoforms in IFN-treated cells: full-length MX2(1-715) 
and MX2(26-715), which lacks the first 25 amino-terminal amino acids that 
function as a nuclear localization signal (NLS) and is essential for the anti-HIV-1 
   
115 
 
activity [226]. Analysis of MX2 mutants in the N-terminal extension and the G 
domain reveal that none of the mutations reduced the capacity of full length 
MX2 to restrict HIV-1 (Fig. 48A), except the truncated MX2(26-715) and 
MX2(M574D), a mutant that prevents MX2 oligomerization resulting in a 
monomeric MX2 protein inactive against HIV-1. These data confirm that the 
antiviral activity of MX2 against HIV-1 is independent of its GTPase domain 
[204, 205] and requires higher order structures and oligomerization [225]. 
Intriguingly, all the MX2 mutants, with the exception of G domain mutant 
MX2(T151A), were inactive against a HIV-1 lentiviral vector harboring the T/F 
RHPA CA (Fig. 48B), confirming the RHPA resistance phenotype to MX2 
inhibition, which was previously mapped to the amino acid positions 87 and 208 
in CA [325]. Particularly, the H87Q mutation is located in the CypA binding loop 
of the CA [108] and it has been shown to render HIV-1NL4.3 refractory to MX2 
inhibition [325], suggesting a function of CypA in MX2-mediated block and that 
likely some HIV-1 strains have evolved to escape MX2 inhibition at the expense 
of losing viral capsid binding to CypA. Attractive is the RHPA sensitivity to the 
mutant MX2(T151A), which contain a mutation that render the protein deficient 
in GTP hydrolysis but not in GTP binding, indicating that this mutation renders 
MX2 active against RHPA, likely by exhibiting an antiviral conformation capable 
to recognize and block the viral target. Several single amino acid substitutions 
in CA have been identified that confer resistance to MX2 [204, 205, 211-213] 
and many of them, such as G89V, N57A/S, A92E as well as N74D, A105T and 
P90A are also known to affect binding to cellular proteins implicated in HIV-1 
nuclear import including CypA, CPSF6, Nup153, and NUP358 [106, 107, 141, 
144, 163, 334]. Interactions with cellular factors that help to protect HIV-1 from 
IFN-α-induced antiviral effectors, as well as the capsid stability and uncoating of 
incoming viral capsids, are thus affected by these particular mutations, one 
consequence of which is the greater sensitivity of relevant mutant viruses to 
IFN-α-induced infectivity blocks. Enhanced interactions between IFN-α-induced 
antiviral effectors and CA alter the infection non-dividing cells and likely may 
modulate certain HIVs nuclear entry and possibly target site selection. 
Further investigations, not associated with this thesis, showed that disruption of 
CypA by CRISPR/Cas9 modestly increased the sensitivity of HIV-1 to IFN-α-
induced blocks [214], indicating that CypA interactions with incoming capsids 
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may help to protect HIV-1 from IFN-α-induced antiviral effectors in THP-1. In 
contrast, genetic disruption of CPSF6 did not increase the sensitivity of wild 
type or CA mutant HIV-1 to IFN-α-induced effectors in THP-1 cells [214], 
arguing that CPSF6 does not play a role in protecting infection from IFN-α-
induced blocks [163, 169].  
8. Conclusion 
SUN1 and SUN2 proteins have been identified in the present study as two NE 
membrane-associated components able to affect HIV-1 infection. The data 
obtained after knockout of these proteins support the idea that endogenous 
SUN2 may be relevant during the early stages of HIV-1 infection, but potentially 
not by the mechanisms seen upon overexpression. The contributions of SUN1 
are less clear, as the gene disruption of SUN1 did not yield a different infection 
phenotype in THP-1, yet overexpression resulted in a potent suppression of 
infection. SUN1 and SUN2 are proteins required for diverse cellular processes 
and their role during HIV infection could be involve mediating telomere 
attachment to the NE and the positioning of the nucleus during cell division, as 
well as DNA damage response (DDR) and the removal of membranes from 
chromatin during mitosis. Since the endogenous SUN1 and SUN2 proteins 
localize to the INM with their amino termini facing the nucleoplasm, one 
hypothesis suggest that the interaction between SUN1 and SUN2 with the 
nuclear CA-containing nucleoprotein complexes [139, 140, 335] may contribute 
to nuclear import and/or possibly dictate the site of HIV-1 integration in the host 
cell genome. However, this need to be further investigated and further studies 
are ongoing with the Debyser lab (KU Leuven, Belgium). The CA protein has 
been showed to be important for HIV-1 nuclear import [138, 141, 163, 336], and 
this work demonstrated that the amino-terminal domains of SUN1 and SUN2 
may interact with HIV-1 in a CA-specific way. Additionally it has also shown that 
CA protein and the capsid core may protect incoming HIV-1 nucleic acids from 
detection by innate pattern recognition receptors [102, 103], as well as IFN-α-
induced effectors, thereby providing dual protection against host defense 
mechanism. 
Overall, in this project, SUN proteins emerge as critical regulators of HIV 
infection, both upon over-expression and at the endogenous level and enhance 
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our understanding of the early post-entry events occurring during HIV-1 
infection. Further mechanistic details may advance the insights of the interplay 
between HIV and host, and reveal a novel target for theraupetic interventation.  
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S Serine 
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SDM Site directed mutagenesis 
SDS Sodium dodecyl sulfate 
SERINC Serin incorporator 
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SIV Simian immunodeficiency virus 
SLFN Schlafen 
SLX Structure-specific endonuclease subunit 
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TCR T-cell receptor 
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TM Transmembrane 
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TSG101 Tumour susceptible gene 101 
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Vpr Viral protein R 
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